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Abstract
Investigation of Long Noncoding RNAs in the
P53 Response to Oncogenic Stress
Ephrath Fisseha Tesfaye
2021
The tumor suppressor protein p53 plays a central role in sensing and
responding to cellular stress, and loss of normal p53 activity is a feature of
most human cancers. P53, functioning as a transcription factor, regulates a
wide network of genes that coalesce to drive many diverse tumor suppressive
cellular processes. Despite three decades of extensive study, it is unclear
which p53 targets are most critical for these tumor suppressive functions
and under which biological contexts. More recent studies have revealed that
the p53 network is not solely comprised of protein coding genes but also
includes many long noncoding RNAs (lncRNAs), which are an abundant but
poorly characterized class of heterogenous RNA molecules. This work aimed
to expand our understanding of the role of lncRNAs in the p53
transcriptional network and the importance of these diverse RNAs in
various p53-regulated processes and/or tumor suppression.
We focused on characterizing the p53 response to stress generated by
hyperactive oncogenes (i.e. oncogenic stress), which is an important but
understudied facet of p53-mediated tumor suppression. By performing
genome-wide analysis of p53 regulation across a panel of cancer cell lines

established from a genetically-engineered mouse model of p53-driven lung
adenocarcinoma, sarcoma, and lymphoma, we uncovered oncogenic stressspecific, tumor type-specific, and p53 outcome-specific patterns of p53 gene
activation and repression, including the activation of several novel and
previously described lncRNAs. We interrogated the contributions of many
of these lncRNAs to p53 pathway function, using a number of locus-specific
genetic and molecular approaches to down- or upregulate lncRNA
expression in vitro. These characterization efforts revealed that local gene
regulation, also known as cis-regulation, is the dominant mode of action for
lncRNAs within the p53 network, in contrast to most previous reports on
individual p53-regulated lncRNAs. We show that this regulation is largely in
the positive direction, suggesting that lncRNAs do not significantly
contribute to p53-mediated gene repression, and demonstrate that lncRNA
cis-regulation can be important for p53-dependent growth arrest in certain
tumor contexts.
Altogether, this work provides novel insights into the p53 response
across different cellular contexts and clarifies the contributions of lncRNAs
to the p53 tumor suppressor network. Namely, we propose that lncRNAs
primarily serve as an important fine-tuning regulatory mechanism. As such,
this work has broader implications on the mechanisms by which lncRNAs as
a class may influence other complex transcriptional networks important in
human health and disease.
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Chapter 1: Background
Long noncoding RNAs and the p53 tumor suppressor network

Sifting through the “junk”
One of the most surprising revelations of the early 21st century, aided by the
advent of modern genomics, was the prodigious amount of transcription present
in the mammalian genome. The discovery that as much as 75% of the human
genome is transcribed, despite less than 2% of it encoding for proteins, challenged
the traditionally held view that in the flow of genetic information, RNAs primarily
serve as intermediary messengers for dictating protein production (with a few
important regulatory exceptions) (Djebali et al. 2012; Rinn and Chang 2012). One
interpretation of this unexpected abundance of expressed RNAs is that many of
these transcripts represent non-functional transcriptional noise, conceptually
progressing from “junk DNA” to “junk RNA.” However, a growing body of work
suggests that noncoding RNAs (ncRNAs) of many different classes can contribute
to biology in important, versatile ways that are continuously being expanded upon.
Long noncoding RNAs (lncRNAs) are one class of ncRNAs, defined by
two simple criteria: a length exceeding 200 nucleotides and a lack of protein coding
potential, as determined by various bioinformatic and/or experimental strategies
(Mercer et al. 2009; Rinn and Chang 2012). LncRNAs have garnered much interest
in recent years, in part due to the sheer number of lncRNA transcripts that have
been uncovered in the human and mouse transcriptomes. According to NONCODE
1

v5 (2018), which is an integrated database of published ncRNA datasets, the
human genome could contain as many as 95,000 lncRNA genes, corresponding to
roughly 170,000 transcripts, while the mouse genome encodes around 90,000
lncRNA genes, producing roughly 130,000 transcripts (Fang et al. 2018). Thus, in
both humans and mice, the number of lncRNA genes and transcripts greatly
surpasses the number of protein coding genes and mRNAs.
Furthermore, transcriptome profiling studies have shown that many
lncRNAs have expression patterns that correlate with specific cell- or tissue-types,
biological processes, or disease states (Cabili et al. 2011; Rinn and Chang 2012; Iyer
et al. 2015; Hung et al. 2011; Guttman et al. 2009). While these associations are
tantalizing, determining whether they reflect functionality remains a massive ongoing endeavor. Encouragingly, large scale efforts to tackle this question on a
genome-wide scale have suggested that dozens, if not hundreds of lncRNA loci
could contribute to essential cellular processes (Liu et al. 2017). Additionally,
several recent studies have revealed important roles for a myriad of individual
lncRNAs, including in cell cycle regulation (Dimitrova et al. 2014; Marín-Béjar et
al. 2013; Marchese et al. 2016), genome maintenance (Lee et al. 2016; Hu et al.
2018), pluripotency (Loewer et al. 2010; Jain et al. 2016), genomic imprinting
(Mancini-Dinardo et al. 2006; Latos et al. 2012), nuclear organization (Sunwoo et
al. 2009; Hacisuleyman et al. 2014; Chen et al. 2016), cell death and survival (Hung
et al. 2011; Li et al. 2017; Chaudhary et al. 2017), differentiation (Kretz et al. 2013;
Yin et al. 2015; Ritter et al. 2019), and immune signaling (Petermann et al. 2019;
Mineo et al. 2020), to name a few examples [also reviewed more extensively in
(Fatica and Bozzoni 2014; Yao et al. 2019)]. However, the rate of lncRNA detection
2

has far out-stripped the rate of lncRNA characterization, leaving the question of
whether this ever-expanding catalogue of lncRNA transcripts consists mostly of
functional “wheat” or biologically insignificant “chaff” an important unanswered
question.

Modes of lncRNA function
LncRNAs greatly increase the complexity of the mammalian genome and
can be expressed from a multitude of genic configurations, including overlapping,
sharing promoters with, or being entirely enclosed within other genes. LncRNAs
can also be expressed from regulatory DNA or noncoding portions of coding
regions, such as promoters, enhancers, and introns (Rinn and Chang 2012) (Fig.
1A). Thus, lncRNAs are highly heterogenous at the level of genomic anatomy as
well as function. Despite this frequent complexity in gene structure, the biogenesis
of most lncRNAs closely resembles that of mRNAs, though this may also be a
reflection of a sequencing-based sampling bias towards the detection of
polyadenylated transcripts (Uszczynska-Ratajczak et al. 2018). Nonetheless, most
identified lncRNA transcripts are produced by RNA polymerase II and are capped,
spliced, and polyadenylated. LncRNAs are, however, in general less efficiently
spliced, less abundant, and less conserved at the primary sequence level than
mRNAs (Derrien et al. 2012; Quinn and Chang 2015), and lncRNA examples with
exceptional processing do exist [e.g. unique 3’ end processing (Wilusz et al. 2012;
Yang et al. 2011a), circularization (Li et al. 2018)].

3

So, what do lncRNAs do, and how do they do it? Perhaps unsurprisingly, it
is impossible to productively answer this question with a single answer, in part due
to the inclusive definition of a lncRNA. While this definition is useful for
distinguishing lncRNAs from protein coding genes and other small regulatory
ncRNAs with well-defined functions (e.g. microRNAs, tRNAs, snRNAs), it is less
helpful in guiding the study of lncRNAs themselves (Rinn and Chang 2012).
However, regardless of the inherent heterogeneity of lncRNAs as a class, all
lncRNAs are fundamentally large RNA molecules. Accordingly, it is predicted that
any lncRNA functions are principally mediated through the formation of complex,
modular RNA structures that interact with other molecules (e.g. protein, RNA,
DNA) in versatile, combinatorial ways (Goff and Rinn 2015) (Fig. 1B).
One way to further classify lncRNAs is based on where in the cell a lncRNA
transcript is normally found. A broad but conceptually useful distinction is
between nuclear and cytoplasmic lncRNAs. This is because lncRNA localization
patterns can vary greatly and have important implications on feasible functions.
Most lncRNAs are nuclear-enriched (Derrien et al. 2012; Cabili et al. 2015), but
many lncRNAs are also found in the cytoplasm. Cytoplasmic lncRNAs have been
reported to play a variety of roles, many related to post-transcriptional gene
regulation. Examples of this include binding to and competing away microRNAs
from target mRNAs (Chen et al. 2015; Faghihi et al. 2010; Hu et al. 2018), serving
as microRNA precursors (Keniry et al. 2012), and directly influencing mRNA
stability (Kretz et al. 2013; Gong and Maquat 2011) or translation (Carrieri et al.
2012; Zhang et al. 2013a) through specific RNA-protein interactions. Nuclear

4

lncRNAs have been linked to regulating gene expression through a variety of
mechanisms, discussed further below.
LncRNAs can also be categorized according to broad modes of action. While
such classifications cannot be made a priori functional interrogation of a lncRNA
locus, limiting their usefulness in predicting lncRNA function, they can prove
helpful in elucidating patterns of function that subsequently expand our
understanding of the various ways lncRNAs can contribute to biology. One such
distinction is between lncRNAs that act near their site of transcription, or in cis,
versus those that exert a function elsewhere, deemed trans-acting lncRNAs (Sun
et al. 2018; Gil and Ulitsky 2020). While cytoplasmic lncRNAs are trans-acting by
definition, nuclear lncRNAs can function in either cis or trans to regulate gene
expression (Sun et al. 2018) (Fig. 1B). Many well-characterized lncRNAs fall into
the category of nuclear, cis-acting lncRNAs and have served as useful paradigms
for how lncRNAs in the nucleus may function.

5

Figure 1: LncRNAs are highly heterogenous but can be grouped by gene structure
and/or broad regulatory modes of action. (A) Examples of the various genomic
architectures lncRNA loci can exhibit. LncRNA genes are often categorized by their relationship to
nearby (intergenic, bidirectional) or overlapping (antisense, sense, intronic) protein coding genes
or regulatory DNA elements (promoters, enhancers). (B) LncRNAs can also be categorized by
modes of action, whether acting locally (cis) or distally (trans) from their sites of transcription to
influence gene expression. Both cis-acting and trans-acting lncRNAs are thought to fundamentally

6

function through the formation of RNA-protein, RNA-RNA, and/or RNA-DNA interactions. TF=
transcription factor. RBP= RNA binding protein.

One important example is XIST (X-Inactive Specific Transcript), which is
amongst one of the first lncRNAs described (Brown et al. 1991). XIST plays a
central role in orchestrating dosage compensation in mammals by driving the
heterochromatinization of one of the two X chromosomes present in females in a
process called X chromosome inactivation (XCI) (Sahakyan et al. 2018). XIST
establishes XCI through multiple mechanisms involving specific interactions
between XIST RNA and various protein complexes. Several chromatin modifying
complexes interact with XIST, including PRC2 (Polycomb Repressive Complex 2)
and SHARP (SMRT- and HDAC-Associated Repressor Protein), and contribute to
epigenetically silencing the chromosome XIST is expressed from (Loda and Heard
2019). In addition to facilitating epigenetic regulation, XIST also promotes cis
repression by interacting with nuclear matrix components to recruit the silenced
X chromosome to the transcriptionally repressive nuclear laminar compartment
(Loda and Heard 2019; Chen et al. 2016). Thus, XIST is able to regulate gene
expression in cis through recruiting and/or otherwise interacting with proteins
that modulate gene expression. Though XIST is unique in its ability to drive
chromosome-wide gene repression, this basic mechanism is broadly applicable to
many nuclear acting lncRNAs, including lncRNAs that act in cis to activate gene
expression (Werner et al. 2017; Gil and Ulitsky 2020), as well as those that regulate
gene expression in trans.

7

Nuclear lncRNAs are uniquely poised to regulate gene regulation, as
illustrated by XIST’s localization being intrinsically linked to its function in
organizing XCI. The lncRNA Airn (Antisense Igf2r ncRNA) is another well-studied
example of lncRNA-mediated cis regulation that drives this point home further.
Airn is expressed from the Igf2r imprinted cluster and is important for the
paternal imprinting of several protein coding genes in this locus, which Airn
accomplishes through multiple mechanisms (Quinn and Chang 2015). Airn is
oriented antisense to and overlapping Igf2r. The act of Airn being transcribed
through Igf2r’s promoter is sufficient to repress Igf2r expression via
transcriptional interference, strongly suggesting that Airn RNA is unlikely to be
important for the silencing of Igf2r (Latos et al. 2012). Thus, Airn exemplifies one
RNA-independent mechanism by which lncRNA loci can still exert cis-regulation:
lncRNA biogenesis. However, Airn RNA may be important for silencing other
genes in the Igf2r imprinted cluster, illustrating the potential multifunctionality of
lncRNA loci. One proposed model for the silencing of Slc22a3, located upstream
of Airn in the same cluster, is that Airn promotes epigenetic silencing through the
recruitment of the H3K9 histone methyltransferase G9a (Nagano et al. 2008).
Therefore, by virtue of both its genomic architecture and localization, the Airn
lncRNA locus is able to modulate local gene expression in both RNA moleculedependent and RNA molecule-independent ways.
It is important to note that these broad modes of lncRNA locus-mediated
cis-regulation are not restricted to gene silencing, and have in fact been more
widely described for lncRNA loci that positively influence the expression of their
neighboring genes (Anderson et al. 2016; Engreitz et al. 2016; Werner et al. 2017;
8

Joung et al. 2017; Gil and Ulitsky 2020). Thus, there is a growing appreciation for
the unique ability of nuclear lncRNAs to enact local gene regulation. Less clear is
the broader impacts of lncRNA-mediated cis-regulation on gene regulatory
networks as a whole, and, ultimately, how important lncRNA cis-regulation is for
the myriad of biological processes lncRNAs have been implicated in.

LncRNAs in cancer
Historically, efforts to elucidate the molecular mechanisms underlying
cancer pathogenesis have focused on genetic and epigenetic alterations in proteincoding genes. However, several pieces of evidence suggest that lncRNAs may also
be important contributors, discussed below and also recently reviewed in (Olivero
and Dimitrova 2020).
First, many lncRNA genes have been found to associate with diseaseassociated genomic alterations, including single nucleotide polymorphisms (SNPs)
and copy number variations (CNVs). One comparison of over 900 GWAS
(Genome-Wide Association Studies) revealed that more than 90% of diseaseassociated SNPs fall within noncoding regions (Maurano et al. 2012), though this
is to some degree expected given the predominance of noncoding regions in the
human genome. Nevertheless, multiple recent efforts to characterize noncoding
transcription across the human genome have found that genomic regions encoding
lncRNAs are enriched for trait-associated SNPs over background intergenic
regions (Hangauer et al. 2013; Iyer et al. 2015). These observations suggest a
possible link between lncRNA loci and disease-associated SNPs, though the
significance of most of these associations remains to be determined.
9

A few examples of cancer-associated SNPs connected to lncRNA expression
have been described. One such lncRNA locus is NBAT1 (Neuroblastoma
Associated Transcript 1), in which a germline SNP located in NBAT1’s second
intron is associated with high risk neuroblastoma and correlated with NBAT1
expression (Pandey et al. 2014). Another example is the lncRNA ANRIL (Antisense
Noncoding RNA in the INK4 Locus; also known as CDKN2B-AS), which is
transcribed antisense to the CDKN2A/B locus (encoding the tumor suppressive
proteins ARF, CDKN2A, and CDKN2B) (Kong et al. 2018). This complex locus
harbors several cancer risk-associated SNPs, some of which interestingly associate
with ANRIL expression levels, but not with those of its overlapping protein coding
genes (Cunnington et al. 2010). As ANRIL expression is increased in many
different cancers and associated with aggressive disease (Kong et al. 2018),
exploring the ways these variants influence the regulation of this locus could be
informative as a model for how such cancer-associated SNPs may mechanistically
contribute to pathophysiology.
Cancer genomes are marked by genomic instability and frequently undergo
amplifications or deletions leading to somatic CNVs (SCNVs) that can contribute
further to malignancy. Common alterations in cancer cells include amplifications
of oncogenes, such as MYC, and loss of tumor suppressor genes, such as those
encoded by the CDKN2A/B locus (Beroukhim et al. 2010). Several lncRNAs have
also been observed to exhibit SCNVs linked to tumorigenesis (Huarte 2015; Hu et
al. 2014). LncRNA FAL1 (Focally Amplified lncRNA on Chromosome 1) was
identified as one of nearly 3,000 lncRNA loci frequently exhibiting copy number
alterations across thousands of patient tumor samples and is overamplified in
10

multiple cancers. Moreover, shRNA knockdown of lncRNA FAL1 was shown to
restrict proliferation in vitro and restrict tumor growth in xenograft experiments
in vivo, demonstrating the oncogenic consequences of overamplifying this lncRNA
(Hu et al. 2014).
PVT1 (Plasmacytoma Variant Translocation 1) is another lncRNA locus
that is frequently over-amplified in cancer, most often with its nearest neighbor,
the proto-oncogene MYC, which is located 70 kb upstream (Guan et al. 2007;
Tseng et al. 2014). In one study, addition of a single extra copy of the genomic
region spanning and including PVT1 and MYC but not MYC alone was shown to
promote tumorigenesis in a breast cancer mouse model, whereas deleting the
entire 300 kb PVT1-MYC locus in HCT116 cells reduced cellular proliferation and
xenograft tumor growth (Tseng et al. 2014), suggesting that PVT1 cooperates with
MYC to drive cancer. However, the complexity of this locus, which includes several
regulatory DNA elements (Cho et al. 2018; Fulco et al. 2016) and multiple RNA
isoforms of PVT1 (Olivero et al. 2020), make it somewhat difficult to interpret
these data and say whether amplification of PVT1 RNA outright drives or
suppresses tumorigenesis. It is likely that both tumor suppressive and oncogenic
mechanisms are at play at this lncRNA locus.
Lastly, it has long been appreciated that lncRNA expression patterns are
often associated with many biological phenomena and/or cellular states. In one
recent comprehensive analysis of over 7,000 RNA-seq datasets, spanning 27
distinct human tissues and cancer states, nearly 60,000 human lncRNAs were
identified. Of these lncRNAs, over 10,000 were found to be significantly
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dysregulated (i.e. downregulated or upregulated) in various cancers compared to
matched normal tissues. Furthermore, the authors were able to segregate cancers
of similar tissues of origin by their lncRNA expression patterns, further
demonstrating the exquisite disease-specificity lncRNAs can have (Iyer et al.
2015). In some cases, lncRNA expression patterns can further be associated with
specific features of cancer prognosis, such as recurrence (Zhou et al. 2018),
metastasis (Ji et al. 2003), invasiveness (Lim et al. 2020), and overall survival
(Gupta et al. 2010; Lim et al. 2020).

Functional studies of cancer-associated lncRNAs
Despite these key observations, the broader role of lncRNAs in cancer
remains poorly understood, primarily due to fact that the majority of these cancerassociated lncRNAs have not yet been functionally dissected using robust loss-offunction (LOF) and gain-of-function (GOF) models. Whether lncRNA expression
patterns

are

the

drivers

or

transcriptional

by-products

of

oncogenic

transformation remains an open-ended question in the field (Olivero and
Dimitrova 2020). Still, a handful of lncRNAs have been suggested to functionally
contribute to cancer development, demonstrating the value of careful case-by-case
interrogation of lncRNA loci. The following is a discussion of three illustrative
examples.
One well-studied example is MALAT1 (Metastasis Associated Lung
Adenocarcinoma Transcript 1). MALAT1 is a highly abundant, conserved lncRNA
that was initially identified in a screen for potential biomarkers for metastatic lung
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cancer, in which high MALAT1 expression was found to be highly predictive of
metastasis and overall poor prognosis in non-small cell lung cancer (NSCLC)
patients (Ji et al. 2003). MALAT1 has since been observed to be upregulated in
many human cancers and has been at the center of efforts to understand the ways
in which lncRNAs can contribute to tumorigenesis [reviewed in (Zhang et al.
2017)]. Early investigations into Malat1 function using mouse models of lung and
breast cancer revealed that exogenous overexpression of Malat1 led to increased
tumor

growth

and

metastasis,

whereas

Malat1

loss

[using

antisense

oligonucleotides (ASOs) or promoter deletion strategies (Zhang et al. 2012)]
impaired these processes (Gutschner et al. 2013; Arun et al. 2016). These data
provided some of the earliest functional evidence for a lncRNA directly influencing
tumorigenesis in vivo. However, in more recent work, Malat1 knockout was shown
to promote metastasis in the same murine breast cancer model. Even more
remarkably, this pro-metastasis phenotype was rescued in a targeted Malat1
overexpression transgenic mouse, suggesting a provocative tumor suppressive role
for this lncRNA (Kim et al. 2018). Notably, this latter study used a different genetic
model for Malat1 knockout, in which a LacZ and synthetic polyadenylation signal
(LacZ+PAS) cassette was inserted roughly 100 bp downstream of Malat1’s
endogenous transcription start site (TSS), leading to premature transcriptional
termination of Malat1-Lacz without disrupting Malat1’s promoter. However, it is
not immediately apparent why these two genetic Malat1 LOF models would yield
completely opposing phenotypes.
Mechanistically, Malat1 localizes to nuclear speckles (Tripathi et al. 2010),
where various roles in regulating transcription have been proposed. These include
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modulating alternative splicing through interactions with splicing factors (Tripathi
et al. 2010) and interacting with chromatin modifying complexes to promote the
relocalization of genes from transcriptionally repressive to transcriptionally active
nuclear bodies (Yang et al. 2011b). Moreover, mapping the genomic binding sites
of MALAT1 RNA in human breast cancer cells using capture hybridization analysis
of RNA targets (CHART) revealed that MALAT1 associates with sites of active
transcription (West et al. 2014). Thus, while Malat1’s exact cellular functions
remain unclear, it is likely that Malat1 acts as a nuclear RNA scaffold to coordinate
gene expression, possibly in a tissue or otherwise context-specific manner. Equally
unresolved is the precise role of Malat1 in tumorigenesis, perhaps in part due to
this functional context-specificity.
The lncRNA HOTAIR (HOX Transcript Antisense RNA) is another wellstudied transcript with altered expression across several cancers compared to
normal tissues (Iyer et al. 2015; Kogo et al. 2011; Gupta et al. 2010). HOTAIR was
initially found in a search for ncRNAs contributing to the temporal and spatial
collinearity of vertebrate HOX gene expression and is expressed antisense to the
HOXC gene cluster (Rinn et al. 2007). Similar to MALAT1, the molecular details of
HOTAIR function remain incompletely understood, despite clear associations
between HOTAIR expression and cancer. Early siRNA knockdown experiments
and in vitro RNA pull down assays suggested that HOTAIR functions in trans to
direct the localization of repressive chromatin modifying complexes (i.e. PRC2 and
CoREST), leading to the epigenetic silencing of genes in the distally located HOXD
cluster and elsewhere in the genome (Rinn et al. 2007; Tsai et al. 2010). HOTAIR
has thus been proposed to contribute to tumorigenesis through driving aberrant
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epigenetic alterations, and indeed high HOTAIR expression correlates with
aggressive disease and/or poor prognosis in colorectal and breast cancers (Kogo et
al. 2011; Gupta et al. 2010). Furthermore, exogenous overexpression of HOTAIR
in murine breast cancer cells was shown to drive the metastatic potential of these
cells in xenograft experiments and lead to global gene dysregulation, possibly
through PRC2 (Gupta et al. 2010). However, more recent work has called into
question the specificity of this proposed lncRNA-PRC2 interaction (Davidovich et
al. 2013), or its necessity for HOTAIR’s ability to drive transcriptional repression
(Portoso et al. 2017).
Genetic dissections of HOTAIR function have also proven perplexing. In
one mouse model in which murine Hotair had been deleted, HoxD gene
derepression

and

apparent

homeotic

transformations

consistent

with

dysregulated HoxD expression were observed (Li et al. 2013). This remarkable
phenotype starkly contrasted with the essentially unchanged HoxD expression
patterns observed in a second knockout mouse in which the entire HoxC cluster,
including Hotair, had been ablated (Schorderet and Duboule 2011). Further
characterization of these and additional Hotair knockout alleles (Lai et al. 2015)
conclusively demonstrated that Hotair loss does not significantly affect mouse
development or HoxD expression (Amândio et al. 2016). Nonetheless, these data
suggesting the dispensability of Hotair in normal development do not preclude the
possibility of HOTAIR dysregulation contributing to tumorigenesis, either through
PRC2-linked epigenetic dysregulation or through other yet-to-be uncovered
mechanisms.
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One additional, well-studied lncRNA with ties to cancer is XIST.
Correlative links between defects in XCI and cancer development have long been
noted, such as the loss of Barr bodies seen in some advanced breast and ovarian
cancers (Pageau et al. 2007). However, it wasn’t until the development of a
conditional knockout mouse in which XIST was deleted in hematopoietic
progenitor cells during embryogenesis, but after the establishment of XCI, that a
direct link between XIST-mediated dosage compensation and tumor suppression
was demonstrated in vivo. In these mice, hematopoietic XIST depletion leads to
global gene dysregulation, including notable X-linked gene reactivation, and the
rapid onset of female-specific hematologic cancer with 100% penetrance (Yildirim
et al. 2013). The potential significance of aberrant XCI in other cancers remains to
be seen.
In summary, several lines of evidence suggest that lncRNAs may contribute
to cancer-related processes, in both oncogenic and tumor suppressive capacities.
However, the number of lncRNAs demonstrated to be important in modulating
tumorigenesis remains only a small fraction of the thousands of lncRNA
transcripts that are expressed in the human and mouse transcriptomes (Iyer et al.
2015; Djebali et al. 2012). More careful in vitro and in vivo dissections of candidate
cancer-associated lncRNAs will be needed to determine whether correlative links
to disease reflect true functional involvement, and ideally, opportunities for
therapeutic intervention.
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The p53 tumor suppressor pathway
One approach to find functional lncRNAs involved in cancer that our group
and others have adopted has been to look for lncRNAs regulated by key oncogenes
[e.g. Myc (Kim et al. 2015; Marchese et al. 2016)] or tumor suppressors, such as
p53 (reviewed below).
p53, encoded by the TP53 gene in humans and Trp53 in mice, is an
important tumor suppressor in the mammalian genome. One commonly used
moniker for p53 is the “guardian of the genome,” due to its central role in sensing
and responding to various cellular stressors (Kastenhuber and Lowe 2017;
Vousden and Prives 2009). Mice deficient for p53 (Trp53-/- or Trp53+/-) are
significantly more prone to spontaneous tumorigenesis (Donehower et al. 1992;
Jacks et al. 1994), and human patients with germline mutations in TP53 suffer Li
Fraumeni Syndrome, which is a disease marked by dramatically increased
susceptibility to a broad spectrum of cancers (Olivier et al. 2010). Furthermore,
p53 is the most frequently somatically mutated gene in human cancer and p53 loss
is often associated with poor clinical indicators, such as advanced tumor grade and
decreased survival (Kandoth et al. 2013).
Key to p53’s tumor suppression is its function as a stress-stabilized
transcription factor (Brady et al. 2011; Kaiser and Attardi 2018), though
transcription-independent roles for cytosolic p53 in regulating mitochondrial
permeabilization and apoptosis have also been observed (Speidel 2010). Indeed,
most p53 mutations that arise in cancer are missense mutations that fall within
p53 protein’s DNA binding domain (Kastenhuber and Lowe 2017), further
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suggesting that the ability of p53 to bind to and regulate target genes is needed for
tumor suppression. In unstressed cells, p53 protein is constitutively expressed but
rapidly degraded. However, upon exposure to various types of stress (e.g. DNA
damage, oncogene activation, hypoxia, nutrient-starvation), p53 protein
accumulates. This is primarily due to the acquisition of post-translational
modifications that disrupt interactions with its main negative regulator, Mdm2
(Mouse double minute 2), which is an E3 ubiquitin ligase that promotes the
proteasomal degradation of p53. The activation of ARF (Alternate Reading Frame
of CDKN2A; also known as p14 in humans and p19 in mice) in response to
oncogenic signaling is another central mechanism by which p53 protein is
stabilized, as ARF binds to Mdm2 and further inhibits Mdm2-p53 interactions
(Horn and Vousden 2007). Once stabilized, p53 transcriptionally regulates a wide
network of genes by binding to specific DNA motifs known as p53 response
elements (p53REs) found in the promoters or gene bodies of targets (Riley et al.
2008).
Activation of the p53 transcriptional network by stress can lead to a myriad
of cellular outcomes and can paradoxically promote both survival and death,
depending on various context-specific factors that are still incompletely
understood. A non-exhaustive list of biological processes in which p53 has been
implicated includes the so-called “canonical” p53 responses of apoptosis and cell
cycle arrest, as well as more recently discovered roles in regulating autophagy,
cellular metabolism, pluripotency, DNA repair, ferroptosis, and genome
maintenance, to name a few examples [reviewed in (Kaiser and Attardi 2018;
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Kruiswijk et al. 2015)]. Elucidating how the many different functions ascribed to
p53 synergize to culminate in tumor suppression is a major area of research.
Another unresolved question related to the remarkable functional diversity of p53
is how this one transcription factor specifies so many different cellular outcomes,
or in other words, what are the molecular determinants of p53 cell fate decisionmaking? Perhaps unsurprisingly, decades of research have yet to uncover a single
universally-applicable answer to this question (Kastenhuber and Lowe 2017).
One setting this question has been explored in is comparing the p53
outcomes of senescence and apoptosis, which are two alternative, permanent ways
by which p53 limits aberrant growth to suppress tumorigenesis (Childs et al. 2014;
Kaiser and Attardi 2018). Apoptosis, or programmed cell death, can be triggered
by severe DNA damage (e.g. genotoxic compounds, irradiation) in many cell types,
but can also be preferentially initiated in certain cell types in a more stress-agnostic
manner (Lowe et al. 1993b; Ventura et al. 2007; Childs et al. 2014). In vivo,
apoptosis can suppress tumor growth through the physical elimination of tumor
cells (Ventura et al. 2007; Symonds et al. 1994). Senescence is a stable state of cell
cycle arrest that is morphologically, epigenetically, and metabolically distinct from
temporary or reversible cell cycle arrest (Campisi and d’Adda di Fagagna 2007).
Multiple stress stimuli can promote senescence, most of which are tied to DNA
damage signaling. For example, elevated levels of reactive oxygen species (ROS),
genotoxic compounds, and, in human cells, natural telomere shortening (leading
to what is referred to as “replicative senescence”) can all trigger senescence
(Muñoz-Espín and Serrano 2014). Persistent oncogenic signaling can also trigger
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senescence (sometimes referred to as “oncogene induced senescence” or OIS),
likely through the activation of similar DNA damage signaling pathways by
oncogene-driven defects in DNA replication or ROS production (Bartkova et al.
2006; Di Micco et al. 2006; Muñoz-Espín and Serrano 2014). Senescence can have
pleiotropic effects on tumorigenesis, at times promoting preneoplastic growth
(Krtolica et al. 2001) or triggering tumor-permissive immune suppression through
the secretion of a characteristic host of inflammatory molecules, extracellular
matrix components, and growth factors known as SASP (senescence-associated
secretory phenotype) (Ruhland et al. 2016; Muñoz-Espín and Serrano 2014). In
other situations, senescence can serve to restrict hyperproliferation (Ventura et al.
2007) or signal the immune clearance of tumor cells (Xue et al. 2007), contributing
to tumor suppression. Thus, apoptosis and senescence are two p53-regulated
cellular processes that are important for tumor suppression, though what factors
govern the initiation of one versus the other in any given situation are unclear.
Much effort has been exerted towards characterizing the p53 regulated
transcriptome, hoping to identify either a core set of universal p53 targets central
to tumor suppression or specific subsets of targets important for specific p53
functions (discussed more in Chapter 2). One early proposed model for how the
latter could come about was based on biochemical observations that p53 bound
with higher affinity to the promoters of target genes involved in cell cycle arrest
than those involved in apoptosis, suggesting that different thresholds of p53 levels
could lead to the preferential activation of either high or low affinity targets,
leading to cell cycle arrest or apoptosis, respectively (Weinberg et al. 2005; Hafner
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et al. 2019). However, this line of thinking has been thrown into question as an
increasing number of genome-wide analyses of p53-dependent gene regulation
show that p53 outcome-specificity does not correlate with the activation of protein
coding genes important for specific p53 functions (Fischer 2017; Andrysik et al.
2017; Verfaillie et al. 2016). For example, p21 (encoded by the gene Cdkn1a) and
Puma (encoded by Bbc3) are key mediators of p53-dependent cell cycle arrest
(Brugarolas et al. 1995) and apoptosis (Nakano and Vousden 2001), respectively.
However, both are consistently activated by p53 across many studies, irrespective
of cell type, stressor, or ultimate p53 outcome initiated (Fischer 2017). Thus, one
main take-away from these global analyses has been that p53 outcome-specificity
is most likely driven by many different mechanisms and contingent upon the type,
intensity, and/or duration of stress encountered, as well as by cell- or tissuespecific factors (Hafner et al. 2019).
Related to these context-specific determinants could be the activation of
individual p53 targets with context-specific functions. Such targets may be
overlooked in large-scale metanalyses of “universal” p53 targets due to either
tissue- or stressor-specific activation. While the first p53 targets identified were
protein coding genes, as our understanding of the breadth of the noncoding
genome grows, so too has our appreciation for the numerous noncoding genes
regulated by p53, first with the identification of microRNA targets of p53 (RaverShapira et al. 2007; Vousden and Prives 2009) and more recently, lncRNAs.
Elucidating how these newly emerging lncRNA targets fit into the broader p53
network is an important, on-going area of research.
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LncRNAs in the p53 pathway
Several recent studies have employed a variety of transcriptome profiling
techniques to identify p53-regulated lncRNAs, many of which will be discussed
shortly. Most focus has been spent on lncRNAs that are transcriptionally activated
by p53, though there is also some evidence for the repression of lncRNA loci by p53
having physiological importance. For example, lncPRESS1 (p53 Regulated and
Embryonic Stem cell Specific) is highly expressed in human embryonic stem cells
and repressed by p53 during differentiation (Jain et al. 2016). shRNA-mediated
knockdown of lncPRESS1 leads to loss of pluripotency and gene expression
changes consistent with differentiation (Jain et al. 2016), suggesting that
repression of lncPRESS1 may be an important aspect of p53’s general role in
restricting pluripotency (Li et al. 2012; Kastenhuber and Lowe 2017). Nonetheless,
most p53-regulated lncRNAs that have been shown to contribute to p53 pathway
function are transcriptionally activated by p53.
Below is a detailed catalogue of p53-activated lncRNAs, with a focus on
lncRNA examples for which evidence of direct regulation by p53 has been
experimentally provided (e.g. p53 binding at lncRNA associated p53REs, p53RE
reporter assays). A comprehensive summary of direct p53-activated lncRNAs can
also be found in Table 1.1.

Nuclear-acting p53-activated lncRNAs
Most p53-activated lncRNAs have been reported to play various roles in the
nucleus. LincRNA-p21 was amongst the earliest identified p53-activated
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lncRNAs, found to be upregulated in a p53-dependent manner in both genotoxic
and oncogenic stress conditions, and is named after its genomic proximity to p21,
located ~15 kb upstream in the mouse genome (Huarte et al. 2010). LincRNA-p21
is conserved, and early siRNA knockdown studies suggested trans-acting roles for
both mouse and human lincRNA-p21: driving global gene repression and
apoptosis in mouse embryonic fibroblasts (MEFs) and repressing translation in
Hela cells (Huarte et al. 2010; Yoon et al. 2012). However, subsequent experiments
using either a genetically engineered mouse in which the lincRNA-p21 promoter
had been deleted or ASO-mediated RNA knockdown suggested that lincRNA-p21
acts solely to promote p21 expression in cis and that the global changes in gene
expression observed upon lincRNA-p21 loss can be attributed to decreased p21
expression (Dimitrova et al. 2014). It is worth noting that this more limited, local
role for lincRNA-p21 is easier to reconcile with its low copy number per cell and
spatial restriction to its site of transcription in MEFs. However, it is conceivable
that human lincRNA-p21, which is exported into the cytoplasm, may have
additional roles.
Mechanism-wise, both lncRNA-mediated recruitment of hnRNP-K
(Dimitrova et al. 2014) and DNA regulatory elements in the lincRNA-p21 locus
(Groff et al. 2016) have been reported to contribute to the cis-activation of p21.
Importantly, MEFs in which lincRNA-p21 has been either genetically or cotranscriptionally depleted have a growth advantage (Dimitrova et al. 2014),
consistent with defects in the G1/S checkpoint, demonstrating the potential for
lncRNA locus-mediated cis-regulation to functionally contribute to p53-regulated
cellular processes.
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Pvt1b is a p53-induced isoform of Pvt1 and another lncRNA our group has
recently demonstrated to regulate gene expression in cis downstream of p53
activation. However, unlike lincRNA-p21’s reinforcing effect on p21 expression,
Pvt1b activation leads to the repression of Myc, located roughly 50 kb upstream in
mice. In MEFs and murine cancer cells, Pvt1b knockdown by ASOs or genetic
disruption of Pvt1b’s p53RE leads to Myc derepression and increased proliferation
in vitro. Most strikingly, in vivo targeting of Pvt1b’s p53RE leads to increased
tumor growth in an autochthonous mouse model of lung cancer, suggesting that
Pvt1b is an important lncRNA component of p53’s tumor suppressive
transcriptional program (Olivero et al. 2020). Precisely how lincRNA-p21 and
Pvt1b mediate positive and negative cis-regulation, respectively, remains
incompletely understood and is likely locus-specific, involving both RNAdependent and -independent mechanisms (Olivero et al. 2020; Cho et al. 2018;
Dimitrova et al. 2014; Groff et al. 2016).
PANDA (p21 Associated NcRNA DNA Damage Activated) was originally
identified in a tiling array screen for novel ncRNAs associated with cell cycle
regulation and is transcribed roughly 5 kb upstream of and antisense to CDKN1A
(p21) (Hung et al. 2011). In human fibroblasts, PANDA expression is induced by
both DNA damage and oncogenic stress (Hung et al. 2011; Puvvula et al. 2014).
Interestingly, PANDA does not seem to be conserved between humans and mice,
despite the syntenic conservation of other p53-regulated lncRNAs encoded in the
CDKN1A/Cdkln1a locus [e.g. LincRNA-p21, DINO (discussed below)]. PANDA has
been reported to play multiple nuclear roles following p53 activation, mediated
through interactions with transcription factors and chromatin modifying
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complexes. In human fibroblasts exposed to DNA damage, PANDA was observed
to limit DNA damage-induced apoptosis by sequestering the transcription factor
NF-YA (Hung et al. 2011).
In more recent work, PANDA was shown to regulate proliferation as well
through distinct, context-specific mechanisms. In unstressed, proliferating human
fibroblasts,

PANDA

interacts

with

hnRNP-U

(Heterogeneous

Nuclear

Ribonucleoprotein U) and BMI1 (BMI1 proto-oncogene, Polycomb Ring Finger),
which is a component of the repressive PRC1 complex. siRNA knockdown of
PANDA in unstressed cells led to the derepression of several genes involved in cell
cycle regulation and the onset of cellular arrest, suggesting that PANDA-hnRNPU-BMI1 interactions may be important for epigenetically silencing pro-arrest
genes (Puvvula et al. 2014). In senescent human fibroblasts, PANDA was observed
to interact with NF-YA and prevent NF-YA-mediated activation of proproliferation genes (Puvvula et al. 2014). Interestingly, either siRNA knockdown
of PANDA or dysregulation of NF-YA protein levels was sufficient to allow escape
from senescence, although p21 levels were also reduced by PANDA knockdown. As
p21 has a well-established role in promoting senescence (Serrano et al. 1997;
Campisi and d’Adda di Fagagna 2007), it is difficult to disentangle the
contributions of PANDA from this effect on p21 RNA. siRNAs have been previously
shown to be able to reduce lncRNA transcription at the chromatin (Stojic et al.
2016), posing the possibility that PANDA regulates p21 expression in cis (being
located only 5 kb downstream). However, it is important to note that Hung et al.
also used siRNAs to knockdown PANDA and did not see a concomitant effect on
p21 RNA levels. Thus, this discrepancy highlights the difficulties of interpreting
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siRNA experiments targeting nuclear lncRNAs. Unfortunately, genetic dissection
of the PANDA locus is currently lacking, making it impossible to determine
whether PANDA truly regulates p21 in cis during cellular stress, similar to
lincRNA-p21.
DINO (Damage Induced Noncoding) is a conserved lncRNA also expressed
from the CDKN1A/Cdkn1a locus. In humans, DINO is transcribed divergently
from the CDKN1A promoter, while mouse Dino is transcribed immediately
upstream of Cdkn1a on the same strand. Though induced by both genotoxic and
oncogenic stress, DINO levels are most drastically elevated in response to DNA
damage, reaching several hundred copies per cell in human fibroblasts treated with
Doxorubicin (Doxo) (Schmitt et al. 2016). Consequently, DINO has thus far been
best characterized in the context of the p53 response to acute DNA damage. In
Doxo-treated cells, DINO depletion by RNAi led to reduced p53 transcriptional
activity and impaired damage-induced cell cycle arrest, suggesting that DINO was
required for full activation of the p53 network. This contribution to p53’s
transcriptional activity was further supported by experiments demonstrating that
DINO directly interacts with and stabilizes p53 protein and that DINO RNA
localizes to the p53REs of several direct p53 targets, perhaps reflecting a role in
directing p53’s localization as well. Importantly, these data were further supported
by experiments performed in MEFs isolated from a Dino promoter deletion mouse.
Dino knockout MEFs treated with Doxo had less p53 protein, decreased p53
transactivity, and increased cellular proliferation, consistent with Dino expression
being important for robust p53 pathway function (Schmitt et al. 2016).
Intriguingly, DINO levels were recently shown to also influence p53 protein
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stability in primary human foreskin keratinocytes expressing viral oncogene
HPV16 E7 (Sharma and Munger 2020). Whether DINO regulates p53 levels during
oncogenic stress through mechanisms similar to or distinct from those employed
during the DNA damage response remains to be investigated.
Similar to DINO, PURPL (p53 Upregulated Regulator of p53 Levels) is a
p53-activated lncRNA that in turn regulates p53 levels. PURPL was identified by
RNA-seq as a nuclear-enriched, DNA damage-induced lncRNA in three human
colorectal cancer cell lines (Li et al. 2017). Either genetic disruption of a PURPLassociated p53RE in clonal HCT116 cells or ASO knockdown of PURPL in multiple
human colorectal cancer cell lines led to increased p53 protein levels (Li et al.
2017). These effects were observed both in the presence and absence of DNA
damage, suggesting PURPL may be important for maintaining appropriately low
levels of p53 in conditions of low stress. RNA pulldown and RNA
immunoprecipitation experiments demonstrated that PURPL interacts with
MYBBP1A and HuR, leading to the disruption of nucleoplasmic MYBBP1A-p53
protein interactions and subsequent p53 protein destabilization. Functionally,
PURPL loss was observed to decrease proliferation and increase apoptosis in vitro
and limit tumor growth in xenograft experiments in vivo, consistent with increased
p53 protein in the absence of PURPL (Li et al. 2017). Thus, PURPL is a p53activated lncRNA that negatively regulates p53 levels, perhaps to restrict improper
p53 pathway activation.
Linc-Pint (p53-Induced Transcript; also known as lincRNA-Mkln1) is a
nuclear-enriched intergenic lncRNA that was first identified as a direct p53 target
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induced by genotoxic and oncogenic stress in the same microarray profiling
experiment that uncovered lincRNA-p21 (Huarte et al. 2010; Marín-Béjar et al.
2013). Under conditions of genotoxic stress, ASO knockdown of linc-Pint in MEFs
and lung cancer cells led to decreased proliferation and increased apoptosis.
Moreover, exogenous overexpression of linc-pint from a retroviral transgene
rescued this phenotype, suggesting linc-pint acts in trans downstream of p53
activation to modulate growth and survival (Marín-Béjar et al. 2013). Mice in
which linc-Pint expression was ablated through a LacZ reporter knockin were
significantly smaller than controls, further suggesting a role for this lncRNA in
growth regulation (Sauvageau et al. 2013). Murine linc-Pint and human orthologue
LINC-PINT have both been reported to interact with PRC2 and regulate the
repression of gene networks related to proliferation, survival, and invasion (Khalil
et al. 2009; Marín-Béjar et al. 2013, 2017). In line with this, ASO knockdown of
LINC-PINT also increased proliferation in multiple human cancer cell lines, while
exogenous overexpression decreased proliferation and invasion in vitro and
decreased tumor growth and metastasis in vivo in xenograft and liver metastasis
mouse models, respectively (Marín-Béjar et al. 2017). Intriguingly, a short, highly
conserved region located within exon 2 of LINC-PINT was shown to be necessary
and sufficient for this anti-invasion phenotype in human colorectal cancer cells
(Marín-Béjar et al. 2017). However, these data must be considered in the context
of recent reports of an exon 2-encoded micropeptide with anti-proliferative effects
expressed from a circular isoform of LINC-PINT (Zhang et al. 2018). Nevertheless,
these studies suggest that the linc-Pint/LINC-PINT locus may play a tumor
suppressive role downstream of p53.
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NEAT1 (Nuclear Enriched Abundant Transcript 1) is a highly abundant,
conserved lncRNA and is best known as an integral architectural component of
nuclear paraspeckles. The functional role of Neat1 in these nuclear bodies is still
incompletely understood but likely related to the regulation of gene expression
(Sunwoo et al. 2009; Clemson et al. 2009; West et al. 2014). Neat1 knockout mice
are viable and develop largely normally, barring subtle defects in mammary gland
and corpus luteum development (Nakagawa et al. 2011; Standaert et al. 2014;
Nakagawa et al. 2014). These data suggest that Neat1 and/or paraspeckles may not
be functionally important under normal physiological conditions but do not
preclude their importance during stress.
In support of this hypothesis, Neat1/NEAT1 is a direct target of p53 and is
induced by DNA damage in multiple mouse and human primary and transformed
cell lines (Mello et al. 2017; Adriaens et al. 2016). In one study, Neat1 knockout
mice were observed to be resistant to carcinogen-induced skin cancer and skin
keratinocytes in carcinogen-exposed knockout mice were seen to proliferate more
slowly than WT controls. These data suggest that Neat1 acts as an oncogene in this
context, likely by preventing the accumulation of DNA damage that would lead to
p53 stabilization and tumor cell death in WT mice (Adriaens et al. 2016). Tumor
suppressive functions have also been ascribed to Neat1 post-p53 activation. In
MEFs expressing the oncogenes E1A and HRasV12, Neat1 knockout promoted
cellular transformation, while exogenous overexpression of Neat1 decreased
transformation, similar to the effects of p53 loss and overexpression in these cells,
respectively (Mello et al. 2017). Neat1 loss also promoted in vivo pancreatic cancer
initiation in a genetically engineered mouse model of pancreatic ductal
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adenocarcinoma, further suggesting that Neat1 may be an important downstream
mediator of p53 tumor suppression in some settings (Mello et al. 2017). Thus, like
many lncRNAs, the contributions of Neat1 to stress responses downstream of p53
activation are likely to be context-specific.
TUG1 (Taurine Upregulated Gene 1) was originally characterized as a
regulator of retinal development (Young et al. 2005) but has since been linked to
many biological processes, including tumorigenesis. TUG1 has been reported to
regulate gene expression through multiple mechanisms, including sponging
miRNAs (Zhou et al. 2019) and recruiting repressive chromatin modifying
complexes to genomic loci (Khalil et al. 2009; Zhang et al. 2014; Zhou et al. 2019).
Within the p53 network, TUG1 is activated by p53 under conditions of genotoxic
stress in multiple primary and transformed cell lines (Guttman et al. 2009; Zhang
et al. 2014). RNAi knockdown of TUG1 in human NSCLC cells led to increased
proliferation in vitro and increased tumor growth in xenograft mouse experiments,
possibly through the epigenetic derepression of HOXB7 (Zhang et al. 2014). While
these data suggest that TUG1 plays a tumor suppressive role downstream of p53 in
these cells, it is important to note that both oncogenic and tumor suppressive roles
have been observed for this lncRNA in other human cancer cell lines (Zhou et al.
2019), suggesting that TUG1 function may be highly context-specific. TUG1 is
conserved in mice as well, and interestingly, a LacZ replacement Tug1 knockout
mouse was shown to have impaired spermatogenesis with no other obvious gross
morphological defects (Lewandowski et al. 2020; Sauvageau et al. 2013), though it
is difficult to say whether this spermatogenesis phenotype stemmed from the loss
of Tug1 expression or the genetic disruption of its neighboring gene, Morc2a, with
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which Tug1 shares a promoter. Nevertheless, this study illuminated the complexity
of the Tug1 genomic locus, which was revealed to contain previously unappreciated
cis-regulatory DNA elements and a conserved, expressed micropeptide
(Lewandowski et al. 2020). Employing similar genetic strategies in the context of
cellular stress will shed further light on the ways these trans- and cis-acting
components of the Tug1/TUG1 locus contribute to cellular processes within the
p53 pathway and beyond.
A recent genome-wide assessment of HCT116 cells treated with DNA
damage identified several p53-regulated (PR) lncRNAs, including two that were
further characterized and named PR-lncRNA 1 and PR-lncRNA 10 (Sánchez et
al. 2014). Both PR-lncRNAs were shown to be required for robust p53 transactivity
in response to genotoxic stress, as ASO knockdown of either led to decreased
induction of several p53 targets. Consistent with decreased p53 activity, PRlncRNA depleted HCT116 cells grew more quickly and were more resistant to DNA
damage-induced apoptosis (Sánchez et al. 2014). The mechanisms by which these
two lncRNAs regulate p53 activity are still unclear, though it is worth noting that
our own closer examination of PR-lncRNA 1’s sequence revealed the presence of
two highly conserved sORFs, one conserved amongst primates and a second
conserved through mice at both the amino acid and nucleotide levels. This raises
the possibility of PR-lncRNA 1 representing a micropeptide-encoding lncRNA, as
has been described at the Tug1 locus and other lncRNA loci (Lewandowski et al.
2020; Anderson et al. 2015; Zhang et al. 2018). The development of additional,
genetic LOF models could greatly facilitate addressing this and other questions
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regarding how these lncRNA loci contribute to p53 pathway function, as well as
directly test their importance in tumor suppression.
In addition to binding to promoters and gene bodies, p53 also frequently
associates with enhancers (Melo et al. 2013; Allen et al. 2014; Younger et al. 2015).
This enhancer binding activity can be important for modulating the expression of
distally located protein coding and lncRNA genes (Melo et al. 2013, 2016). Linc475 is one lncRNA regulated by a p53 bound enhancer and is induced by genotoxic
stress in human breast cancer and melanoma cell lines. Both siRNAs and CRISPRCas9 deletion of the p53 bound enhancer element in clonal MCF7 cells led to
depleted linc-475 levels and cell cycle defects that could be attributed to decreased
p21 levels (Melo et al. 2016). Further experiments demonstrated that less RNA Pol
II and p53 were present at p21’s promoter in the absence of linc-475, suggesting
that this lncRNA is important for optimal p21 induction, and subsequently a robust
cell cycle arrest response to DNA damage. How linc-475 exerts this apparent trans
nuclear function is unclear.
LED (LncRNA Activator of Enhancer Domains) is another lncRNA
associated with p53 activity at enhancers. LED is activated by DNA damage in a
p53-dependent manner in multiple human cancer cell lines (Léveillé et al. 2015;
Allen et al. 2014). siRNA knockdown of LED in MCF7 cells led to the dysregulation
of hundreds of genes and increased proliferation. This could be explained in part
by significantly less p21 levels in LED depleted cells. In a transcriptional reporter
assay, LED knockdown was shown to decrease the transcriptional activity of a p53
bound enhancer associated with p21, suggesting that LED promoted p21
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expression by affecting the activity of this p53 bound enhancer, possibly through
regulating H3K9 acetylation (Léveillé et al. 2015). As LED RNA also associated
with hundreds of sites in the human genome and LED knockdown correlated with
decreased enhancer RNA (eRNA) production from several other p53-responsive
enhancers, LED seems to be an important lncRNA mediator of p53-dependent
enhancer activation through yet-to-be fully fleshed out mechanisms (Léveillé et al.
2015). Interestingly, LED’s promoter is often hypermethylated in cancer,
particularly in acute lymphocytic leukemia, suggesting

that epigenetic

dysregulation of this lncRNA is associated with disease (Léveillé et al. 2015).
PINCR (p53-Induced Noncoding RNA) is another lncRNA directly
activated by p53 and linked to enhancer activity (Chaudhary et al. 2017). PINCR
was identified as a lncRNA induced by DNA damage in a panel of human colorectal
cancer cell lines, and ASO knockdown or genetic PINCR knockout in clonal cell
lines was observed to sensitize cells to stress-induced apoptosis. Interestingly,
exogenous overexpression of PINCR was able to partially rescue this phenotype,
suggesting a trans-acting mechanism for PINCR. Transcriptomic analysis revealed
that PINCR depletion impaired the DNA damage-dependent induction of several
p53 target genes involved in cell cycle arrest and survival. Mechanistic studies
revealed that PINCR interacts with nuclear matrix component Matrin 3, likely
facilitated by six Matrin 3 binding motifs present in PINCR RNA, and that PINCRMatrin 3 interactions were important for p53 binding to enhancers associated with
three tested p53 target genes (Chaudhary et al. 2017). Thus, PINCR appears to act
as an RNA scaffold to facilitate interactions between some p53 regulated genes and
distal enhancers during the p53 response to DNA damage. How pervasive this
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transcriptional co-activator role is throughout the genome or its importance in
other biological contexts remains an interesting open-ended question.

Cytoplasmic-acting p53-activated lncRNAs
Given that most p53-regulated lncRNAs identified thus far are
predominantly nuclear localized and appear to exert nuclear functions, less is
known about the role(s) p53-activated lncRNAs play in the cytoplasm. Below are
two examples for which we have some mechanistic understanding.
GUARDIN is a lncRNA activated by p53 during the DNA damage response
and has been implicated in modulating p53’s genome maintenance functions (Hu
et al. 2018). In multiple human cancer cell lines, shRNA knockdown of GUARDIN
led to decreased proliferation and increased cell death in vitro, and GUARDIN
depleted HCT116 cells contributed to significantly smaller tumors in xenograft
mouse experiments. Interestingly, GUARDIN knockdown only affected cell
viability in p53-proficient cells, suggesting that GUARDIN tempers the cytotoxic
effects of p53 stabilization in some cancer cells. In line with this, exogenous
overexpression of GUARDIN was sufficient to reverse this p53-dependent
cytotoxicity in one human NSCLC cell line (Hu et al. 2018). Mechanism-wise,
GUARDIN was shown to promote genome stability and cell survival under
conditions of genotoxic stress in multiple ways. These include stabilizing TERF2
(Telomeric Repeat Binding Factor 2) by sequestering mir23a (TERF2 being an
important component of the telomere protecting Shelterin complex) and
stabilizing BRCA1 (Breast Cancer Type 1), which plays a central role in DNA repair,
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by facilitating interactions between BRCA1 and its stabilizing binding partner
BARD1 (BRCA1 Associated RING Domain 1) (Hu et al. 2018). Thus, GUARDIN
acts in the cytoplasm to post-transcriptionally regulate multiple targets involved
in genome maintenance and repair.
LincRNA-RoR (Regulator of Reprogramming) was first identified in a
microarray screen for lincRNAs involved in pluripotency, where it was
demonstrated to positively regulate reprogramming through RNAi LOF and
exogenous overexpression GOF experiments (Loewer et al. 2010). Later work
revealed that lincRNA-RoR is directly activated by p53 in human cancer cell lines
treated with DNA damage and that, intriguingly, lincRNA-RoR and p53 protein
levels are negatively correlated (Zhang et al. 2013a). siRNA knockdown and
transgene

overexpression

experiments

demonstrated

that

lincRNA-RoR

negatively regulates DNA damage-induced p53 translation, likely through
interacting with phosphorylated hnRNP-I (also known as PTBP1) in the cytoplasm
(Zhang et al. 2013a). hnRNP-I has been previously shown to bind to p53 mRNA
and regulate cap-independent p53 translation (Grover et al. 2008), which is an
important aspect of p53’s activation during stress (Halaby et al. 2015), suggesting
that lincRNA-RoR may interfere with this stress-driven p53 activation. Indeed,
lincRNA-RoR overexpression reduced apoptosis and prevented cell cycle arrest in
cells exposed to genotoxic stress, suggesting that lincRNA-RoR GOF prevented
robust p53 pathway activation. Thus, lincRNA-RoR represents yet another p53activated lncRNA that adjusts the p53 response to DNA damage by tuning p53
levels, here at the level of p53 protein translation.
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Conclusion
Despite decades of research, many questions regarding how p53 senses and
responds to such a wide range of stress inputs to suppress tumorigenesis remain
incompletely answered. Studying lncRNAs in the p53 network can provide
valuable new insights into these old questions, as well as provide perspective on
the roles lncRNAs may play in cancer more broadly. The above examples illustrate
the many ways by which p53-activated lncRNAs can contribute to p53 pathway
function. In reviewing in vitro, and when available, in vivo functional
characterization data regarding these lncRNAs, it becomes readily apparent that
p53-activated lncRNAs can perform many diverse functions through a myriad of
mechanisms of action. One over-arching theme that emerges, however, is that
lncRNA loci often modulate the transcriptional output of the p53 network, whether
globally (e.g. by modulating p53 protein levels or p53 transactivity), at a limited
subset of p53 targets, or on an individual locus basis. Another commonality that
emerges is that p53-activated lncRNAs often have tissue- or stress-specific
functions. To this point, it is important to note that most searches for p53-activated
lncRNAs have focused on lncRNAs induced in response to DNA damage. The
functional characterizations of lncRNAs in other stressor contexts has the potential
to expand our understanding of the ways in which the p53 network integrates and
responds to different stresses. Nevertheless, this growing body of work suggests
that p53-activated lncRNAs add an important regulatory layer to the p53 network
and may represent an underexplored pool of “effectors” of p53 pathway function(s)
and/or tumor suppression.
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Table 1.1: LncRNAs reported to be directly activated by p53
LncRNA

m&h

Context
studied
Geno

GUARDIN

h

Geno

LED

h

Onco

Linc-475

h

Onco

Linc-Pint

m&h

Geno;
Onco

LincRNAp21

m&h

Geno

Nuclear: Positive cis-regulation of p21  G1/S
check-point reinforcement.
Cytoplasmic: (human) Repress translation

LncRNARoR
Loc285194

m&h

Geno

h

Geno

Neat1

m&h

Geno;
Onco

h

Geno;
Onco

PR-lncRNA
1

m&h

Geno

PR-lncRNA
10

h

Geno

PINCR

h

Geno

PURPL

h

Geno;
Onco

Pvt1b

m&h

Geno;
Onco

TUG1

m&h

Onco

Cytoplasmic: Repress p53 translation during
stress  restrict p53 pathway activation
Cytoplasmic: Negatively regulate miR-211 
restrict cellular proliferation
Nuclear: (1) Dampen DNA damage response
 restrict p53 stabilization; promote
tumorigenesis in vivo (2) Regulate global gene
expression restrict transformation in vitro
and tumorigenesis in vivo
Nuclear: (1) Sequester NF-YA  promote
survival or restrict proliferation; (2) Recruit
hnRNP-U and BMI1 to repress a subset of genes
 promote proliferation
Nuclear: Promote p53 transactivation 
ensure robustness of p53 response to DNA
damage
Nuclear: Promote p53 transactivation 
ensure robustness of p53 response to DNA
damage
Nuclear: Promote promoter-enhancer
interactions at a subset of p53 targets through
Matrin 3 interactions promote survival
Nuclear: Destabilize p53 protein in low stress
conditions  regulate proliferation and
promote survival
Nuclear: Negative cis-regulation of Myc 
restrict proliferation in vitro and tumorigenesis
in vivo
Nuclear: Recruit epigenetic machinery to
repress HOX7B  restrict proliferation
Cytoplasmic: Suppress IRES-dependent p27
translation  regulate proliferation

DINO

PANDA

Cons

Proposed function(s) in
p53 pathway
Nuclear: Promote p53 transactivation;
(Unknown): Promote p53 protein stability 
ensure robustness of p53 response to DNA
damage
Cytoplasmic: Stabilize TERF2 by sponging
mir23a; stabilize BRCA1-BARD1 interactions 
promote genome stability and survival
Nuclear: Promote enhancer activity at a subset
of p53-responsive enhancers; promote p21
expression  regulate proliferation
Nuclear: Promote p21 expression  regulate
proliferation and oncogene-induced senescence
Nuclear: Recruit PRC2 to epigenetically
silence a network of genes  restrict
proliferation and invasion

Ref(s)

(Schmitt et al.
2016)
(Hu et al.
2018)
(Léveillé et al.
2015)
(Melo et al.
2016)
(Huarte et al.
2010; MarínBéjar et al.
2017, 2013)
(Dimitrova et
al. 2014; Yoon
et al. 2012;
Huarte et al.
2010)
(Zhang et al.
2013a)
(Liu et al.
2013b)
(Adriaens et
al. 2016; Mello
et al. 2017)
(Hung et al.
2011; Puvvula
et al. 2014)
(Sánchez et al.
2014)
(Sánchez et al.
2014)
(Chaudhary et
al. 2017)
(Li et al. 2017)
(Olivero et al.
2020)

(Zhang et al.
2014)
TRMP
h
Onco
(Yang et al.
2018)
Cons= conservation (m= mouse; h= human); Geno= genotoxic stress; Onco= oncogenic stress
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Chapter 2: Project Framework
Overview
LncRNAs are increasingly being implicated in a wide array of complex
cellular and organismal processes [see Chapter 1; also recently reviewed in (Yao
et al. 2019)]. Most lncRNAs have been proposed to function by regulating gene
expression through a variety of mechanisms, including influencing transcription
(Dimitrova et al. 2014; Marín-Béjar et al. 2013; Melo et al. 2016), posttranscriptionally regulating mRNA localization, stability, or translation (Hu et al.
2018; Kretz et al. 2013; Carrieri et al. 2012), or post-translationally modulating
protein localization or stability (Li et al. 2017; Schmitt et al. 2016; Hung et al. 2011;
Lee et al. 2016; Hu et al. 2018). Additionally, many lncRNAs are dysregulated in
numerous diseases, including several human cancers (Iyer et al. 2015; Olivero and
Dimitrova 2020), suggesting that lncRNA expression could be tied to cancer
pathogenesis. However, the importance of lncRNA-mediated gene regulation in
human health and disease is incompletely understood.
P53 is a universal tumor suppressor that transactivates a wide network of
protein coding and noncoding target genes in response to stress to restrict
tumorigenesis (Vousden and Prives 2009). As reviewed in Chapter 1, several
studies within the past decade have identified lncRNAs that are transcriptionally
activated by p53 and important for various p53-regulated processes. However,
comparisons across studies in which individual p53-activated lncRNAs are
characterized make it difficult to gain an accurate sense of the true extent to which
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lncRNAs contribute to the p53 pathway. Additionally, a comprehensive
understanding of the mechanisms by which p53-activated lncRNAs modulate this
important transcriptional network is also lacking. This is in part due to the fact that
most genome-wide searches for p53-regulated lncRNAs have been performed in
the context of genotoxic stress (i.e. stress induced by DNA damaging agents) (see
Table 1.1). p53 can also be activated by the aberrant expression of oncogenes (e.g.
over-amplification or the acquisition of constitutively activating mutations)
(Serrano et al. 1997; Horn and Vousden 2007), which leads to cellular
hyperproliferation and a multifaceted stress called oncogenic stress. Key
characteristics of oncogenic stress that lead to p53 stabilization include the
persistent activation of mitogenic and DNA damage response pathways (Bartkova
et al. 2006; Di Micco et al. 2006; Meek 2009; Collado and Serrano 2010).
Seminal work from the Attardi lab (Stanford) suggests that the p53
transcriptional response to oncogenic stress is likely distinct from that initiated by
acute DNA damage. p53 regulates transcription through two transactivation
domains (TADs) (Sullivan et al. 2018). Simultaneous mutation of both TADs
significantly impairs the ability of mouse embryonic fibroblast (MEFs) to respond
to either genotoxic or oncogenic stress, as p53’s ability to activate a robust p53
network is severely compromised. Double TAD mutated p53 is also unable to
suppress tumorigenesis in vivo in cancers of multiple tissues of origin, reinforcing
the importance of p53-dependent transcriptional regulation in tumor suppression
(Brady et al. 2011; Jiang et al. 2011).
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However, the cellular consequences of mutating either TAD independently
are surprisingly dependent on the type of stressor faced, despite both TAD
mutations compromising p53 activation to varying extents (Brady et al. 2011). In
MEFs exposed to genotoxic stress, loss of TAD1 is sufficient to significantly impair
DNA damage-induced cell cycle arrest and apoptosis. In contrast, TAD1 mutation
does not impede the initiation of oncogene-induced senescence in MEFs,
suggesting that the antiproliferative p53 response to oncogenic signaling does not
rely on the same p53 targets as the response to genotoxic stress (Brady et al. 2011).
Interestingly, the lncRNA Neat1 is one p53 target that has been reported to
function in a similar, stress-specific manner, namely in that Neat1 activation
downstream of genotoxic stress is dispensable for the p53 response to DNA
damage but essential for p53 pathway function in response to oncogene-induced
cellular transformation (Mello et al. 2017). These observations beg the question
whether a distinct cohort of lncRNAs are activated by p53 during the response to
oncogenic stress.
Another set of related, important questions in the p53 field is what
determines the spectrum of targets that are activated by p53 in any given setting
and how target selection relates to the distinct downstream cellular outcomes of
p53 activation. In an effort to address these questions, recent years have seen many
research groups employ genome-wide p53 binding and RNA profiling to
characterize the p53 transcriptional response across a number of biological
contexts. These include the response to genotoxic stress (Kenzelmann Broz et al.
2013; Younger et al. 2015; Li et al. 2012; Catizone et al. 2019; Zhang et al. 2013b),
as well as the p53 response to oncogenic signaling, either by pharmacologically
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stabilizing p53 in cancer cell lines or driving the overexpression of specific
oncogenes (Allen et al. 2014; Tonelli et al. 2017; Andrysik et al. 2017; Menendez et
al. 2013). Table 2.1 provides a detailed catalogue and cross-study comparison of
these genome-wide profiling experiments.
However, despite the variety of biological settings sampled, disentangling
the contributions of cell type-intrinsic versus stimuli-intrinsic effects of p53
activation has proven extremely challenging. Some studies have concluded that
p53 function is primarily determined by the type of stress stimuli encountered
(Menendez et al. 2013). Others have suggested that cell identity plays a pivotal role
in determining where p53 binds in the genome (Nikulenkov et al. 2012; Botcheva
and McCorkle 2014) and/or which genes are transactivated (Tonelli et al. 2017;
Catizone et al. 2019; Zhang et al. 2013b), regardless of stress stimuli or ultimate
cellular outcome. In contrast to both models, one recent metanalysis of fifteen
human p53 ChIP-Seq datasets observed that p53 binding is largely invariant,
irrespective of either cell or stimuli identity (Verfaillie et al. 2016). However, eleven
of the datasets analyzed in this study were collected under genotoxic conditions,
highlighting the need for further investigation of the p53 response to oncogenic
stress. Especially lacking in the field are comparisons across diverse tumor types.
In order to answer these important questions related to p53-regulated
lncRNAs and broader p53 pathway function, my research broadly aimed to (1)
characterize the p53 transcriptional response to oncogenic stress, and (2) identify
and functionally interrogate the contributions of p53-activated lncRNAs in a
number of cellular responses triggered by oncogenic stress. In Chapter 3, I work
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towards

addressing

these

aims

through

surveying

the

p53-regulated

transcriptomes of three different tumor types, revealing important principles of
gene regulation in the p53 pathway and implications for lncRNAs in these
processes. In Chapter 4 and Chapter 5, I focus on the careful molecular
dissection of several p53-activated lncRNA loci identified in Chapter 3 to further
address aim (2), namely asking whether lncRNAs function downstream of p53 to
modulate the decision between initiating apoptosis or senescence in response to
oncogenic signaling.

Model systems
Oncogenic stress
Central to this work were two in vitro model systems for the study of p53
pathway function. To model the p53-dependent response to oncogenic stress, we
took advantage of a well-established genetically engineered mouse model of p53driven tumorigenesis: the KrasLA2-G12D/+; p53LSL/LSL; Rosa26-CreERT2 (KPR)
mouse (Ventura et al. 2007; Feldser et al. 2010). In this mouse, p53 has been
genetically inactivated by the insertion of a loxP-flanked transcription-translation
STOP cassette into the first intron of both Trp53 alleles, leading the complete loss
of p53 expression (Ventura et al. 2007). Additionally, KrasG12D (i.e. a constitutively
active oncogenic mutant of Kras) is spontaneously activated in vivo through
somatic recombination at a targeted KrasLA2-G12D allele. This leads to the
heterozygous expression of KrasG12D in a subset of cells throughout the mouse
(Johnson et al. 2001). Importantly, somatic TP53 and KRAS mutations are often
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concurrent in many human cancers, especially in adenocarcinomas of the lung and
other tissues, making this model of oncogenic stress clinically relevant (The Cancer
Genome Atlas).
Loss of p53 and gain of oncogenic KrasG12D leads to the rapid development
of a spectrum of cancers in KPR mice, including lung adenocarcinomas, thymic
lymphomas, and sarcomas (Johnson et al. 2001), from which cell lines can be
established. Importantly, p53 expression can be restored in KPR mice or tumorderived cell lines by administering 4-hydroxytamxifen (Tam), which drives the
nuclear translocation of CreERT2 expressed from the Rosa-26 locus, leading to the
excision of the STOP cassette (Ventura et al. 2007; Feldser et al. 2010). Thus, the
KPR mouse represents an ideal model for studying p53-dependent gene regulation
and p53 pathway function downstream of oncogenic stress. The use of this model
in probing p53 outcome-specificity is discussed further in Chapter 3.

Genotoxic stress
As Table 2.1 illustrates, p53 has been most extensively studied in the
context of genotoxic stress. While this is undoubtedly an important area of
research in its own right, this predominance is also likely in part due to the fact
that many of the earliest insights into p53’s cellular functions were made in the
context of the DNA damage response (Kastan et al. 1992; Lowe et al. 1993b;
Brugarolas et al. 1995). MEFs exposed to various genotoxic insults (e.g. ionizing
irradiation, UV, pharmacological compounds) represent a long-established in
vitro system for studying novel components of the p53 pathway. As such, MEFs
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have well-characterized p53 cellular responses and well-established assays for
testing various p53 functions (Attardi et al. 2004; Lowe et al. 1994). MEFs exposed
to the Doxorubicin (Doxo; a chemotherapeutic topoisomerase II inhibitor) served
as a complementary in vitro system for probing the functions of multiple newlyidentified p53-activated lncRNAs within this work.

Tools for the study of lncRNA loci
As the study of lncRNAs matures as a field, it is becoming increasingly clear
that experimental approaches to manipulate lncRNA expression must be tailored
to the specific lncRNA locus under study, often more so than for protein coding
genes. The following is a brief discussion of the merits and caveats of common
lncRNA loss-of-function and gain-of-function strategies, many of which were
employed in this work.

LncRNA loss-of-function (LOF)
While the ease of genetic manipulation has been greatly augmented in
recent years by CRISPR-Cas9 technology, effective genetic inactivation of lncRNA
loci is still challenging. This is due to the fact that our understanding of the RNA
sequences important for lncRNA function remains imprecise. Genetic lncRNA
knockouts have, by necessity, most often consisted of large-scale promoter or gene
body deletions (Bassett et al. 2014; Kopp and Mendell 2018), unlike the targeting
of protein coding genes which can be functionally inactivated by introducing small
insertions and deletions that disrupt open reading frames (ORFs). One important
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caveat of these large-scale deletion models is that potentially important DNA
elements are also ablated along with lncRNA expression. Additionally, deletions
targeting annotated promoters may not completely abrogate the use of alternative
lncRNA transcription start sites. Thus, while large-scale deletions can be an
effective LOF strategy for the initial characterization of a novel lncRNA locus, more
precise genetic strategies are more ideal and, increasingly, more common. Two
such strategies are inserting premature transcription termination signals or
deleting more limited sequences (e.g. splice sites, DNA regulatory motifs).
CRISPR-Cas9 based epigenetic inhibition (CRISPRi) (Gilbert et al. 2013) has also
proven to be a useful alternative or complementary approach for stably
inactivating lncRNA loci (Kopp and Mendell 2018).
Another vital consideration for performing lncRNA LOF experiments is
endogenous lncRNA localization. RNA interference (RNAi) is one common
strategy for lncRNA LOF and has been historically used to target both cytoplasmic
and nuclear lncRNAs. However, the efficacy of RNAi in targeting nuclear lncRNAs
(or nuclear subpopulations of lncRNAs) has been called into question (Lennox and
Behlke 2016), making the results of some of these lncRNA studies difficult to
interpret. Antisense oligonucleotides (ASOs) are a commonly used alternative to
RNAi and work to deplete RNA levels by triggering endogenous nuclear RNase H
activity, leading to co-transcriptional RNA degradation and potentially premature
transcriptional termination (Lai et al. 2020; Lee and Mendell 2020). Thus,
depending on ASO design, ASO-mediated knockdown alone can be insufficient to
determine whether an observed phenotype is through the loss of a lncRNA
transcript or disrupted lncRNA biogenesis (i.e. perturbed transcription, splicing).
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Nonetheless, ASOs function in the nucleus and thus can be an effective tool for
knocking down both nuclear and cytoplasmic lncRNAs.
A third developing technology for lncRNA knockdown is CRISPR-Cas13
RNA targeting, Cas13 being a type VI CRISPR-associated RNA-guided RNase. A
number of CRISPR-Cas13 platforms have recently been reported to be both more
specific and more effective at knocking down both nuclear and cytoplasmic RNAs
than position-matched shRNAs (Abudayyeh et al. 2017; Cox et al. 2017;
Konermann et al. 2018). The ability to target nuclear lncRNAs in a genetically
encodable system such as CRISPR-Cas13 would be invaluable, as ASOs are
transient and thus less-suited for use in longer-term functional assays. However,
CRISPR-Cas13 has not been widely adopted as a tool for RNA knockdown yet,
likely due to still enigmatic gRNA design rules. Once a better understanding of
what constitutes an effective Cas13 guide has been established, CRISPR-Cas13 is
certain to greatly facilitate lncRNA characterization efforts.

LncRNA gain-of-function (GOF)
The most commonly employed lncRNA GOF stratagem is transgene
overexpression, in which full length or mutant lncRNA sequences are introduced
into cells through either stable or transient means. However, it is important to note
that such transgene overexpression systems can only be deemed true GOF (i.e.
informative about the endogenous function of a lncRNA) for lncRNAs that act in
trans. In fact, rescuing lncRNA LOF through the introduction of a lncRNA
transgene is a crucial experiment in proving true trans lncRNA functionality. Such
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approaches are less appropriate for the study of lncRNA-mediated cis-regulation,
as cis-acting lncRNAs, by definition, exert their functions at their sites of
expression. Driving lncRNA expression from elsewhere in the genome would not
be expected to positively or negatively affect expression from its endogenous locus.
To circumvent this issue, molecular tools to recruit ectopically expressed lncRNAs
to their endogenous genomic loci have been developed (Shechner et al. 2015) but
have not been as widely employed as means to locally manipulate gene regulation.
One such approach is CRISPR-Cas9 based gene activation (CRISPRa) (Gilbert et
al. 2013). CRISPRa is suitable for both trans- and cis-acting lncRNA GOF, as
lncRNA upregulation is achieved by increasing the transcriptional activity of the
endogenous lncRNA locus.

In summary, efficiently and specifically manipulating the expression of
lncRNAs can be technically challenging. For lncRNA LOF in particular, it can be
vital to employ multiple, orthogonal strategies in order to elucidate the functional
feature(s) of a lncRNA locus. Additionally, the appropriateness of traditional (i.e.
protein coding gene-oriented) LOF and GOF tools should be judiciously assessed
on a lncRNA-by-lncRNA basis. In this work, multiple locus-specific strategies were
employed to functionally characterize the many diverse lncRNAs under study.
Specific experimental details and rationales can be found in Chapters 3-5.
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Table 2.1: Survey of genome-wide p53 ChIP-Seq and RNA profiling studies
Ref
(Akdemir et al. 2014)
(Catizone et al. 2019)
(Huarte et al. 2010)
(Kenzelmann Broz et al.
2013)
(Lee et al. 2010) *
(Li et al. 2012)
(McDade et al. 2014)

RNA
profiling
RNA-seq
RNA-seq
Microarray
RNA-seq
Microarray
Microarray
Microarray

Cell line(s)

Stressor

Category

hESCs
IMR90
MEFs
MEFs

Doxorubicin
Etoposide
Doxorubicin
Doxorubicin

Geno
Geno
Geno
Geno

Doxorubicin
Doxorubicin
Cisplatin

Geno
Geno
Geno

Doxorubicin

Geno

Actinomycin D
Etoposide
Doxorubicin

Geno
Geno
Geno

Doxorubicin
Doxorubicin

Geno
Onco;
Geno
Onco;
Geno
Onco;
Geno
Onco;
Geno
Onco
Onco

(Smeenk et al. 2011)

Microarray

(Younger et al. 2015)

RNA-seq

(Zhang et al. 2013b) *
(Li et al. 2017)

Microarray
RNA-seq

(Menendez et al. 2013)

Microarray

mESCs
mESCs
Primary human
keratinocytes
Primary human
keratinocytes
U2OS
U2OS
MEFs; Human
fibroblasts
MEFs; mESCs
HCT116; RKO;
SW48
U2OS

(Sánchez et al. 2014)

RNA-seq

HCT116

5-FU

(Tonelli et al. 2017)

RNA-seq

Doxorubicin

(Allen et al. 2014)
(Andrysik et al. 2017)
(Brady et al. 2011)

GRO-seq
RNA-seq;
GRO-seq
Microarray

Eμ-Myc; Arf-/lymphoma
HCT116
HCT116; MCF7;
SJSA
MEFs

(Chaudhary et al. 2017)

Microarray

(Huarte et al. 2010)

Microarray

(Léveillé et al. 2015)
(Menendez et al. 2013)
(Nikulenkov et al.
2012)
(Tonelli et al. 2017)

GRO-seq
Microarray
Microarray

HCT116; RKO;
SW48
KrasG12D; p53LSL/LSL
lung cancer
MCF7
U2OS
MCF7

Eμ-Myc;
p53ERTAM/+
lymphoma
Eμ-Myc; Arf-/lymphoma
(Yang et al. 2018)
Microarray
p53-Tet-ON
H1299
*= ChIP followed by microarray analysis employed; all other
sequencing; Geno= genotoxic stress; Onco= oncogenic stress
RNA-seq
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Doxorubicin

Nutlin-3
Nutlin-3
Exogenous
HrasV12
Nutlin-3

Onco

Endogenous
KrasG12D
(p53 activation)
Nutlin-3
Nutlin-3
Nutlin-3

Onco

Endogenous
Eμ-Myc
(p53 activation)
Nutlin-3

Onco

p53-induction

Onco

Onco

Onco
Onco
Onco

Onco

studies used high throughput

Chapter 3:
Cis-regulatory lncRNAs in the p53 response to oncogenic
stress

Part of the work described in this chapter is being prepared as a manuscript for
publication as follows: Tesfaye, E., Bendor, J., Martínez-Terroba, E., Zamudio,
J., and Dimitrova, N. Core and outcome-specific signatures of p53 restoration in
cancer modulated by cis-regulatory lncRNAs. Co-author contributions that
have also been included in this thesis are specified in figure legends and/or text.

Introduction
The ability of p53 to sense and respond to oncogenic signaling is an important
facet of its potent tumor suppressive capabilities (Brady et al. 2011; Kaiser and
Attardi 2018). Yet, the p53 response to oncogenic stress is poorly understood, in
part due to the dearth of global analyses comparing said response across diverse
tumor types (discussed in Chapter 2; Table 2.1). Especially under-explored are
the contributions of p53-activated lncRNAs to how p53 responds to oncogenic
signalling across different cancer contexts. Detailed in this chapter is some of our
work towards a more comprehensive understanding of the p53 transcriptional
response to oncogenic stress and the regulatory roles previously described and
novel lncRNAs play in it, achieved by performing a global survey of three different
tumor types derived from the same genetically engineered mouse model of cancer.
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Primarily discussed here are my main contributions to this project, namely the
identification of stressor-specific, lineage-specific, and p53 outcome-specific
transcriptional programs across our mouse model of cancer and the
characterization of a cohort of newly-identified p53-activated lncRNAs (continued
in Chapters 4 and 5).

Results
Genome-wide profiling of the p53 response to oncogenic stress
In collaboration with Jesse Zamudio (J. Zamudio; UCLA), a quantitative
biologist, we performed genome-wide p53 ChIP-seq and RNA-seq across a panel
of lung adenocarcinoma (LA), sarcoma (SA), and lymphoma (LY)-isolated cell
lines from the KPR mouse model of cancer, which is an established model for
studying the p53 pathway (Ventura et al. 2007; Feldser et al. 2010) and described
in detail in Chapter 2. In brief, in this model, oncogenic stress is derived from an
activated KrasG12D allele, and p53 expression is inactivated by the homozygous
insertion of a loxP-flanked transcriptional STOP cassette into the endogenous p53
locus. Importantly, p53 expression can be restored by the addition of Tam, which
removes the STOP cassette, thus allowing the analysis of events downstream of p53
in the presence of oncogenic stress (Fig. 2A).
We utilized a panel of six cell lines derived from three distinct KPR tumor
types: two LA, two SA, and two LY. CreER-mediated recombination of the p53
locus in these isolated cell lines was confirmed at 24h post Tam treatment by
genotyping (Fig. 2B), and restoration of p53 expression was confirmed by qRTPCR (Fig. 2C). Following p53 restoration, p53 protein is stabilized by the presence
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of oncogenic stress, as evidenced by immunoblotting (Fig. 2D) and the activation
of transcriptional targets of p53, such as p21 (El-Deiry et al. 1993) (Fig. 2C, D).
In addition to these molecular indicators of p53 restoration, KPR cell lines
also displayed cellular outcomes consistent with previously described in vivo p53
responses. p53 activation has been reported to lead to tumor regression via
senescence in murine LA and SA tumors (Feldser et al. 2010; Ventura et al. 2007)
and apoptosis in lymphoma (Ventura et al. 2007). Following p53 restoration, we
observed induction of apoptosis in LY cells, but not LA and SA cells (Fig. 2D), and
growth arrest in LA and SA cells, as expected. Positive staining for β-galactosidase
activity at 168 hours post p53 restoration in LA and SA cells was consistent with
these cells having underwent oncogene induced senescence (Serrano et al. 1997)
(Fig. 2E). Thus, these data established KPR-derived cells as a suitable model to
investigate oncogenic-stress specific, tumor type-specific, and p53 outcomespecific transcriptional programs.
We first queried where in the genome p53 binding occurred across the three
tumor types by performing p53 ChIP-seq in one LA (LA2), one SA (SA1), and one
LY (LY1) cell line. In parallel to our p53 ChIP-seq analysis, we analyzed RNA-seq
data from the full panel of two LA (LA1 and LA2), two SA (SA1 and SA2) and two
LY (LY1 and LY2) cell lines, allowing us to determine how p53 binding events
related to transcriptional changes. Both p53 ChIP-seq and RNA-seq experiments
were performed at 24 hours following mock treatment or Tam-mediated p53
restoration by Nadya Dimitrova (N. Dimitrova). A schematic of this experimental
pipeline can be found in (Fig. 2F). Bioinformatic analyses to identify regions bound
by p53 and expressing transcripts differentially regulated in response to p53
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restoration were performed by N. Dimitrova and J. Zamudio, yielding a list of
peak-associated transcripts that N. Dimitrova and I interrogated further. 4,391
p53-bound peaks were identified across the three tumor types, corresponding to
4,745 individual peak-associated transcripts. Notably, 1,036 peaks did not have
any detectable transcripts, consistent with previous reports of p53 frequently
associating with intergenic regions, such as enhancers and repetitive elements
(Léveillé et al. 2015; Wang et al. 2007). Overlap analysis of both transcriptassociated and intergenic peaks was performed by J. Zamudio and revealed that
94% of p53 binding events were tumor type-specific, with only 44 sites (1%) being
bound by p53 across all three tumor types, suggesting that p53 binding is perhaps
driven more by cell- or tissue-specific factors than stressor type, as has been
previously suggested (Tonelli et al. 2017; Catizone et al. 2019; Smeenk et al. 2011;
Nikulenkov et al. 2012).
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Figure 2: Characterization of the p53 response to oncogenic stress. (A) Schematic of the
KrasLA2-G12D/+; p53LSL/LSL; Rosa26-CreERT2 (KPR) mouse model and isolated tumor-derived cell
lines. Tam-mediated p53 restoration (p53 “ON”) and subsequent p53 stabilization by oncogenic
stress is indicated by a red nucleus. Six independent KPR cell lines, two per indicated tumor type,
were used in this work. (B) Genotyping of indicated KPR cell lines and treatments. Expected bands:
WT (p53 “ON”/restored) = 364 bp; LSL (p53 “OFF”/ unrestored) = 278 bp. (C) qRT-PCR analysis
of p53 and p21 mRNA relative to endogenous control RNA Gapdh. Data show mean ±SEM (n=3
biological replicates). *p <0.05, ** p<0.01, and **** p<0.0001, unpaired t test. (D)
Immunoblotting for p53, p21, and CC3 protein. β-tubulin served as a loading control. (E)
Senescence-associated β-galactosidase staining in indicated LA and SA KPR cells and treatments.
(F) Diagram of p53 ChIP-Seq and RNA-seq experiments, including summary of identified p53bound peaks and de novo assembled transcriptome results. p53 ChIP-seq was performed in LA2,
SA1, and LY1 cells, whereas RNA-Seq was performed in all KPR cell lines. p53-responsive
transcripts were called based on log2FC (FDR >0.05).
In (F), original ChIP-seq and RNA-seq experiments were performed by N. Dimitrova.
Transcriptome assembly and p53 ChIP-Seq peak-transcript associations were performed by J.
Zamudio.
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Identification of core and senescence-specific p53 signatures
Of the 4,745 peak-associated transcripts, 1,573 were differentially regulated
in response to p53 restoration. 685 genes were upregulated >2-fold while 888
genes were downregulated >2-fold across the three tumor types (Fig. 3A, C).
Differentially regulated genes fell into three categories: 1) Tumor type specific (LA,
SA, or LY-specific); 2) Outcome-specific (senescence or apoptosis); and 3) Core
(common). In order to gain a better understanding of the make-up of the specific
p53 transcriptional program(s) enacted in each category, and whether any unique
signatures explained the different behaviors of each KPR tumor type, we
performed gene set enrichment analysis (GSEA) on each category.
Of the transcripts transcriptionally activated by p53, 61 were induced across
all three tumor types, including many known p53 targets such as p21, Mdm2,
Sesn2, and Bbc3 (Puma) (Fig. 3A). Unsurprisingly, GSEA of this core induced set
of transcripts revealed significant enrichment for factors previously implicated in
the p53 pathway and/or various processes regulated by p53, such as the DNA
damage response and apoptosis (Fig. 3B). Moreover, in silico motif analysis of the
p53 peaks associated with these transcripts performed by J. Zamudio via p53scan
(Smeenk et al. 2008) revealed an enrichment for the canonical p53 response
element (p53RE) (Fig. 3E), further supporting direct regulation by p53. Thus, we
were able to identify a core set of genes regulated by p53 in response to oncogenic
stress across multiple tumor contexts.
In search for a potential apoptosis signature, we next investigated the
transcripts upregulated uniquely in LY cells. However, while we did find
enrichment for the p53 pathway itself (Fig. 3A), we found little overlap with
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apoptosis gene sets and no enrichment of the p53RE (Fig. 3E), suggesting that
other factors beyond transcriptional regulation by p53 may play a more important
role in driving apoptosis in LY cells. Similar GSEA analysis of the 51 genes induced
in LA and SA but not LY cells did not reveal any significantly enriched datasets,
indicating the lack of a senescence-specific p53 activated signature.
In contrast to the well-characterized role of p53 in gene activation, the
functional importance of and mechanisms underlying p53-mediated gene
repression are less clear (Vousden and Prives 2009; Fischer et al. 2014). By
examining the 888 peak-associated transcripts which were downregulated >2fold, we noticed that a large proportion (35%) of these genes fell within the
“senescence-specific” category (i.e. repressed only in both LA and SA cells) (Fig.
3C). In contrast, only 3 genes were repressed across all three tumor types, none of
which contained p53REs (Fig. 3C, F). These data suggested that p53-mediated
transcriptional repression is likely not a dominant feature of the p53
transcriptional network, at least in the context of oncogenic stress, but perhaps is
a feature of outcome-specificity, specifically senescence.
Indeed, GSEA of the 312 downregulated senescence-specific genes
highlighted the repression of genes involved in the cell cycle, which is consistent
with reduced proliferation during senescence (Fig. 3D). In addition, we discovered
significant overlaps with E2F and DREAM targets (Fig. 3D), which is in line with
a previously proposed model in which repression downstream of p53 is mediated
by the p21/E2F/DREAM transcriptional complex (Engeland 2018; Uxa et al.
2019). Only 17% of all p53 repressed genes contained a p53RE, compared to 30%
of p53 induced genes (Fig. 3E, F), and this number was not further enriched in
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senescence-repressed genes (Fig. 3F). However, as 56 of the 312 senescencerepressed genes (18%) did contain recognizable p53REs, it remains possible that
p53 binding may still be important for repression at some loci, whether through
contributing to the localization of E2F/DREAM components or through other
mechanisms.
In summary, these data indicated that senescence, but not apoptosis or the
core p53 response to oncogenic stress, is distinctly characterized by pervasive p53mediated repression. Moreover, senescence-specific transcriptional repression
may possibly be mediated through a repressive partner, such as the
p21/E2F/DREAM complex.
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Figure 3: Pathway analysis of p53-responsive transcriptome reveals core and
outcome-specific p53 signatures. (A) Venn diagram showing distribution of p53-induced
(log2FC>1) transcripts across indicated KPR tumor types. Arrows designate results of GSEA of
indicated gene category, with FDR q value shown. Highlighted gene categories: Core= LA, SA, and
LY. Senescence= LA and SA. Apoptosis= LY. (B) GSEA of Core p53-induced category, using the H
and C2 collections of MSigDB. Top ten enriched gene sets ranked by q values were plotted. Gene
sets related to the p53 pathway are highlighted in red. (C) Venn diagram showing distribution of
p53-repressed (log2FC<1) transcripts across indicated KPR tumor types. (D) GSEA of Senescence
p53-repressed category, as described in (B). Gene sets related to cell cycle regulation are
highlighted in red. (E-F) p53-responsive transcript distributions across indicated gene categories
in relation to p53RE status as determined by p53scan on transcript-associated p53 peaks. (E) p53induced transcripts (F) p53-repressed transcripts.
In (E) and (F), p53scan motif analysis was performed by J. Zamudio on all Induced and Repressed
transcripts.
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Many lncRNAs are activated by oncogenic stress following p53
restoration
We next focused on the identification and characterization of lncRNAs
activated by p53 in our KPR model, wondering whether lncRNAs played an
important role in the p53 response to oncogenic stress. Among the genes that were
induced by p53 in KPR cells more than 2-fold, 21 lncRNAs were identified
(described in Table 3.1). Interestingly, barring three transcripts which had
previously been characterized as p53 targets, [lincRNA-p21 (Dimitrova et al. 2014;
Huarte et al. 2010); Neat1 (Adriaens et al. 2016; Mello et al. 2017), and Pvt1
isoform Pvt1b (Olivero et al. 2020)], the remaining lncRNAs were either novel or
not previously associated with the p53 pathway. These novel lncRNAs were named
as follows: antisense (as) according to genes overlapped in the antisense
orientation, sense (s) respective to overlaps in the sense orientation, or long
intergenic noncoding RNAs (lincRNAs) according to the nearest neighboring
protein coding gene. Three lncRNAs, 2310008N11Rik (Zfp703 >150kb), Gm10801
(Lrrc4c >1Mb), and Gm10721 (Alkbh8 >300kb) were located in gene deserts and
were thus simply referred to by their MGI identifiers, unless otherwise noted. Of
the 21 p53-induced lncRNAs, 13 were further identified by p53Scan to contain
associated p53REs, providing a basis for direct regulation by p53 (Table 3.1).
To confirm that these RNAs were truly noncoding, protein coding potential
was assessed using the Coding Potential Assessment Tool (CPAT), which is a
commonly employed, alignment-free algorithm for assessing the probability of a
given nucleotide sequence containing a translated ORF (Wang et al. 2013). As
expected, previously described lncRNAs lincRNA-p21, Airn, Neat1, Malat1, and
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Pvt1 all had CPAT scores significantly lower than the protein-coding cut-off
assigned to the mouse transcriptome (CPAT score >0.440), suggesting a lack of
coding potential. Of the novel transcripts, all but one (Galnt2l-s) were similarly
below the coding threshold, suggesting that these transcripts represent bona fide
lncRNAs (Table 3.1).

Table 3.1: LncRNAs activated by p53 during the oncogenic stress response
#

Name

Class

p53Scan

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

lincRNA-p21
Zmat3-as
Bahcc1-as
lincRNA-Spag9
lincRNA-Gadd45γ
Airn
2310008N11Rik (lncRNA 7)
lincRNA-Klhdc4
Neat1
Malat1
Pvt1
Gm10801
lincRNA-Zfp945
Adamts9-as
Rhod-as
Sesn2-s
Bfsp2-as
Anks1-as
Kdm4c-as
Gm10721
Ltc4s-as

Intergenic
A.S overlap
A.S overlap
Intergenic
Intergenic
A.S overlap
Intergenic
Intergenic
Intergenic
Intergenic
Intergenic
Intergenic
Intergenic
A.S overlap
A.S overlap
S. overlap
A.S overlap
A.S overlap
A.S overlap
Intergenic
A.S overlap

YES
YES
YES
YES
YES

Bold= lncRNAs selected for further characterization

YES
YES
YES
YES
YES
YES
YES

YES

CPAT
score
0.246
0.176
0.229
0.046
0.243
0.243
0.044
0.995
0.087
0.056
0.119
0.064
0.122
0.124
0.304
0.050
0.052
0.213
0.005
0.065
0.042

Coding
label
NO
NO
NO
NO
NO
NO
NO
Yes
NO
NO
NO
NO
NO
NO
NO
NO
NO
NO
NO
NO
NO

Thirteen lncRNAs were selected for initial characterization experiments
(bolded in Table 3.1). Criteria for selection included likelihood of direct regulation
by p53, previous implication in the p53 pathway or other cancer-associated
processes, and likely overall abundance as initially determined in our RNA-seq
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data. p53-dependent induction of these select lncRNAs across the panel of KPR
cancer cell lines was validated by qRT-PCR. In agreement with our RNA-seq
analysis, 10/13 lncRNAs were induced >2-fold upon 24h Tam treatment in at least
three of the six cell lines, barring Neat1, Malat1, and Ltc4s-as. 12/13 lncRNAs met
this threshold of induction in at least one KPR cell line. Interestingly, we were
unable to confirm p53-dependent induction of Neat1 at this early time point,
implying a lack of direct regulation by p53 in contrast to previous studies (Fig. 4A).
When a later time point (72h Tam) was examined, all 13 lncRNAs met this >2-fold
threshold of induction, suggesting p53-regulated lncRNAs may be induced with
different transcriptional dynamics (Fig. 4A). Of note, five lncRNAs (Pvt1b, Zmat3as, Bahcc1-as, 2310008N11Rik, and Rhod-as) were induced across all six KPR cell
lines at both early (24h) and late (72h) time points, thus potentially encompassing
a core set of oncogenic stress-specific, p53-activated lncRNAs.

p53-activated lncRNAs are nuclear-enriched and co-regulated with
their nearest neighboring mRNAs
We next sought to determine the subcellular localization patterns of the
selected lncRNAs using subcellular fractionation followed by qRT-PCR, assessing
RNA levels in the cytoplasm (CP), nucleoplasm (NP), and at the chromatin
interface (CHR) in an LA1-derived clonal cell line (LA1.1). As anticipated, control
transcript Kcnq1ot1 was enriched in the chromatin fraction, whereas control
transcripts Rn7sl and Gapdh were enriched in the cytoplasm (Fig. 4B).
Furthermore, lncRNAs previously reported to be enriched in the nucleus
(lincRNA-p21, Pvt1, Neat1, and Malat1) were similarly distributed in KPR cells as
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well (Fig. 4B). Intriguingly, we determined that this nuclear-enrichment was
common to all tested p53-activated lncRNAs, with most enriched specifically at the
chromatin. These general patterns of subcellular localization also held true in wild
type MEFs treated with Doxo, demonstrating that these subcellular localization
patterns were conserved in the p53 response to genotoxic stress as well (Fig. 4C).
Curious about the implications of this pervasive chromatin-enrichment, we
next assessed the p53-responsiveness of each selected lncRNA’s overlapping
and/or nearest neighboring protein coding genes, wondering whether lncRNA
localization reflected lncRNA-mediated local gene regulation. As observed in the
parental KPR cells, p53 restoration also induced lncRNA expression in LA1.1 cells
(Fig. 4D). Strikingly, we found that most lncRNA-associated protein coding genes
were also upregulated in response to p53 (Fig. 4D). These data suggested that
lncRNAs that are activated by p53 in response to oncogenic stress are frequently
transcriptionally co-regulated with nearby protein-coding genes. Notably, this
correlation was positive for the majority of lncRNA-mRNA pairs investigated, with
the only exception being Pvt1b, which showed a negative correlation with its
upstream neighbor, Myc.

Figure 4: LncRNAs activated by p53 in response to oncogenic stress are chromatinenriched and positively correlated with neighboring mRNAs. (A) qRT-PCR analysis of
lncRNA levels relative to Gapdh in indicated KPR cell lines treated with 24h or 72h Tam,
normalized to untreated cells. n.e.= not expressed. Data show mean ± SD (n=2 biological
replicates). (B-C) Heat map representation of qRT-PCR analysis after subcellular fractionation.
Rn7sl and Kcnq1ot1 served as fractionation controls for cytoplasmic and chromatin-associated
fractions, respectively. Also shown is Gapdh mRNA, as an additional control. CP= cytoplasmic. NP=
nucleoplasmic. CHR= chromatin-associated. (B) LA1.1 cells treated with 24h (left panel) or 72h
(right panel) Tam. (C) Primary MEFs treated with 24h 0.5 µM Doxo. (D) Correlation plots of qRTPCR analysis of RNA induction upon 24h Tam treatment in LA1.1 cells. Represented are lncRNA
and corresponding neighboring and/or overlapping mRNA levels relative to Gapdh, normalized to
untreated LA1.1 cells. LincRNA-p21 plotted against p21 and Pvt1b plotted against Myc are
highlighted in green and red, respectively. Data show mean values (n=3 biological replicates).
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To further examine the relationship between p53-activated lncRNAs and
their neighboring mRNAs, we next sought to establish a genetic lncRNA LOF
strategy. We turned to CRISPR-Cas9 mutagenesis of lncRNA-associated p53REs,
reasoning that as p53 is a sequence-specific transcription factor, genetic
disruptions of the DNA element recognized by p53 should specifically abrogate
p53-dependent lncRNA induction. Of the 13 lncRNAs selected for validation, 11
(excluding Neat1 and Malat1) had p53REs identifiable by p53scan (Tables 3.1,
3.2). Most lncRNA-associated p53REs were located at or near promoter regions,
with 8 out of 11 (73%) p53REs being found either upstream of a lncRNA’s TSS or
within the lncRNA gene’s first exon or first intron, similar to what has been
observed for protein coding p53 targets (Table 3.2) (Riley et al. 2008).
To test the feasibility of our p53RE mutagenesis approach, we selected 7
lncRNAs for which we were able to design gRNAs that were highly specific
(specificity score by CRISPOR (Haeussler et al. 2016) >70/100) and predicted to
direct Cas9 cleavage within or adjacent to a p53RE sequence. Introduction of Cas9
and lncRNA p53RE-targeting (ΔRE) gRNAs into a clonal LA2-derived cell line,
LA2.5 (cell lines generated by J. Bendor), abrogated the Tam-induced upregulation
of 5 of the 7 targeted lncRNAs, confirming direct transcriptional regulation by p53
(Fig. 5A). Two lncRNAs, 2310008N11Rik and Rhod-as, were not affected by this
approach. This was likely due to the inefficient disruption of their p53REs by the
designed gRNAs, as was revealed by Sanger sequencing individual alleles from
populations of cells expressing Cas9 and non-targeting (Con) or ΔRE gRNAs (Fig.
5B).
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Table 3.2: Descriptions of lncRNA-associated p53 response elements (p53REs)
#

LncRNA

1
2
3

lincRNA-p21
Zmat3-as

4
5
7

lincRNA-Spag9
lincRNA-Gadd45γ
2310008N11Rik
(lncRNA 7)
Pvt1

11
15

Bahcc1-as

p53RE
Location
Exon 1
Promoter
Downstream
Intron 1
Exon 3

AGGCAAGCCCGGGCAAGgCC
AGACATGCCTGGGCTTGTTT
GAACAAGCaT (GTAGACAGA)
GcACATGTTC
GGACTTGTTgGGACATGTCC
AGGCATGCCT (G) tGACATGCCT

Exon 1

AGACATGTCTGAGCAAGCCT

p53RE Sequence

Promoter

tGACAAGTTTGGGCTTGTTC
GAGCTAGCTC(TG)GcACATGgCa(GA)
Rhod-as
Intron 1
tGtCATGaaT
GGAtTTGCCT (GGACTTGAG)
16 Sesn2-s
Promoter
AcGCTcGCTT
GGACATGTAA (CGAAGGGCCTGCCC)
17 Bfsp2-as
Intron 5
GGGCATGTCC
GGACTTGCCTGGACTTGCTC
21 Ltc4s-as
Intron 1
P53RE consensus sequence= RRRCWWGYYY(n)RRRCWWGYY; n=0-15 nt
*Inefficient disruption of p53RE sequence experimentally determined (Fig. 5A)
†Prohibitively low gRNA specificity score

Suitable
PAM?
YES
YES
No
YES
YES
*No
YES
*No
No
†

No
YES

To assess the consequences of this p53RE mutagenesis on local gene
expression and broader p53 pathway function, we turned to our LA1.1 cells, which
are a better characterized model for LA function within the lab. As a positive
control, we added lincRNA-p21 to our list of targeted p53-regulated lncRNA loci,
and focused on lncRNA loci in which we were able to achieve efficient mutagenesis
as determined by TIDE (Tracking of Indels by Decomposition) (Brinkman et al.
2014) analysis of sequenced Con and ΔRE LA1.1 populations (Fig. 5C). Similar to
what was observed in LA2.5 cells, lncRNA ΔRE-expressing LA1.1 cells exhibited
significantly less lncRNA induction upon Tam-treatment compared to cells
expressing control gRNAs (Fig. 5C). As expected, the downregulation of lincRNAp21 (73% knockdown) in cells expressing gRNA ΔRE-lincRNA-p21 was
accompanied by a corresponding 24% decrease in p21 levels compared to control
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cells, whereas Pvt1b downregulation (81%) in Tam-treated ΔRE-Pvt1b cells led to
a 58% increase in Myc expression, confirming previously reported regulatory
relationships at these loci (Dimitrova et al. 2014; Olivero et al. 2020).
Intriguingly, we discovered that mutagenesis of the p53REs associated with
three previously undescribed lncRNAs, Zmat3-as, lincRNA-Gadd45γ, and Ltc4sas, also resulted in reduced expression of their respective neighboring and/or
overlapping genes, compared to control cells (Fig. 5C). Of note, for Ltc4s-as, which
is transcribed antisense to two protein-coding genes (Ltc4s and Maml1), only Ltc4s
was significantly reduced in ΔRE-Ltc4s-as-expressing cells, while Maml1
expression was not significantly affected, suggesting that coregulation by p53 at
this complex locus is tightly regulated. The regulatory relationship between Ltc4sas and its overlapping neighbors is further explored in Chapter 5.
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Figure 5: LncRNA p53 response element (p53RE) mutagenesis reveals co-regulatory
relationships. (A) Top- schematic of pilot CRISPR-Cas9 p53RE mutagenesis experiment. Vector
shown= BRD001 (see supplementary table 1). Bottom- qRT-PCR of indicated lncRNA levels in
LA2.5 cells expressing corresponding ΔRE-targeting gRNAs. Data shown as log2FC normalized to
LA2.5 cells expressing non-targeting (Con) gRNA ±SD (n=2 biological replicates). (B) i.
Schematics for indicated lncRNA/mRNA genomic loci and p53RE mutagenesis strategies. Green=
p53RE location (asterisks), p53RE sequence (text). Brown= ΔRE gRNA targeted PAM. ii.
Representative control and ΔRE mutated alleles identified by Sanger sequencing. Red=
characterization of p53RE indels. (C) qRT-PCR detection of indicated lncRNAs and associated
mRNAs in indicated LA1.1 cells and treatments, normalized to cells expressing control gRNAs.
TIDE mutagenesis efficiencies (Mut.) are noted in red text. Data show mean ±SEM (n=3-5
biological replicates). *p <0.05, ** p<0.01, ***p<0.001, and **** p<0.0001, ns= not significant,
unpaired t test.
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Novel p53 target lincRNA-Gadd45γ positively regulates Gadd45γ in cis
Given the role of lincRNA-p21 in promoting the expression of p21 and the
role of Pvt1b in transcriptionally repressing Myc, we next wondered whether
Zmat3-as, lincRNA-Gadd45γ, and Ltc4s-as might also influence the expression of
their neighboring genes. Given the overlapping genomic contexts of Zmat3-as and
Ltc4s-as, making functional dissociation of the lncRNA and mRNA transcripts
more challenging, we initially chose to focus on lincRNA-Gadd45γ, which
represents a discrete transcriptional unit located 125k b downstream of Gadd45γ
(Growth arrest and DNA damage-inducible 45 gamma). Furthermore, Gadd45γ
is a poorly characterized member of a family of proteins that are involved in cell
cycle regulation and survival, some through the p53 pathway (E. Tamura et al.
2012), though Gadd45γ is not thought to be directly regulated by p53 itself. Thus,
multiple features of the lincRNA-Gadd45γ/Gadd45γ locus made it an attractive
candidate for further study.
We next explored the possibility that lincRNA-Gadd45γ might play a
functional role in promoting the expression of Gadd45γ, analogous to lincRNAp21 and p21. To determine whether loss of p53 binding at the lncRNA locus or loss
of the lncRNA transcript itself contributed to the effects on Gadd45γ regulation
observed in ΔRE- lincRNA-Gadd45γ cells, we turned to CRISPR-based epigenetic
modulation of the lincRNA-Gadd45γ locus. First, we inhibited lincRNA-Gadd45γ
expression via transcriptional interference by targeting Cas9 downstream of its
TSS using a 12-nt dead RNA (dRNA), which allows the recruitment of catalytically
active Cas9 without supporting nuclease activity (Fig. 6A-top) (Dahlman et al.
2015). Importantly, this approach allowed us to abrogate lincRNA-Gadd45γ
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expression in a manner removed from p53-dependent regulation at this locus. We
observed a 50% decrease in lincRNA-Gadd45γ levels and a corresponding 30%
decrease in Gadd45γ expression in Tam-treated LA1.1 cells expressing targeting
dRNAs compared to controls (Fig. 6A-bottom). Thus, these data demonstrated
that some aspect of lincRNA-Gadd45γ biogenesis or RNA positively regulates
lincRNA-Gadd45γ expression in the p53-dependent response to oncogenic stress.
In the converse experiment, we used the CRISPR-Synergistic Activation
Mediator (SAM) system to induce the expression of lincRNA-Gadd45γ in either
the absence or presence of p53. In this CRISPRa platform, catalytically active Cas9
is recruited to a site upstream of the TSS using a dRNA fused to MS2 repeats, which
in turn serve to recruit a complex of transcriptional activators fused to the MS2binding protein (MBP-HSF1-p65)(Fig. 6B-top) (Dahlman et al. 2015; Olivero et al.
2020). In an experiment performed by E. Martínez-Terroba (who also developed
the molecular reagents used in this specific CRISPRa platform), CRISPRa of
lincRNA-Gadd45γ led to a 28-fold and 26-fold upregulation of lincRNA-Gadd45γ
over control dRNAs in the absence and presence of p53, respectively. Importantly,
p53-independent activation of lincRNA-Gadd45γ via CRISPR-SAM was marked
by a 9-fold increase in Gadd45γ levels as well, further suggesting that transcription
from the lncRNA locus is sufficient to promote Gadd45γ expression (Fig. 6Bbottom).
As a third orthogonal approach to depleting lincRNA-Gadd45γ levels, we
employed antisense oligonucleotides (ASOs), which decrease target RNA levels
through both RNase-H-dependent and transcription-based mechanisms (Lai et al.
2020; Lee and Mendell 2020). Two independent lincRNA-Gadd45γ targeting
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ASOs were designed and introduced into LA1.1 cells and RNA levels compared to
a non-targeting control ASO (Con) (Fig. 6C-top). Interestingly, while both ASO1
and ASO2 led to a significant decrease in lincRNA-Gadd45γ expression in Tamtreated LA1.1 cells (96% and 93% knockdown, respectively), only ASO2 led to a
corresponding 47% decrease in Gadd45γ levels (Fig. 6C-bottom). Curious as to
whether this discrepancy stemmed from each ASO targeting a different
complement of lincRNA-Gadd45γ isoforms, we designed an additional two qPCR
primers against lincRNA-Gadd45γ. While primer pairs (1) and (2) revealed
comparable levels of lincRNA-Gadd45γ knockdown for both ASO1 and ASO2,
primer pair (3) showed that solely ASO2 yielded a significant 26% decrease in
lincRNA-Gadd45γ, paralleling the effect observed on Gadd45γ (Fig. 6C-bottom).
These data are suggestive of the presence of alternate lncRNA isoforms that
differentially contribute to Gadd45γ regulation.
Taken together, these data indicate that the production of lincRNAGadd45γ is both necessary and sufficient to modulate Gadd45γ expression,
analogous to other cis-regulatory lncRNAs, and expands the number of known cisregulatory lncRNAs within the p53 network.
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Figure 6: LincRNA-Gadd45γ positively regulates Gadd45γ in cis. (A) Top- Design of
lincRNA-Gadd45γ CRISPRi experiment. Bottom- qRT-PCR analysis of lincRNA-Gadd45γ and
Gadd45γ levels relative to Gapdh in indicated LA1.1 cell lines and treatments. (B) Top- Design of
lincRNA-Gadd45γ CRISPRa experiment. Bottom- qRT-PCR analysis of normalized lincRNAGadd45γ and Gadd45γ levels relative to Gapdh in indicated LA1.2 cell lines and treatments. (C)
Top- Diagram of lincRNA-Gadd45γ locus, indicating locations of ASOs (2) and qPCR primer pairs
(3). Bottom- qRT-PCR detection of Gadd45γ and indicated lincRNA-Gadd45γ amplicons in LA1.1
cells treated with indicated ASOs and Tam. Green asterisks indicate p53RE. Data show mean ±SEM
(n=3 biological replicates). *p <0.05, ** p<0.01, ***p<0.001, and **** p<0.0001, ns= not
significant, unpaired t test.
In (B), CRISPRa was performed by E. Martínez-Terroba.
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Pvt1b-Myc co-regulation is necessary for p53’s anti-proliferative
response to oncogenic stress
Lastly, we examined whether genetic inhibition of the p53-activated
lncRNAs lincRNA-p21, Pvt1b, Zmat3-as, lincRNA-Gadd45γ, and Ltc4s-as affected
the antiproliferative outcome observed upon p53 activation in LA cell lines. To
assess proliferation, we performed growth curve, BrdU incorporation, and colony
formation assays with control, ΔRE-lincRNA-p21, ΔRE-Pvt1b, ΔRE-Zmat3-as,
ΔRE-lincRNA-Gadd45γ, and ΔRE-Ltc4s-as cells. As expected, control cells
underwent permanent cell cycle arrest following Tam-mediated p53 restoration
and failed to grow or form colonies (Fig. 7A-D). We found that ΔRE-Pvt1b cells
overcame in part the permanent growth arrest and formed colonies (Fig. 7A-D). In
contrast, inhibition of either Zmat3-as, lincRNA-Gadd45γ, or Ltc4s-as did not
significantly affect cellular proliferation and/or clonogenicity (Fig. 7A-D). While
ΔRE-lincRNA-p21 cells did exhibit a slight growth advantage at earlier time points
(Fig. 7B), likely reflecting the decreased levels of G1/S check point mediator p21 in
these cells, this growth advantage was lost over time and ultimately did not
contribute to defects in sustained growth arrest or increased colony formation
capability.
We also assessed the effects of lncRNA inhibition on apoptosis, which is not
the normal p53 response initiated in LA cells but could theoretically be triggered
by the loss of key p53 targets important for driving LA-specific p53 cell fate
decisions. As expected, p53 restoration did not promote apoptosis or decrease
viability in control cells, in contrast to positive control cells additionally treated
with acute DNA damage (Fig. 7E, F). This resistance to cell death in response to
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oncogenic stress was unaffected by the inhibition of lincRNA-p21, Pvt1b, Zmat3as, or lincRNA-Gadd45γ (Fig. 7E, F).
Thus, these data demonstrate that, barring Pvt1b, loss of no individual p53activated lncRNA was sufficient to bypass oncogenic stress-mediated arrest, and
that furthermore, lncRNAs are unlikely to significantly contribute to p53 cell fate
decision making in LA cells.
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Figure 7: Contributions of lncRNA-mRNA co-regulation to p53’s antiproliferative
response to oncogenic stress. (A) Cumulative cell numbers of Tam-treated control (indicated
in red) or lncRNA ΔRE gRNA-expressing LA1.1 cells over time. (B) BrdU incorporation in LA1.1
cells expressing indicated gRNAs following 24h Tam and 2h BrdU treatment. Cells were scored for
BrdU (FITC) incorporation by immunofluorescence and total number BrdU positive nuclei plotted
over total scored nuclei per cell line. (C) Representative images of colony formation assays in Tamtreated LA1.1 cells expressing indicated gRNAs. (D) Quantification of (C). (E) Immunoblotting for
CC3 in LA1.1 cells expressing indicated gRNAs and indicated treatments (Doxo= 1 µM). (F)
Viability assayed by Trypan blue exclusion in LA1.1 cells expressing indicated gRNAs and
treatments (Doxo= 1 µM). Data in (A-D, F) represent mean values ±SEM (n=3-4 biological
replicates). *p <0.05, ** p<0.01, and ***p<0.001, unpaired t test.
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Data summary and conclusions
Collectively, these data represent a comprehensive investigation of the p53
response to oncogenic signaling and the gene networks that underlie common,
tumor type-specific, and senescence- or apoptosis- specific p53 responses to this
stress. Importantly, we uncovered a small core set of genes, including several novel
lncRNAs, that were directly activated by p53 in all KPR tumor types, providing an
important resource for future studies into the universal effects of p53 re-activation
in cancer settings.
Our data refutes the hypothesis that p53 decision-making is driven by the
activation of unique, outcome-specific transcriptional networks, as we did not find
any

obvious

senescence-specific

of

apoptosis-specific

programs.

These

observations were initially surprising, given the striking, apparently stressoragnostic outcome-specificity of our KPR tumor-derived cell lines. However, this
conclusion is consistent with an emerging model of p53 pathway function in which
p53 is thought to activate a multifunctional and likely redundant core network,
regardless of biological context (Andrysik et al. 2017; Verfaillie et al. 2016). In this
model, context-specific p53 cellular responses would arise from cell- or stressorspecific “interpretations” of this core p53 network, which could be p53independent. Interestingly, we did reveal a previously unappreciated connection
between p53-mediated gene repression and oncogenic stress-induced senescence,
but not apoptosis. The mechanism and importance of this repression remains to
be explored further.
This work also greatly expands the known catalogue of p53-activated
lncRNAs, linking 16 previously undescribed lncRNAs to the p53 transcriptional
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network, and specifically, the p53 response to oncogenic stress. Interestingly, a
number of previously described lncRNAs induced by p53 in response to genotoxic
stress (see Table 1.1), were not found in our work, suggesting significant species, cell line- or stress-dependent variability in the cohort of lncRNAs activated by
p53. We found that most p53-activated lncRNAs remain at the chromatin,
presumably at their sites of transcription (Werner and Ruthenburg 2015), and that
many are co-regulated with their neighboring genes. These localization and
regulatory patterns lead us to suppose that the primary role of p53-activated
lncRNAs is cis-regulation, as exemplified by lincRNA-p21, Pvt1b, and two newly
characterized lncRNAs: lincRNA-Gadd45γ (this chapter) and Ltc4s-as (discussed
further in Chapter 5). Notably, the inhibitory function of Pvt1b appears to be
unique in the p53 network and not a general mechanism by which p53 enacts gene
repression as we did not find other examples of negative lncRNA-mRNA coregulation. This suggests that lncRNA-mediated cis activation, but not cis
repression is a key feature of the p53 transcriptional network.
Barring Pvt1b, loss of no individual tested p53-activated lncRNA was
sufficient to bypass oncogenic stress-induced growth arrest. We interpret this to
mean that the highly redundant nature of p53’s anti-growth response to oncogenic
stress extends beyond just protein coding p53 targets and applies to lncRNA
targets of p53 as well. Interestingly, these data also suggest that negative
correlations between lncRNAs and neighboring protein coding genes, while
uncommon, may be indicative of functionally important lncRNA-mRNA coregulatory relationships.

75

Nevertheless, these data demonstrate the potential for p53-activated lncRNAs
to contribute to p53 pathway regulation, and in the case of Pvt1b, the potential
functional importance of cis-regulation in mediating p53 growth suppression. This
concept of lncRNAs contributing to p53 regulated cellular responses, in possibly,
context-dependent ways, is explored further in Chapter 4 and Chapter 5.

76

Chapter 4:

Characterization of novel p53-activated lncRNA
2310008N11Rik

Introduction
2310008N11Rik, hence-forth referred to as lncRNA 7, is one of the several
previously undescribed p53-activated lncRNAs we identified in Chapter 3, and is
an intergenic, spliced and poly-adenylated lncRNA of three exons located in a gene
desert on chromosome 8 (Fig. 8A). This chapter is an in-depth characterization of
this novel gene, which was chosen as an interesting p53-induced lncRNA for
further study for several reasons, most notably its robust induction and expression
profile across our KPR and genotoxic stress models, unique localization patterns,
and possible conservation between mice and humans. Here, we investigate the role
of lncRNA 7 in regulating p53-dependent cell cycle arrest and survival using
exogenous overexpression and CRISPR-based epigenetic manipulations for
lncRNA LOF and GOF.

Results
2310008N11Rik (lncRNA 7) is a previously undescribed lncRNA
To confirm that this unstudied RNA was truly noncoding, protein coding
potential was assessed in two ways. First, as discussed in Chapter 3, the Coding
Potential Assessment Tool (CPAT) was employed. Full length lncRNA 7 had a
CPAT score below the protein-coding threshold assigned to the mouse
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transcriptome, suggesting a lack of coding potential (Table 3.1). Second, a
number of recent publications have highlighted the potential of lncRNA loci to
encode expressed and translated micropeptides. LncRNA-encoded micropeptides
can be overlooked by both in silico coding assessment tools and mass proteomic
analyses due to their small size (<100 amino acids) and potential non-canonical
start codon usage, but are often identifiable by strong peaks of evolutionary
conservation (Lewandowski et al. 2020; Anderson et al. 2015). As lncRNA 7 is
found both in the nucleus and cytoplasm (Fig. 4B, C) and thus feasibly able to
associate with the ribosome, manual binformatic analysis was performed to rule
out the presence of any small but potentially translated ORFs within lncRNA 7 that
may have been missed by CPAT. Using NCBI ORFinder, two putative small ORFs
(sORFs) were identified, predicted to yield micropeptides of 13 (sORF1) and 21
(sORF2) amino acids (Fig. 8B). However, comparing these putative peptides to
publicly available protein databases yielded no significant matches within
eukaryotes. Additional comparison of the RNA sequences of these putative
peptides also revealed a lack of sequence conservation, further suggesting the
absence of translated sORFs. In summary, lncRNA 7 was deemed unlikely to be
micropeptide-encoding and thus represent a true novel lncRNA.

LncRNA 7 is induced by oncogenic and genotoxic stress in a p53dependent manner
In our original RNA-seq experiment in the panel of KPR cell lines, lncRNA
7 was most robustly induced at 24h Tam treatment in the four independent lung
adenocarcinoma (LA) and sarcoma (SA) cell lines, which undergo senescence upon
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p53 restoration (LA1, LA2, SA1, SA2). In contrast, lncRNA 7 was less markedly
upregulated at this time point in the two lymphoma (LY) cell lines (LY1, LY2),
which undergo p53-dependent apoptosis. This observation was confirmed by qRTPCR in the same panel of six KPR cell lines (Fig. 8C), firmly establishing lncRNA 7
as being induced in a p53-dependent manner under conditions of oncogenic stress
and hinting at senescence-specific regulation.
Intriguingly, lncRNA 7 shares synteny, if not primary sequence similarities,
with a lncRNA located in the corresponding region on human chromosome 8,
LINC01605 (Fig. 8A). Looking through publicly available data on p53 binding
throughout the human genome (Wei et al. 2006), we noticed that p53 bound near
LINC01605 in human colorectal cancer cells treated with 5-fluorouracil, leading us
to wonder whether LINC01605 represented a putative human orthologue of
lncRNA 7. Supporting this hypothesis, we saw that in human osteosarcoma (U2OS)
cells with in-tact p53, LINC01605 was upregulated upon Nutlin-3 treatment,
which stabilizes p53 protein through antagonizing interactions with MDM2 (Nag
et al. 2013), signifying p53-dependent regulation of this human lncRNA (Fig. 8D).
Moreover, LINC01605 has been recently reported to play a role in human colon
cancer, indicating another link between this locus and cancer signaling pathways
(Forrest et al. 2018). Thus, lncRNA expression from this region under conditions
of oncogenic stress may be conserved in mice and humans.
Further characterization revealed that lncRNA 7 was also induced under
conditions of p53 stabilization in other cellular contexts. As discussed in Chapter
2, MEFs treated with Doxo represent a well-established in vitro system to study
p53-dependent processes downstream of genotoxic stress (Attardi et al. 2004).
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LncRNA 7 upregulation was observed in Doxo-treated primary MEFs at as early as
8h post-treatment, comparable to direct p53 target p21, and reached an average of
5-fold induction at 24h (Fig. 8E). To further establish that this induction was
directly through p53, lncRNA 7 levels were also assessed in p53LSL/LSL; Rosa26CreERT2 (p53-restorable) MEFs. In these MEFs, p53 is constitutively inactivated
by the homozygous insertion of a LoxP-flanked STOP cassette into the endogenous
p53 locus. Upon treatment with Tam, Cre-mediated excision of the STOP cassette
restores p53 expression (Ventura et al. 2007). While treatment with Doxo had
negligible effects on lncRNA 7 and p21 induction in the absence of Tam, significant
induction was observed in p53-restorable MEFs upon Tam and Doxo treatment,
indicating that induction relied on p53-proficiency (Fig. 8F). Of note, a milder
induction of both lncRNA 7 and p21 was also observed in Tam only treated cells
(Fig. 8F), likely reflecting a milder p53 response triggered by the stress naturally
accumulated over time in cells lacking p53 (Ventura et al. 2007).
In further support of direct regulation by p53, lncRNA 7 was found to
harbor a p53 response element (p53RE) within its first exon. The sequence of this
p53RE perfectly matches the consensus p53RE motif and contains two directly
juxtaposed half sites, both of which are features associated with high affinity
p53REs (Riley et al. 2008). Indeed, p53 ChIP-qPCR confirmed p53 binding at this
site upon p53 restoration (Fig. 8G).
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Figure 8: LncRNA 7 (2310008N11Rik) is a novel, p53-regulated lncRNA. (A) Schematic
of lncRNA 7 locus, with nearest neighboring genes indicated in relation to distance from lncRNA
7’s TSS. Asterisk indicates p53RE location. Shading marks region of shared genic synteny with
human chromosome 8, centered around LINC01605. (B) Full length lncRNA 7 sequence and ORF
analysis. Two putative sORFs identified by NCBI ORFinder are highlighted in orange. Results of
peptide and nucleotide sequence conservation analysis are noted below. (C) qRT-PCR analysis of
lncRNA 7 relative to endogenous control RNA Gapdh in the indicated KPR cell lines and
treatments. Data show mean ±SEM (n=3 biological replicates). *p <0.05 and ** p<0.01, unpaired
t test. (D) qRT-PCR analysis of LINC01605 relative to GAPDH in U2OS cells and indicated
treatment (Nutlin= 5 µM). Data show mean ±SD (n=3 technical replicates). (E) qRT-PCR analysis
of lncRNA 7 and p21 relative to Gapdh in primary MEFs treated with 0.5 µM Doxo, normalized to
untreated control. Data show mean ±SEM (n=3 biological replicates). ** p<0.01, unpaired t test.
(F) qRT-PCR analysis of lncRNA 7 and p21 relative to Gapdh in p53LSL/LSL; Rosa-CreERT2(p53restorable) MEFs treated as indicated (Doxo= 0.5 µM). Data show mean ±SD (n=2 biological
replicates). (G) Top= lncRNA 7 p53RE sequence compared to consensus sequence. Bottom=
Enrichment of p53 binding at lncRNA 7’s p53RE or a control region (gene desert) by ChIP followed
by qRT-qPCR. Data show mean ±SD (n=3 technical replicates).
In (G), p53 ChIP was performed by N. Dimitrova (qRT-PCR was performed by E. Tesfaye).
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Taken together, these data established that lncRNA 7 is a novel lncRNA
directly activated by p53 in multiple biological contexts and suggested that lncRNA
7 may play a significant role in the p53 pathway, either contributing to p53’s cell
fate decision making in response to oncogenic stress or as a more general regulator
of p53 activity. To test these hypotheses, we next set out to establish efficient,
locus-appropriate LOF and GOF tools. Subcellular fractionation revealed that
although lncRNA 7 is nuclear-enriched, a sizeable (~40%) fraction is also found in
the cytoplasm in both KPR cells and primary MEFs (Fig. 4B, C). As discussed in
Chapter 3, this cytoplasmic localization pattern was revealed to be somewhat
unique to lncRNA 7 amongst the p53-responsive lncRNAs identified in our study.
With this localization pattern and lncRNA 7’s status as an intergenic lncRNA in
mind, the following GOF and LOF approaches were employed in order to
interrogate lncRNA 7 function.

Exogenous overexpression of lncRNA 7 yields no discernable effects on
p53 pathway function
As lncRNA 7 was initially identified as being preferentially upregulated in
cells that undergo senescence, we first tested whether over-expressing lncRNA 7
might affect cellular proliferation. While transgene overexpression (OE) is
unsuitable for studying locally acting lncRNAs, the large fraction of endogenous
lncRNA 7 found in the cytoplasm prompted as to investigate a potential transacting role by first taking an exogenous lncRNA OE approach. Full-length lncRNA
7 cDNA was stably introduced into cells using a retroviral vector, with an empty
vector (EV) construct serving as a negative control. High levels of lncRNA 7 OE
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were achieved in both KPR cells (LA1, LA2, SA1, SA2) and primary MEFs, reaching
levels several hundred-fold beyond those achieved via endogenous activation upon
either Tam or Doxo treatment, respectively (Fig. 9A).
With these two in vitro models established, cellular proliferation was
assessed in both the absence and presence of p53, rationalizing that if lncRNA 7
works as a downstream target of p53, its OE might be able to recapitulate some
aspect(s) of p53 activity in lieu of activation of the rest of the p53 network.
However, lncRNA 7 OE had no significant effect on proliferation rates in either
normally growing early passage primary MEFs, p53-deficient MEFs (i.e. p53restorable MEFs -Tam), or p53-deficient KPR cells. These data suggested that
exogenous OE of lncRNA 7 does not promote senescence or cell cycle arrest in these
diverse biological contexts (Fig. 9B). To test whether lncRNA 7 was perhaps indeed
a necessary component of p53’s antiproliferative response but not sufficient to
drive growth arrest in the absence of a competent p53 pathway, proliferation was
also assessed in p53-proficient, p53-restorable MEFs. As predicted, Tam-treated
p53-restorable MEFs grew at a slightly slower rate than un-restored, p53-deficient
cells, reflecting a p53-dependent antigrowth response to stress accumulated in
these cells prior to p53-restoration. However, this growth rate was comparable
between lncRNA-7- and EV-expressing control cells, suggesting that exogenous OE
of lncRNA 7 does not promote growth arrest in the presence of a competent p53
network but no additional stress (Fig. 9B).
Primary MEFs exposed to low levels of DNA damage undergo senescence,
as detected through morphological changes (enlarged nuclei, enlarged and
flattened cellular shape) and positive senescence-associated β-galactosidase (SA-β
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gal) staining (Campisi and d’Adda di Fagagna 2007). To test whether exogenous
OE of lncRNA 7 modulated this stress-induced senescence in MEFs, SA-β gal
activity was monitored in lncRNA 7- and EV-expressing primary MEFs treated
with low levels of Doxo for one week. MEFs over-expressing lncRNA 7 were as
proficient at undergoing senescence as EV-expressing cells (Fig. 9C). LncRNA 7
exogenous OE similarly had no significant effect on growth arrest in Tam-treated
LA and SA KPR cells (Fig. 9D). Thus, transgene OE of lncRNA 7 did not appear to
have any discernable effects on cellular proliferation in multiple independent cell
lines, nor in response to either genotoxicity-induced or oncogene-induced growth
arrest.
Next, we tested whether lncRNA 7 might not promote cellular arrest, but
rather prevent the initiation of an alternative cell fate upon p53 activation.
Increased resistance to pro-apoptotic signals is a commonly observed feature in
senescent cells (Childs et al. 2014; Soto-Gamez et al. 2019). Curious as to whether
lncRNA 7 might play a pro-survival role, we assessed the effects of lncRNA 7
exogenous OE on apoptosis in our primary MEF and LA and SA KPR models.
While primary MEFs are predisposed to undergo p53-dependent cell cycle
arrest in response to genotoxic stress, acute exposure to high levels of DNA damage
can drive apoptosis (Attardi et al. 2004; Kastan et al. 1992). In the absence of Doxo,
exogenous lncRNA 7 OE had no effect on viability in primary MEFs (Fig. 9E).
Under pro-apoptotic conditions (i.e. treatment with 1 µM Doxo), apoptosis as
measured by cleaved caspase 3 (CC3) was detectable in both lncRNA 7- and EVexpressing cells. However, no significant differences were observed between the
two conditions, indicating lncRNA 7 OE did not modulate the apoptotic response
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to genotoxic stress in primary MEFs (Fig. 9E). E1A-expressing MEFs also undergo
apoptosis in response to DNA damage in a specifically p53-dependent manner, and
thus represent a widely-employed model to study components of the p53 pathway
that contribute to apoptosis (Lowe et al. 1993a). Aiming to refine our investigation
of lncRNA 7’s role in modulating apoptosis downstream of p53, control- or E1Aexpresssing p53-restorable MEFs were stably infected with EV or lncRNA 7 and
treated with Tam to restore p53 and Doxo to induce apoptosis. Similar to what was
observed in primary MEFs, lncRNA 7 OE did not have any effect on the extent of
apoptosis observed in E1A-sensitized MEFs exposed to genotoxic stress (Fig. 9F).
Also investigated were the effects of lncRNA 7 OE on viability in LA and SA
KPR cells, which preferentially undergo p53-dependent senescence rather than
apoptosis. As expected, EV-expressing control LA cells did not undergo
appreciable apoptosis, either in the absence (-Tam) or presence (+Tam) of p53,
confirming that p53-restoration is insufficient to drive apoptosis in these cells.
This phenotype was not altered by lncRNA 7 OE (Fig. 9G). Hypothesizing that
lncRNA 7 OE may confer cytoprotective effects solely under pro-apoptotic
conditions, apoptosis was assessed in p53-restored LA and SA KPR cells treated
with high levels of acute genotoxic stress (1 µM Doxo). While Doxo treatment was
indeed able to drive SA cells to undergo apoptosis, lncRNA 7 OE had no significant
effect on the extent of this apoptosis (Fig. 9H). Thus, these data altogether suggest
that exogenous lncRNA 7 OE does not alter p53 outcome-specificity or pathway
robustness in primary MEFs or KPR cells.
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Figure 9: LncRNA 7 exogenous OE does not affect cellular proliferation or apoptosis
under genotoxic or oncogenic stress. (A) qRT-PCR analysis of lncRNA 7 in primary MEF and
KPR cell lines expressing either lncRNA 7 overexpression (OE; L7) or empty vector (EV) control
and treatments (Doxo= 0.5 µM). Data show mean ±SEM (n=3 biological replicates). *p <0.05 and
** p<0.01, unpaired t test. (B) Growth curves in indicated EV and L7 cell lines and treatments
passaged over time. For primary MEF experiments, data represent mean ±SEM (n=3 biological
replicates), unpaired t test at each passage. For p53-restorable and KPR cell lines, data are
representative. (C) Senescence-associated β-galactosidase staining in indicated cell lines and
treatment. (D) Cumulative cell numbers over time in indicated Tam-treated EV and L7 KPR cell
lines. (E) Left= Representative immunoblot for CC3 protein in indicated cell lines and treatments.
α-tubulin served as a loading control. Right= Densitometry analysis of CC3 levels relative to loading
control, normalized to EV. Data show mean ±SEM (n=3 biological replicates). ns=not significant,
unpaired t test. (F) Immunoblotting for CC3 protein in indicated cell lines treated with 48h Tam
and 24h 0.5 µM Doxo. α-tubulin served as a loading control. (G) Representative FACS plots of EV
and L7 LA KPR cells, untreated or treated with 48h Tam prior to Annexin V/PI analysis. (H)
Immunoblotting for CC3 protein in indicated cell lines treated with 48h Tam and 24h 0.5 µM Doxo.
α-tubulin served as a loading control.
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affect

cellular

proliferation during specifically the oncogenic stress response
Next in our efforts to characterize lncRNA 7 was to develop strategies to
manipulate the endogenous expression of lncRNA 7, starting with a suitable LOF
approach. While CRISPR-Cas9 mutagenesis of lncRNA-associated p53REs proved
to be highly effective for the molecular dissection of several other p53-activated
lncRNAs (see Chapter 3), the lack of compatible PAM sites precluded the use of
this genetic strategy for lncRNA 7 (Fig. 5A, B). Instead, we turned to CRISPRinhibition (CRISPRi) to epigenetically silence the lncRNA 7 locus. CRISPRi was
achieved by recruiting nuclease-deficient Cas9 fused to the transcriptionally
repressive Krüppel- associated box domain of Kox1 (dCas9-KRAB) (Gilbert et al.
2013) to lncRNA 7’s TSS. With this approach, we aimed to take advantage of the
fact that lncRNA 7 resides in a gene desert, thus minimizing the likelihood of
CRISPR-based modulation of the locus directly interfering with the expression of
other nearby genes.
A panel of eight lncRNA 7-targeting gRNAs were designed, selected for high
specificity (score >70/100 via CRISPOR) and TSS proximity. gRNAs were screened
for efficacy in p53-restorable MEFs engineered to stably express dCas9-KRAB
(Fig. 10A, B). Remarkably, all tested guides were able to knockdown lncRNA 7
levels by 70-85% compared to a non-targeting control (Con) gRNA (Fig. 10B).
Three of the most efficient gRNAs (gRNAs #7, #9, #10) were selected for further
functional investigation of the consequences of lncRNA 7 loss on p53 pathway
function in MEFs. Despite achieving high levels of lncRNA 7 knockdown, no overt
effects on cellular proliferation were observed, as assayed through either growth
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curve analysis (Fig. 10C-left) or BrdU incorporation (Fig. 10C-right). Similarly, no
consistent effects on DNA damage-induced apoptosis were observed (Fig. 10D).
Taken together, these data suggested that lncRNA 7 is dispensable for the p53
response to genotoxic stress in MEFs.

Figure 10: Epigenetic silencing of lncRNA 7 locus does not affect p53 pathway
function in p53-restorable MEFs. (A) Diagram of PAM locations of designed lncRNA 7targeting gRNAs. Ex1= exon 1. (B) qRT-PCR detection of dCas9-KRAB in engineered p53restorable-dCas9-KRAB MEFs and lncRNA 7 levels in indicated gRNA-expressing cells and
treatments, relative to Gapdh (Doxo= 0.5 µM). C= nontargeting control gRNA. Data show mean
±SD (n=3 technical replicates). (C) Left= Growth curves in indicated cell lines and treatments.
Right= BrdU incorporation in indicated cell lines following 24h Tam and 4h BrdU treatment. Cells
were scored for BrdU (FITC) incorporation by immunofluorescence and total number BrdU
positive nuclei plotted over total scored nuclei per cell line. (D) Two representative immunoblots
for CC3 and p53 protein levels in indicated cell lines and treatments. β-tubulin served as a loading
control.
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Next we assessed the effects of lncRNA 7 LOF in our KPR oncogenic stress
model, hypothesizing that lncRNA 7 may be induced by p53 across many different
contexts but only functionally important in certain cell-type- and/or stressorspecific settings, as has been previously suggested for other p53 targets (Mello et
al. 2017; Kastenhuber and Lowe 2017). Surprisingly, screening the same lncRNA
7-targeting gRNAs in LA1.1 cells stably expressing dCas9-KRAB revealed that
dCas9-KRAB-mediated CRISPRi yielded 40-60% lncRNA 7 knockdown compared
to non-targeting control gRNA-expressing cells, in contrast to the 70-85%
knockdown observed in MEFs (Fig. 11A-left). These differences in CRISPRi efficacy
may reflect cell-intrinsic differences in chromatin state at this locus. The three top
LA1.1 performing gRNAs were subsequently introduced into parental LA1 cells
engineered to express a Doxycycline (Doxy)-inducible dCas9-KRAB construct,
which would facilitate more precise timing of LOF experiments (Fig. 11A-right). Of
the three gRNAs tested, only one guide (gRNA #12) appeared to confer a slight
growth defect, despite all three guides yielding comparable levels of lncRNA 7
knockdown (Fig. 11A, B). This phenotype was initially encouraging and explored
further in experiments detailed in Chapter 5, in which the role of lncRNA 7 and
several other senescence-associated lncRNAs is more finely examined.

Modest transcriptional activation of endogenous lncRNA 7 does not
affect cellular proliferation in LA KPR cells
As discussed in Chapter 1 and Chapter 3, lncRNAs can very broadly be
grouped as functioning near (cis-acting) or distal to (trans-acting) their sites of
transcription, with each category having unique constraints on the types of suitable
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LOF and GOF approaches. Considering the results of our exogenous lncRNA 7 OE
experiments, we wondered whether the apparent lack of an appreciable phenotype
stemmed from lncRNA 7 indeed playing a local, cis-regulatory role. In that
scenario, a transgenic OE GOF approach would not be expected to have a
phenotype, as transgenic lncRNA 7 would not be properly localized to its
endogenous site of function. To experimentally address this hypothesis, we turned
to CRISPRa as an alternative GOF strategy. Specifically, we employed gRNAmediated recruitment of nuclease-dead Cas9 fused to four copies of the
transcription activator VP16 (dCas9-VP64) (Gilbert et al. 2013) to promote the
transcriptional upregulation of lncRNA 7 from its endogenous locus.
Three gRNAs targeting lncRNA 7’s TSS (gRNAs #9, #10, #12; annotated in
Fig. 10A) were tested in LA1.1 and LA1 cells engineered to constitutively express
dCas9-VP64. gRNA #12 did not yield lncRNA 7 upregulation in either LA1.1 or LA1
cells. In contrast, gRNAs #9 and #10 led to the upregulation of lncRNA 7 levels to
4x and 8x above a nontargeting control gRNA (Con) in un-restored LA1.1 cells,
reaching roughly 22% and 50% of the lncRNA 7 levels observed upon full p53
restoration. In p53-restored LA1.1 cells, gRNAs #9 and #10 activated lncRNA 7 to
2x and 4x above control, respectively (Fig. 11C-Left). LncRNA 7 CRISPRa was
slightly more efficient in LA1 cells, with gRNA #9 yielding 5x upregulation (24%
full lncRNA 7 induction) and gRNA #10 yielding 11x upregulation (55% full
lncRNA 7 induction) in un-restored cells, and 6x and 5x upregulation, respectively,
upon Tam-treatment (Fig. 11C-Right). Thus, recruitment of dCas9-VP64 to
lncRNA-7’s TSS was able to drive modest induction of lncRNA 7 for two of the three
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gRNAs tested, suggesting that CRISPRa efficacy positively correlates with
proximity to TSS, as has been previously reported (Konermann et al. 2014).
Next, the effects of lncRNA 7 CRISPRa on cellular proliferation were
assayed, both in the absence and presence of p53. Upregulation of endogenous
lncRNA 7 had no effect on cellular proliferation in the absence of p53, as measured
by growth curve analyses in both LA1 and LA1.1 cells (Fig. 11D). This was despite
gRNA #10 driving lncRNA 7 expression in un-restored cells to levels approaching
that seen in control gRNA-expressing cells upon p53 activation (Fig. 11D).
Similarly, lncRNA 7 activation did not significantly affect growth arrest upon p53
restoration in either Tam-treated LA1.1 or LA1 cells (Fig. 11E). Taken together,
these CRISPRa data suggested that locally-acting lncRNA 7 may not contribute to
p53’s antiproliferative response to oncogenic stress, despite lncRNA 7 being
activated by p53 in such conditions. Alternatively, a threshold of lncRNA 7
transcription might be required for function, and the levels of activation achieved
using solely the recruitment of dCas9-VP64 may be insufficient. The functional
consequences of significantly higher endogenous lncRNA 7 activation are further
explored in Chapter 5.

91

Figure 11: Assessing lncRNA 7 CRISPRi and CRISPRa in KPR LA cells. (A) qRT-PCR
detection of dCas9-KRAB in LA1.1 and LA1 cells engineered to stably express dCas9-KRAB and
lncRNA 7 levels in indicated gRNA-expressing cells and treatments, relative to Gapdh. Data show
mean ±SD (n=3 technical replicates). (B) Cumulative cell numbers over time in indicated Tamtreated LA1-dCas9-KRAB cell lines. (C) qRT-PCR detection of dCas9-VP64 in LA1.1 and LA1 cells
engineered to stably express dCas9-VP64 and lncRNA 7 levels in indicated gRNA-expressing cells
and treatments, relative to Gapdh. Data show mean ±SD (n=3 technical replicates). (D) Growth
curves in indicated cell lines and treatments. (E) Cumulative cell numbers over time in indicated
Tam-treated cell lines.
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Data summary and conclusions
These data firmly establish lncRNA 7 as a novel lncRNA directly activated
by p53 in multiple cellular and stressor contexts. Moreover, we confirm the
presence of a syntenic human lincRNA (LINC01605) that is also p53-responsive in
Nutlin 3-treated human osteosarcoma cells, suggesting conserved p53 regulation,
though the importance of this p53 regulation in human cells is an intriguing
unknown.
Although we found that lncRNA 7 was strongly induced by DNA damage in
MEFs, we were unable to find any evidence for lncRNA 7 significantly contributing
to cellular proliferation, senescence, or apoptosis in this context. Similarly,
exogenous OE of lncRNA 7 did not influence the p53 outcomes of LA and SA cells,
despite the preferential induction of lncRNA 7 in these four senescing KPR cell
lines. These data suggest that lncRNA 7 does not function in trans to modulate
oncogenic stress-driven cellular senescence. It is also unlikely that trans-acting
lncRNA 7 has cytoprotective effects against either genotoxic or oncogenic stress, at
least in LA and SA cells and MEFs, which are naturally resistant apoptosis. Thus,
we conclude that lncRNA 7 is unlikely to exert any functions in trans downstream
of p53 activation, despite its cytoplasmic localization.
The effects of lncRNA 7 LOF and GOF in KPR cells is explored further in
Chapter 5, building upon the epigenetic tools developed in this chapter.
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Chapter 5:
Senescence-associated lncRNAs in p53 pathway function

Introduction
The underlying drivers of p53 cell fate decision making, or why certain
cellular conditions lead to one p53 stress response versus another, remain poorly
understood (see Chapters 1 and 2). Senescence is an irreversible state of
proliferative arrest that can be triggered by a number of stress stimuli and is
characterized by distinct morphological, epigenetic, molecular, and secretory
phenotypes (Campisi and d’Adda di Fagagna 2007). Cellular senescence is thought
to act as a safeguard against the persistent growth of cells that have accumulated
irreparable DNA damage. As such, senescence has been implicated in numerous
homeostatic processes, including tissue repair and immune clearance, as well as
several

age-associated

pathologies,

such

as

neurodegeneration,

chronic

inflammation, tissue degeneration, and cancer (Muñoz-Espín and Serrano 2014;
Campisi 2013). In cancer, senescence can be both tumor suppressive and
oncogenic, largely due to the pleiotropic effects of the proinflammatory SASP
(senescence-associated secretory phenotype) (Muñoz-Espín and Serrano 2014;
Collado and Serrano 2010). Nonetheless, p53 is known to be an important
upstream activator of oncogene-induced senescence (Serrano et al. 1997; Campisi
and d’Adda di Fagagna 2007) and p53-dependent senescence can be an important
barrier to tumor progression in vivo (Xue et al. 2007; Ventura et al. 2007; Feldser
et al. 2010; Li et al. 2014).
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In this chapter, we address the long-standing question of why p53 elicits
senescence in certain tumor types while apoptosis is initiated in others (Ventura et
al. 2007; Symonds et al. 1994). Specifically, we investigate the importance of p53activated lncRNAs that are preferentially expressed during oncogene-induced
senescence over oncogene-driven apoptosis. While a handful of lncRNAs have
previously been associated with senescence (Abdelmohsen et al. 2013; Hu et al.
2014; Ghanam et al. 2017), the broader importance of lncRNAs in establishing or
maintaining senescence driven by oncogenic stress is incompletely understood.

Results
Identification of senescence-associated lncRNAs
To identify candidate lncRNA loci that may contribute to p53 outcomespecificity, we leveraged a key feature of the KPR mouse model in which cell lines
derived from distinct tumor types respond differently to Tam-mediated p53
restoration (Fig. 2). Namely, lung adenocarcinoma cell lines (LA1, LA2) and
sarcoma cell lines (SA1, SA2) undergo senescence with no appreciable apoptosis,
thus representing an ideal in vitro system to identify novel factors contributing to
p53-mediated senescence across four independent cell lines representing two
independent tissue contexts. As detailed in Chapter 3, 21 lncRNAs were found via
genome-wide p53 ChIP-seq and RNA-seq analyses to be activated by p53 across
various KPR cell lines (Table 3.1). Amongst these 21 lncRNAs, closer examination
of expression patterns across the six KPR cell lines revealed that several lncRNAs
were preferentially upregulated in LA and SA cells upon p53-restoration,
compared to the two independent lymphoma cell lines (LY1, LY2) (Fig. 12A).
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Curious as to whether these apparent senescence-specific expression
patterns reflected a shared function, four of these oncogenic-stress induced
lncRNAs were selected for further study (2310008N11Rik [lncRNA-7], Bfsp2-as,
Ltc4s-as, and Neat1), first confirming the expression patterns observed in our
RNA-seq dataset via qRT-PCR across the six KPR cell lines (Fig. 12B). All four
lncRNAs were also induced in primary MEFs exposed to acute DNA damage, as
would be expected of direct targets of p53 (Fig. 12C). Interestingly, lncRNA-7,
Bfsp2-as, Ltc4s-as, and Neat1 levels also accumulated in MEFs under sustained
exposure to low levels of DNA damage, which also promotes senescence (Fig. 12D).
Indeed, lncRNA expression patterns paralleled those of key mediators of
senescence, p21 and p16 (Serrano et al. 1997), which also accumulated over
exposure time as is characteristic of cells undergoing senescence (Lin et al. 1998;
Campisi and d’Adda di Fagagna 2007) (Fig. 12D).
In searching for other p53-regulated lncRNAs that may also have outcomespecific expression patterns, a striking senescence-specificity was revealed for
9230114K14Rik (henceforth referred to as lincRNA-RAPT1). While lincRNARAPT1 did not meet our stringent filtering criteria to be called as an oncogenic
stress-responsive, p53-activated lncRNA in our genome-wide KPR dataset, it had
previously been implicated as a target of p53 (Guttman et al. 2009) and clearly
demonstrated p53-dependent induction in Tam-treated KPR cells (Fig. 12B) and
DNA damage-treated MEFs (Fig. 12C, D). Thus, lncRNA-7, Bfsp2-as, Ltc4s-as,
Neat1, and lincRNA-RAPT1 were determined to be induced by both oncogenic
stress and genotoxic stress, with induction patterns suggestive of a role in
senescence.
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Figure 12: Several p53-activated lncRNAs have senescence-associated expression
patterns. (A) RNA-seq values (log2 FC) in indicated KPR cell lines treated with 24h Tam
normalized to untreated samples. (B) qRT-PCR analysis of indicated lncRNAs relative to Gapdh in
indicated KPR cell lines. Fold change were calculated by normalizing to untreated cells. Data show
mean ±SEM (n=3 biological replicates). *p <0.05, ** p<0.01, and *** p<0.001, unpaired t test. (C)
qRT-PCR detection of indicated lncRNAs in primary MEFs treated with 24h mock or 24h 0.5 µM
Doxo. Data show mean ±SEM (n=3 biological replicates). *p <0.05, ** p<0.01, and *** p<0.001,
unpaired t test. (D) qRT-PCR detection of indicated lncRNAs and p21 and p16 mRNA in primary
MEFs treated as indicated. Data show mean ±SD (n=3 technical replicates).
In (A), RNA-seq was performed by N. Dimitrova (see Fig. 2).
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Characterization of lincRNA-RAPT, a novel p53-activated lncRNA
LincRNA-RAPT1 was selected for functional characterization first, due in
part to the availability of powerful genetic tools developed and initially
characterized in our lab by N. Dimitrova, and several unique features of this
lncRNA locus (described shortly).
LincRNA-RAPT1 is a polyadenylated, 9.1 kb-long transcript comprised of
four exons. While lincRNA-RAPT1 had previously come up as a transcript that was
induced by DNA damage in a p53-dependent manner in one of the earliest
genome-wide lincRNA datasets (Guttman et al. 2009), it had not been functionally
followed up on nor established to be a true direct target of p53. Our own
investigation of the lincRNA-RAPT1 locus revealed the presence of multiple p53
response elements (p53REs) within lincRNA-RAPT1’s first intron (Fig. 13A),
providing evidence for direct regulation by p53 and a basis for the p53-dependent
induction patterns observed in our two in vitro model systems (Fig. 12B, C). In the
UCSC genome browser, lincRNA-RAPT1 is annotated as RIKEN cDNA
9230114K14Rik, with several variants reflecting alternative splicing patterns and
multiple TSSs and termination sites (Fig. 13A). Deep RNA-sequencing of primary
MEFs performed by N. Dimitrova provided further evidence for the presence of
multiple transcript variants, while also revealing that full length (FL) lincRNARAPT1 in fact extends 8 kb beyond the last annotated termination site (Fig. 13A).
Intriguingly, early sequence analysis performed by N. Dimitrova also
identified a short (15 nt) region of complementarity between lincRNA-RAPT1 and
p53 mRNA’s 5’ untranslated region (5’ UTR) (Fig. 13B). Of note, this region of
complementarity, which fell within the extended lincRNA-RAPT1 exon four,
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corresponded to a region of p53 mRNA also predicted to base-pair with its own 3’
UTR. Such 5’UTR-3’UTR interactions had previously been shown to be important
for promoting the translation of human p53 under conditions of stress (Chen and
Kastan 2010; Chen et al. 2012). Thus, we were intrigued by the possibility that
lincRNA-RAPT1 may contribute to either p53 outcome-specificity or general p53
pathway robustness, potentially though RNA-RNA interactions with p53 itself.
In order to further interrogate the role of lincRNA-RAPT1 in the p53
network, two complementary genetic mouse models were developed prior to my
taking on the project and will be briefly described here. Care was taken to design a
knockout strategy that would abolish p53-dependent lincRNA-RAPT1 expression
without affecting the expression of Dhx15, which is a protein coding gene that
lincRNA-RAPT1 shares a promoter with (Fig. 13A). Dhx15 (also known as Prp43)
is a DEAD/DEAH box RNA helicase implicated in ribosome biogenesis and
spliceosome disassembly (Combs et al. 2006). Unlike lincRNA-RAPT1, Dhx15 did
not appear to be significantly regulated by p53 (Fig. 13E). While it is unclear how
two genes sharing a promoter can be differentially regulated as such, it is possible
that the intronic location of lincRNA-RAPT1’s p53REs provide an explanation.
Importantly, Dhx15 has not been previously implicated in senescence. Thus, we
concluded that lincRNA-RAPT1 and Dhx15 are unlikely to be functionally linked.
To avoid disrupting the shared promoter while designing a conditional
knockout (KO) allele, loxP sites were inserted within the first and second introns
of lincRNA-RAPT1. This allele will be referred to as the floxed (fl) allele (Fig. 13Ctop). The lincRNA-RAPT1 constitutive KO (null; -) allele was subsequently
generated by crossing lincRNA-RAPT1fl/fl mice to transgenic mice constitutively
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expressing Cre recombinase, leading to the generation of mice in which the region
between the two loxP sites has been excised. Importantly included in this excised
region are lincRNA-RAPT1’s p53REs (Fig. 13C-bottom).
The

following

lincRNA-RAPT1

characterization

experiments

were

performed in early passage primary MEFs of two complementary lincRNA-RAPT1
genetic backgrounds: (1) lincRNA-RAPT1fl/fl; Rosa26-CreERT2 or (2) lincRNARAPT1-/- vs lincRNA-RAPT1+/+. For conditional KO experiments, lincRNARAPT1fl/fl; Rosa26-CreERT2 MEFs were isolated from homozygous crosses
between lincRNA-RAPT1fl/fl; Rosa26-CreERT2 mice. In these cells, the addition of
Tam facilitates in vitro CreER-mediated recombination of the floxed allele and loss
of lincRNA-RAPT1 expression. Mock treatment served as a control, allowing
isogenic comparisons of wild type (WT) and KO cells (Fig. 13D- top). Importantly,
this strategy led to a 95% decrease in lincRNA-RAPT1 levels, effectively abolishing
p53-dependent induction, whereas Dhx15 expression was not significantly affected
(Fig. 13E). For constitutive KO experiments, littermate lincRNA-RAPT1+/+ and
lincRNA-RAPT1-/- MEFs were isolated from crosses of lincRNA-RAPT1+/heterozygotes (Fig. 13D-bottom).
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Figure 13: LincRNA-RAPT1 (9230114K14Rik) locus and development of knockout
mouse models. (A) Top= UCSC genome browser view (mm10) of Riken cDNA 9230114K14Rik,
henceforth referred to as lincRNA-RAPT1. Bottom= Schematic of Dhx15 / lincRNA-RAPT1 locus,
including previously unannotated region of lincRNA-RAPT1 exon 4 identified by RNA-seq. p53REs
are marked by asterisks. (B) Schematic of 15 nt region of complementarity between lincRNARAPT1 and p53 mRNA 5’ UTR (highlighted in blue). Also illustrated is predicted complementarity
between p53 mRNA 5’ UTR and 3’ UTR. (C) Schematic of floxed (fl) and null (-) lincRNA-RAPT1
alleles, with important features labeled as indicated. p53UCS= p53 UTR complementary sequence.
(D) Matings and in vitro drug treatments for generating primary MEF cell lines of indicated
genotypes. (E) qRT-PCR detection of lincRNA-RAPT1 and Dhx15 in primary MEFs of indicated
genotypes and treatments relative to Gapdh, normalized to WT untreated cells (Doxo=0.5 µM).
Data show mean ±SEM (n=2 biological replicates). ** p<0.01 and *** p<0.001, ns= not significant,
unpaired t test.
In (A), lincRNA-RAPT1 unannotated region indicated was identified by N. Dimitrova via RNA-seq
(data not shown). In (B), 15 nt p53UCS was identified by N. Dimitrova. Mouse alleles/genetic
models described above and in text were developed by N. Dimitrova, though all characterization
experiments shown and discussed in this chapter were performed by E. Tesfaye.
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To determine whether loss of lincRNA-RAPT1 led to any changes in
proliferation, growth curve analyses were performed in lincRNA-RAPT1 WT and
KO MEFs. Despite the drastic reduction in lincRNA-RAPT1 levels achieved, no
significant differences in proliferation rate were observed (Fig. 14A). As lincRNARAPT1-deficient MEFs appeared to grow normally, suggesting lincRNA-RAPT1
did not regulate growth arrest downstream of p53, we next wondered whether
lincRNA-RAPT1 may regulate other aspects of p53 activity. A few p53-activated
lncRNAs have been reported to regulate p53 activity in positive feedback loops (see
Table 1.1), though none have been reported to interact with p53 mRNA. Given
lincRNA-RAPT1’s short region of complementarity with p53 mRNA’s 5’ UTR, we
questioned whether the loss of lincRNA-RAPT1 affected p53 RNA and/or protein
levels. In constitutive KO MEFs, p53 mRNA levels were not significantly altered
compared to WT MEFs in either the presence or absence of DNA damage (Fig.
43B). This was also true in conditional KO MEFs (Fig. 14D), implying that
lincRNA-RAPT1 did not influence p53 mRNA transcription and/or stability.
Given that cellular stress promotes the translation of p53 mRNA (Takagi et
al. 2005) and p53 protein stabilization (Horn and Vousden 2007), we next
questioned whether lincRNA-RAPT1 promoted p53 protein levels during stress.
Increases in p53 protein were detectable in both WT and lincRNA-RAPT1 KO
MEFs at as early as 6h Doxo treatment (Fig. 14C). However, in comparing
littermate WT and constitutive KO MEFs, significant variability in p53 protein
levels was consistently observed, even amongst independent littermate WT
controls (Fig. 14C). Considering this apparent variability in p53 protein levels,
which could stem from heterogeneity in basal p53 levels or handling stress, we
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decided to focus on our conditional lincRNA-RAPT1 KO model, which allows
isogenic comparisons. Similar experiments in lincRNA-RAPT1 conditional KO (i.e.
Tam-treated) and WT (i.e. mock-treated) MEFs demonstrated no consistent effect
on p53 protein levels at either 6h or 24h Doxo treatment (Fig. 14E). Given the
accumulation of lincRNA-RAPT1 under pro-senescent conditions (Fig. 12B, D), we
also tested whether lincRNA-RAPT1 loss affected p53 levels under conditions in
which MEFs undergo senescence and did not see a significant difference compared
to control MEFs (Fig. 14F), though substantial variability in p53 protein levels
across biological replicates was observed.
Curious about potential biological explanations for this persistent
phenotypic variability, in which several experiments in multiple independentlyderived cell lines suggested some level of positive correlation between lincRNARAPT1 and p53 protein levels, we next performed more experiments further
characterizing our lincRNA-RAPT1 KO allele. Single molecule RNA FISH (smRNA
FISH) of WT and KO MEFs treated with DNA damage (Doxo) to induce lincRNARAPT1 expression revealed the persistence of cytoplasmic lincRNA-RAPT1 signal
in KO cells, albeit at drastically reduced levels (Fig. 14G-top). These data were
consistent with the endogenous localization pattern of WT lincRNA-RAPT1 as
determined by subcellular fractionation (Fig. 14G-bottom), as well as our qRT-PCR
data showing highly efficient (>90%) but not complete lincRNA-RAPT1
knockdown in KO cells.
In order to better characterize the RNA products of this persistent
transcription from the lincRNA-RAPT1 locus in KO cells, we designed a series of
qRT-PCR primers spanning lincRNA-RAPT1, aiming to capture transcript variants
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utilizing the locus’ many alternate start, splice, and termination sites (Fig. 14Htop). Surprisingly, absolute transcript abundance analysis using these primers in
WT and KO MEFs exposed the presence of quantifiable amounts of lincRNARAPT1 in KO MEFs (Fig. 14H-bottom), leading us to conclude that the lincRNARAPT1 KO allele is in fact a hypomorph.
In summary, our work establishes lincRNA-RAPT1 as a direct target of p53,
though its contributions to downstream processes regulated by p53 and possibly
p53 regulation remain to be fully explored using alternative LOF strategies.
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Figure 14: Characterization of lincRNA-RAPT1. (A) Growth curves in primary MEFs of
indicated genotypes. Data represent mean cell numbers ±SEM (n=4 biological replicates), unpaired
t test at each passage. (B) qRT-PCR analysis of lincRNA-RAPT1 and p53 mRNA in primary MEFs
of indicated genotypes and treatments relative to Gapdh (Doxo=0.5 µM). Data show mean ±SEM
(n=3 biological replicates). * p<0.05, ns= not significant, unpaired t test. (C) Immunoblotting for
p53 protein in indicated cells and treatments. HSP90 served as a loading control. (D) qRT-PCR
analysis of lincRNA-RAPT1 and p53 mRNA in primary MEFs of indicated genotypes and
treatments relative to Gapdh, normalized to untreated WT MEFs (Doxo=0.5 µM). Data show mean
±SEM (n=3 biological replicates). *** p<0.001 and **** p<0.0001, ns= not significant, unpaired t
test. (E, F) Left= Representative immunoblot for p53 protein in indicated cells and treatments
(Doxo in (E) =0.5 µM). HSP90 served as a loading control. Right= Densitometry analysis of p53
protein levels relative to loading control. Data show mean ±SEM (n=3 biological replicates). ns=not
significant, paired t test. (G) Top= smRNA-FISH of lincRNA-RAPT1 in indicated cells treated with
24h 0.5 µM Doxo. Note- background signal in nuclei from Doxo autofluorescence. Bottom= qRTPCR detection of controls (Rn7sl= cytoplasm; Kcnq1ot1= chromatin) and lincRNA-RAPT1 after
subcellular fractionation in WT primary MEFs treated with 24h 0.5 µM Doxo. CP= cytoplasmic.
NP= nucleoplasmic. CHR= chromatin-associated. (H) Top= Diagram indicating locations of qRT-
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PCR primers across lincRNA-RAPT1 exons. Bottom= Copy number calculations for lincRNARAPT1 as detected by qRT-PCR with indicated primer pairs in WT and KO MEFs

Description

of

oncogenic

stress-induced,

senescence-associated

lncRNAs
In order to determine whether additional lncRNAs contributed to p53
cellular decision making in our KPR model, we selected four candidates from our
list of oncogenic stress-induced lncRNAs that were found to have senescenceassociated expression patterns (Fig. 12). The lncRNAs selected were:
2310008N11Rik (lncRNA 7), Bfsp2-as, Ltc4s-as, and Neat1. Of these four
lncRNAs, only Neat1 had been previously studied and is a monoexonic intergenic
lncRNA located on chromosome 19 (Fig. 15A-iv). Interestingly, Neat1 has recently
been implicated in the p53 response to oncogenic stress (Mello et al. 2017)
(discussed further in Chapter 1).
The three other senescence-associated lncRNA candidates had not been
previously studied, nor linked to the p53 pathway. LncRNA 7 is an intergenic
lncRNA located on chromosome 8 (Fig. 15A-i) and is discussed more in Chapter
4, which is an in-depth characterization of this novel lncRNA.
Ltc4s-as (RIKEN cDNA AK157916) is a 1.2 kb spliced and polyadenylated
transcript of three exons (Fig. 15A-ii). As touched upon in Chapter 3, Ltc4s-as is
transcribed antisense to two protein-coding genes, Ltc4s and Maml1. Ltc4s
(Leukotriene C4 synthase) encodes an enzyme involved in the conversion of
arachidonic acid to cysteinyl leukotrienes, which are important lipid inflammatory
mediators. Although it has not been previously implicated in the p53 pathway,
Ltc4s has been linked to anaphylaxis and other inflammatory responses in humans
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(Funk 2001; Lam and Frank Austen 2002). Maml1 (Mastermind-like protein 1) is
a transcriptional co-activator in the Notch signaling pathway and, interestingly,
has been reported to also interact with p53 protein and promote p53
transactivation in human breast cancer cells (Zhao et al. 2007; Yun et al. 2015). In
contrast to Ltc4s-as and Ltc4s, which were found to be transcriptionally activated
in multiple LA and SA KPR cells lines upon Tam treatment, Maml1 expression was
not significantly altered by either p53 restoration or mutagenesis of Ltc4s-as’
p53RE (Fig. 5C), suggesting that Maml1 is not regulated in a p53-dependent
manner.
Bfsp2-as (RIKEN cDNA 5830418P13Rik) is a polyadenylated transcript 2.2
kb in size, comprised of six exons, and is transcribed antisense to the gene Bfsp2
(Beaded filament structural protein 2) (Fig. 15A-iii). Bfsp2 is an ocular lensspecific intermediate filament important for eye development (Perng et al. 2007).
While Bfsp2 did emerge as a p53-responsive gene in a previously published
genome-wide dataset (Tonelli et al. 2017), it has never been studied in the context
of the p53 stress response nor implicated in any known p53-regulated cellular
processes.

Functional investigation of the role of lncRNAs in mediating p53
outcome-specificity in response to oncogenic stress
Candidate loci determined, we elected to take CRISPR-based approaches to
epigenetically down or up-regulate lncRNA expression, which is a strategy that has
been employed to functionally interrogate noncoding loci with great success in
recent years (Liu et al. 2017; Joung et al. 2017; Fulco et al. 2016). For senescence107

associated

lncRNA

LOF,

we

employed

CRISPR-based

transcriptional

interference/inhibition (CRISPRi). In this system, catalytically inactive Cas9 fused
to the KRAB (dCas9-KRAB) was recruited to the TSSs of target loci in a gRNAdirected manner (Fig. 15B). We anticipated that both steric transcriptional
interference from dCas9 and epigenetic repression from KRAB-mediated
recruitment of repressive chromatin modifiers would lead to the knockdown of
target lncRNA expression (Gilbert et al. 2014; Thakore et al. 2015). Two TSStargeting gRNAs were designed for each senescence-associated lncRNA, with care
being taken to design guides with high specificity (scores >70/100 via CRISPOR)
and suitability for both CRISPRi and CRISPRa manipulations (Fig. 15A- right).
In order to interrogate the effects of lncRNA loss on either the
establishment or maintenance of senescence in LA and SA KPR cells, a Doxyinducible dCas9-KRAB system was selected, which would allow more temporal
control over lncRNA LOF. LA1 and SA1 cell lines stably expressing (TRE)dCaS9KRAB were established and confirmed to undergo senescence upon Tam-mediated
p53 restoration with dynamics comparable to parental LA1 and SA1 cells (Fig. 16A,
B). Individual lncRNA TSS-targeting gRNAs were stably introduced into LA1dCas9-KRAB or SA1-dCas9-KRAB cells and cells were Doxy-treated for 5-10 days
to induce dCas9-KRAB expression and allow sufficient time for KRAB-mediated
epigenetic repression (Kearns et al. 2014). Knockdown efficacy was assessed by
qRT-PCR, using the average lncRNA expression levels in cell lines expressing two
independent, non-targeting gRNAs as controls. Surprisingly, no knockdown was
observed across our panel of lncRNA-targeting gRNAs in SA1-dCas9-KRAB cells,
even when gRNAs validated to facilitate efficient CRISPRi in other, non-SA cell
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lines were assessed. Thus, our data reinforces the notion that both gRNA-specific
features and cell-intrinsic factors contribute to CRISPRi efficacy.

Figure 15: CRISPRi and CRISPRa strategies of senescence-associated lncRNA LOF
and GOF. (A) Locus schematics for four (i-iv) candidate senescence-associated lncRNAs. Light
blue boxes show PAM locations of designed lncRNA TSS-targeting gRNAs. (B) Details of CRISPRi
strategy and two-vector system for introducing necessary components: (1) dCas9-KRAB; (2) gRNA.
(C) Details of CRISPRa (VP64 CRISPR-SAM) strategy and two-vector system for introducing
necessary components: (1) dCas9-VP64; (2) gRNA-MS2; HSF-p65-MBP.
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Of the four senescence-associated lncRNAs targeted in LA1-dCas9-KRAB
cells, we were able to robustly knockdown Ltc4s-as and lncRNA 7. For Ltc4s-as,
gRNA 1 yielded a 53% knockdown and gRNA 2 yielded a 23% knockdown,
compared to the average of two independent control gRNAs (Fig. 16C). For lncRNA
7, gRNA 1 led to a 48% decrease in lncRNA 7 levels, while gRNA 2 led to a 13%
knockdown (Fig. 16C), compared to control average levels. One gRNA targeting
Bfsp2-as, gRNA 2, strangely led to a significant increase in Bfsp2-as RNA levels
(Fig. 16C). However, a closer examination of cells expressing this gRNA revealed
the dysregulation of several other p53-regulated genes, suggesting that this gRNA
had off-target effects and was not worth investigating further. Neat1 levels were
not significantly reduced in LA1-dCas9-KRAB cells.
We next asked whether the observed decreases in Lct4s-as and lncRNA 7
levels influenced cellular proliferation or survival in LA1-dCas9-KRAB cells. As
both lncRNAs are very lowly expressed in the absence of p53, most of the following
experiments were performed in p53-restored cells. However, we did determine
that epigenetic repression of either loci had no significant effect on the ability of
LA1-dCas9-KRAB cells to form colonies in the absence of p53 (Fig. 16D),
suggesting the unlikelihood of these lncRNA loci contributing to p53-independent
functions related to proliferation and/or survival.
In p53-proficient cells, knockdown of either Ltc4s-as or lncRNA 7 had no
effect on growth rate (Fig. 16E) or the establishment of senescence (Fig. 16F).
Moreover, colony formation was similarly unaffected (Fig. 16G), suggesting that
lncRNA loss did not significantly disrupt the maintenance of senescence. Lastly,
we examined whether lncRNA CRISPRi modulated either resistance or sensitivity
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to apoptosis, both of which have been observed in human cells of various
backgrounds that have undergone senescence (Marcotte et al. 2004; Childs et al.
2014). As was observed in parental LA and SA cells, LA1-dCas9-KRAB cells did not
undergo apoptosis upon p53-restoration, as measured by cleaved caspase 3 (CC3)
levels, and this was unaffected by Ltc4s-as or lncRNA 7 reduction (Fig. 16H-i). On
average, treatment with 24h 1 µM Doxo drove p53-proficient LA1-dCas9-KRAB to
undergo apoptosis to comparable levels in control gRNA-expressing and lncRNA
targeting gRNA-expressing cells, though considerable variability in CC3 levels was
observed even amongst control cells (Fig. 16H). More tellingly, CC3 levels did not
correlate with lncRNA knockdown efficiencies. Thus, we concluded that loss of
Ltc4s-as and lncRNA 7 did not alter either growth, senescence or apoptosis in LA1
cells.
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Figure 16: CRISPRi of lncRNA 7 or Ltc4s-as does not affect proliferation or survival
in LA KPR cells. (A, B) Left= qRT-PCR detection of p53 mRNA and dCas9-KRAB in engineered
LA1 (A) and SA1 (B) cell lines treated as indicated. Data show mean ±SD (n=3 technical replicates).
Right= Senescence-associated β-galactosidase staining in indicated cell lines and treatments. (C)
qRT-PCR analysis of indicated lncRNAs in Tam-treated LA1-dCas9-KRAB cells expressing noted
gRNAs. Data show RNA levels relative to Gapdh, normalized to the average of two non-targeting
control gRNAs. Mean values ±SEM (n=3 biological replicates). * p<0.05, **p<0.01, and
****p<0.0001, unpaired t test. (D) Representative images of colony formation assays in untreated
LA1-dCas9-KRAB cells expressing indicated gRNAs. (E) Cumulative cell numbers in Tam-treated
LA1-dCas9-KRAB cells expressing indicated gRNAs after 3d. Data show mean values ±SEM (n=3
biological replicates), one-way ANOVA= no significant differences. (F) Quantification of SA β-gal
assays in indicated cell lines and treatment. Data show mean ±SD (n=10 technical replicates). (G)
Representative images of colony formation assays in Tam-treated LA1-dCas9-KRAB cells
expressing indicated gRNAs. (H) Immunoblots for CC3 (i, ii) and cPARP (iii) protein levels in
indicated cell lines and treatments (Doxo= 1.0 µM). α-tubulin or β-tubulin served as a loading
controls.

112

In Chapter 4, we discovered that recruitment of the CRISPR-SAM module
to lncRNA 7’s TSS in p53-deficient LA1 cells was able to upregulate lncRNA 7
expression 5-11x fold over a non-targeting control gRNA, reaching 24%-55% of the
levels of lncRNA 7 induction observed upon p53-restoration in these cells (Fig.
11C). While this level of CRISPRa did not yield an observable effect on cellular
proliferation, we wondered whether this perhaps stemmed from an insufficient
amount of upregulation. Thus, in order to interrogate the functional consequences
of Ltc4s-as and lncRNA-7 GOF in our LA1 and SA1 systems, we revisited the
CRISPR-SAM system described in Chapter 4 and made the following
modifications to see if we could maximize CRISPRa even further: in place of
shortened ‘dead’ RNAs and nuclease-proficient Cas9, full length gRNAs and
nuclease-dead Cas9 fused with four copies of the transcriptional coactivator VP16
(dCas9-VP64) were employed, as the recruitment of this combination of
coactivators has been reported to even further improve the synergistic activating
effects of CRISPR-SAM (Konermann et al. 2014) (Fig. 15C). dCas9-VP64expressing LA1 and SA1 cell lines were established, and as expected, p53restoration in both cell lines led to the acquisition of features of senescence, such
as senescence-associated morphological changes and β-Gal staining (Fig. 17A, B).
Using the same two independent gRNAs per lncRNA employed for
CRISPRi, we assessed the efficacy of this improved dCas9-VP64 CRISPR-SAM
system in transcriptionally activating Ltc4s-as and lncRNA 7. Two non-targeting
gRNAs served as controls. Although we did not observe significant p53-dependent
induction of Ltc4s-as in control LA1-dCas9-VP64 cells treated with Tam for 24h,
we were able to achieve roughly 4x (gRNA 1) and 2x (gRNA 2) upregulation of this
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lncRNA in both untreated and Tam treated cells, thus reaching levels of Ltc4s-as
induction greater than those induced by p53 at this time point (Fig. 17C-left).
Ltc4s-as was more highly expressed in SA1-dCas9-VP64 cells, induced 3-4x upon
24h p53-restoration in control gRNA-expressing cells (Fig. 17D-left). Interestingly,
Ltc4s-as CRISPRa was also more effective in this cell line, achieving 9x (gRNA 1)
and 3x (gRNA 2) upregulation over controls in untreated cells, or 304% (gRNA 1)
and 85% (gRNA 2) of the levels of Ltc4s-as seen upon p53-mediated induction in
these cells (Fig. 17D-left).
dCas9-VP64 CRISPR-SAM of lncRNA 7 was also highly efficient. In
unrestored LA1-dCas9-VP64 cells, gRNA 1 led to a 16x upregulation of lncRNA 7,
and gRNA 2 led to a 290x upregulation, compared to nontargeting control gRNAs.
Notably, this level of activation in p53-deficient cells represented 65% and 1184%
of the lncRNA 7 levels achieved upon p53-restoration in these same cells (Fig. 17Cright). As was seen for Ltc4s-as, lncRNA 7 CRISPRa was even more effective in
SA1-dCas9-VP64 cells, where gRNA 1 promoted 77x upregulation and gRNA 1 433x
upregulation of lncRNA 7, driving lncRNA 7 expression to at or 600% p53-driven
induction levels (Fig. 17D-right). Thus, dCas9-VP64 CRISPR-SAM of Ltc4s-as and
lncRNA 7 was highly efficient in transcriptionally upregulated these two
senescence-associated lncRNAs to levels reaching or considerably exceeding
endogenous, p53-dependent activation levels.
Given the association between Ltc4s-as and lncRNA 7 induction and
senescence-onset, we next asked whether promoting the transcriptional
upregulation of these loci affected this process. In the absence of p53, Ltc4s-as and
lncRNA-7 upregulation did not have any appreciable effects on LA1-dCas9-VP64
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and SA1-dCas9-VP64 proliferation (Fig. 17E), suggesting that expression of these
lncRNA loci in themselves was not sufficient to initiate cellular arrest. Colony
formation assays in p53-restored LA1-dCas9-VP64 further supported this
conclusion, with no differences observed in the number of colonies formed in
lncRNA upregulated cells compared to controls, though cells in which lncRNA 7
had been upregulated appeared to form morphologically distinct colonies (Fig.
17F). Furthermore, neither Ltc4s-as nor lncRNA 7 upregulation affected sensitivity
to Doxo-induced apoptosis in either LA1-dCas9-VP64 or SA1-dCas9-VP64 cells
(Fig. 17G). Taken altogether, these CRISPRi and CRISPRa data suggested that
Ltc4s-as and lncRNA 7 are not integral to either the establishment or maintenance
of senescence in response to oncogenic stress and are unlikely to individually
contribute to the p53 outcome-specificity observed in LA and SA KPR cells.
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Figure 17: CRISPRa of lncRNA 7 or Ltc4s-as does not affect proliferation or survival
in LA and SA KPR cells. (A, B) Left= qRT-PCR detection of p53 mRNA and dCas9-VP64 in
engineered LA1 (A) and SA1 (B) cell lines treated as indicated. Data show mean ±SD (n=3 technical
replicates). Right= Senescence-associated β-galactosidase staining in indicated cell lines and
treatments. (C, D) qRT-PCR analysis of indicated lncRNAs in Tam-treated LA1-dCas9-VP64 (C)
or SA1-dCas9-VP64 (D) cells expressing noted gRNAs. Data show RNA levels relative to Gapdh,
normalized to untreated control gRNA 1. Mean values ±SD (n=3 technical replicates). (E) Growth
curves of indicated cell lines in the absence of Tam. (F) Representative images of colony formation
assays in Tam-treated LA1-dCas9-VP64 cells expressing indicated gRNAs. (G) Immunoblots for
CC3 and cPARP protein levels in indicated cell lines and treatments (Doxo= 1.0 µM). HSP90 served
as a loading control.
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Given this lack of an obvious senescence phenotype in our CRISPRi and
CRISPRa systems and our discovery of a broader cis-regulatory lncRNA signature
in the p53 transcriptional response to oncogenic stress (Chapter 3), we lastly
asked whether Ltc4s-as and lncRNA 7 may instead exert more local functions
regulating gene expression. In multiple KPR cell lines tested, lncRNA 7 was the
only p53-responsive gene within a window encompassing 250 kb upstream of its
TSS and 700 kb downstream of its termination site, assessing a generous window
given lncRNA 7 being located in an otherwise gene-depleted region of chromosome
8 (Fig. 8A). As no other genes were either induced or repressed >2-fold upon p53
restoration in this region, we concluded that lncRNA 7 expression was unlikely to
be tied to that of any of its neighbors.
In contrast, Ltc4s-as expression positively correlated with that of Ltc4s, but
not Maml1, in multiple KPR cell lines. Furthermore, p53RE mutagenesis
experiments performed in Chapter 3 demonstrated that Ltc4s-as and Ltc4s were
co-regulated by p53, independent of Maml1. Curious about the effects of
transcriptionally silencing or upregulating Ltc4s-as on its associated protein
coding genes, we assessed Ltc4s and Maml1 levels in our LA1 CRISPRa and
CRISPRi cell lines. Consistent with our p53RE mutagenesis data, we saw a strong
positive correlation (R=0.85) between Ltc4s-as and Ltc4s levels and no correlation
between Ltc4s-as and Maml1 (R=0.00) (Fig. 18A).
Given the proximity and potential overlap of Ltc4s-as’ and Ltc4s’
promoters, raising the possibility that CRISPR-based epigenetic manipulations of
one could directly affect the other, we decided to take an alternative approach to
reduce Ltc4s-as levels by designing an antisense oligonucleotide (ASO) targeting
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its third exon. Introducing this ASO into LA1.1 cells led to a roughly 30% decrease
in Ltc4s-as RNA, both in the presence (+Tam) and absence (-Tam) of p53,
compared to a non-targeting control ASO (Con) (Fig. 18B). Ltc4s levels were also
reduced in these cells, by 27% and 41% in unrestored and p53 restored cells,
respectively. As this ASO targeted a unique (i.e. non-overlapping) region of Ltc4sas more than 50 kb downstream of either its or Ltc4s’ TSS, it is unlikely that the
observed Ltc4s knockdown stemmed from direct ASO-mediated interference of
the protein coding gene’s transcription. Notably, ASO depletion of Ltc4s-as did not
significantly affect Maml1 (Fig. 18B), consistent with the results of our other Ltc4sas LOF and GOF experiments. Taken altogether, these data led us to conclude that
either Ltc4s-as’ transcription or RNA is important for optimal expression of Ltc4s,
but not Maml1, firmly establishing the Ltc4s-as locus as an additional, previously
undescribed cis-regulatory lncRNA locus within the p53 network.
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Figure 18: Ltc4s-as positively regulates Ltc4s, but not Maml1, in cis. (A) Correlation
plot of Ltc4s-as levels against Ltc4s and Maml1 levels, as detected by qRT-PCR upon 24h Tam
treatment in CRISPRa and CRISPRi experiments performed in LA1 cells. RNA values relative to
Gapdh were calculated and normalized to control gRNAs within each respective experiment before
plotting normalized values. Simple linear regression analyses were performed on Ltc4s-as vs Ltc4s
and Ltc4s-as vs Maml1 levels. Lines of best-fit, goodness of fit values, and significance of slopes are
indicated on graph. (B) qRT-PCR analysis of Ltc4s-as, Ltc4s, and Maml1 in mock or Tam-treated
LA1.1 cells transfected with indicated ASOs. RNA values relative to Gapdh were normalized to
control (Con) ASO-treated cells in each Tam condition. Data show mean ±SEM (n=4 biological
replicates). ** p<0.01, ***p<0.001, and **** p<0.0001, ns= not significant, unpaired t test.
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Data summary and conclusions
Broadly, the research detailed in this chapter explores the hypothesis that
lncRNA expression patterns can be reflective of functional significance. In the case
of p53-dependent senescence driven by oncogenic stress (or in the case of
lincRNA-RAPT1, genotoxic stress), we were unable to find evidence for lncRNAs
significantly contributing to cellular senescence, despite these lncRNAs being
transcriptionally activated in a senescence-specific manner. For lincRNA-RAPT1,
further work (utilizing alternative LOF approaches) will be necessary to determine
whether this senescence-associated lncRNA contributes to p53 pathway function
in other ways. Of the two lncRNAs we were able to efficiently knockdown in our
KPR model systems, lncRNA 7 and Ltc4s-as, we did not observe any phenotypes
related two key aspects of the senescent state, proliferation and survival,
suggesting that these lncRNAs are not necessary for the establishment or
maintenance of oncogene-induced senescence. Furthermore, transcriptional
upregulation of these lncRNAs did not alter the cell fates of LA and SA cells,
demonstrating that induction of these lncRNAs is not sufficient to initiate or
accelerate senescence.
One interpretation of these data is that outcome-specific lncRNA expression
patterns are the consequence and not the cause of specific cell fates. It is possible
that the same yet-to-be determined factors that determine the outcome-specificity
of KPR cells also influence the outcome-specific expression patterns of lncRNAs,
which are as a class known to be more cell- or tissue-specific than mRNAs (Cabili
et al. 2011). This is a meaningful conclusion, as questions regarding the biological
significance of these oft-observed associations between lncRNA expression
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patterns and cellular states are longstanding in the field. Here, we have tested one
such correlation in a biological system perfectly set-up to do so.
It is also possible that senescence-specific lncRNAs do functionally
contribute to senescence but do so in incremental and/or redundant ways that
would not be uncovered by individual lncRNA LOF experiments. Importantly, it is
exceedingly rare for the loss of individual protein coding targets of p53 to have
dramatic effects on pathway function or tumorigenesis (discussed further in
Chapter 6). Thus, it remains possible that a network of senescence-associated
p53-activated lncRNAs work in concert to ensure a robust, sustained
antiproliferative response to oncogenic stress.
Cis-acting lncRNAs, such as the ones we describe in Chapter 3 and here,
would be well-suited to finely regulate a broad, flexible network of genes not
directly regulated by p53 themselves towards this end. The Ltc4s-as locus
illustrates how gene-specific this lncRNA-mediated cis-regulation can be, in which
we see that Ltc4s but not Maml1 expression is modulated by Ltc4s-as expression,
despite the lncRNA overlapping both protein coding genes. Ltc4s’ role in
proinflammatory signaling, which is a phenotype associated with senescence in
vivo, also raises the possibility of a model in which the functional importance of
lncRNA-mediated cis-regulation could be highly context-specific.
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Chapter 6: Summary and Perspectives
Our research expands our understanding of the ways in which lncRNAs
contribute to the regulation of gene networks, as well as provides new insights into
gene regulation by the central tumor suppressor p53. LncRNAs have garnered a
significant amount of attention over the past decade or so as a largely untapped
pool of potentially important biomolecules, including within the p53 pathway
where many have been implicated as important effectors of p53 function (see
Chapter 1). But the extent to which lncRNAs contribute to the p53 pathway
remains ambiguous. This is in part due to cross-study comparisons of individual
lncRNA studies often being complicated by variability in approaches taken or
biological conditions under which the p53 pathway was studied. For example,
whether lncRNAs contribute to the p53 response in a stress-specific manner is
largely unknown. Here, we have employed a powerful in vitro model of p53-driven
tumorigenesis and multiple state-of-the art lncRNA LOF and GOF tools to address
several important questions about the role of p53-activated lncRNAs within the
p53 response to oncogenic stress.
As sequencing technologies have become more sensitive and robust, so too
has the catalogue of known lncRNA genes and associated transcripts grown (Fang
et al. 2018; Uszczynska-Ratajczak et al. 2018). Understandably, determining what
fraction of these many thousands of uncharacterized transcripts represent
biologically important RNAs has been a pressing challenge in the study of
lncRNAs. The operational definition of lncRNA and an incomplete understanding
of the relationship between lncRNA primary sequence and lncRNA function have
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made a priori predictions of importance impractical. Instead, various approaches
to further subdivide lncRNAs based on observed expression patterns have often
served as starting points for functional studies. These expression pattern-based
associations have been especially provocative in the context of cancer, where
lncRNAs have been noted to be transcriptionally regulated in ways that exquisitely
parallel various aspects of cancer pathophysiology [e.g. tissue of origin or
metastatic vs nonmetastatic disease (Iyer et al. 2015; Ji et al. 2003; Gupta et al.
2010)]. Our work adds to this wealth of cancer-associated lncRNA data by greatly
expanding the number of known lncRNAs regulated by p53. Importantly, our work
provides evidence for direct regulation by p53 for many of these previously
undescribed lncRNAs, thus giving a more complete picture of the total p53regulated lncRNA transcriptome.
An additionally important facet of our work is that these lncRNAs are
induced by p53 in response to oncogenic stress and may thus represent a stressorspecific cohort of lncRNAs. This is supported by the observation that many
lncRNAs that have previously been shown to be activated by p53 in the context of
genotoxic stress (Table 1.1) did not come up in our list of lncRNAs. While it is
possible that this is a reflection of cell type-specific differences rather than stress
stimuli, it is worth noting that our KPR model allowed us to assess the p53
response to oncogenic stress across six unique cell lines and three distinct
tumors/tissue types of origin, thus permitting us to sample a breadth of cellular
contexts. Importantly, we identified five lncRNAs (Pvt1b, Zmat3-as, Bahcc1-as,
2310008N11Rik, and Rhod-as) which were significantly upregulated by p53 across
all cell lines and tumor types. Prior to this study, none of these five Core-induced
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lncRNAs, nor the majority of the other lncRNAs we identified as p53-activated in
our KPR model had been previously linked to the p53 pathway. Thus, these data
suggest that our work has in fact identified a set of lncRNAs linked to specifically
p53 regulation in the context of oncogenic stress and support a previously
proposed model in which the transcriptional networks enacted by p53 in response
to acute genotoxic stress and oncogenic stress are at least partially distinct from
each other (Brady et al. 2011; Kastenhuber and Lowe 2017).
Surprisingly, we found an extremely limited overlap between the lncRNAs
identified in our work and previously published p53-activated lncRNAs, restricted
to only lincRNA-p21 and Neat1, which are established direct targets of p53 (Huarte
et al. 2010; Mello et al. 2017), and Malat1, which has been reported to be regulated
by a distal p53 bound enhancer (Melo et al. 2016). Thus, even lncRNAs that have
been demonstrated to be p53-responsive in other in vitro models of oncogenic
stress were not identified as such in our KPR model. For some lncRNAs, such as
the human-specific lncRNA PANDA, our data simply confirm previously noted
absences of orthologous mouse genes. For others (e.g. GUARDIN, LED, Linc-Pint),
it is possible that our results reflect species-specific differences in p53 network
activation. However, it is important to note that most studies of human lncRNAs
in the context of the p53 response to oncogenic stress have been performed in a
limited number of human cancer cell lines, thus making cell line-specific
differences in p53 regulation an equally likely possibility. Notably, our
identification of a p53-responsive human lncRNA at the genomic location syntenic
to 2310008N11Rik (lncRNA 7) in this work and our lab’s previous description of
an orthologous human PVT1B isoform (Olivero et al. 2020) demonstrate that at
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least two of the five lncRNAs we found to be activated by p53 across all KPR tumor
types are also regulated by p53 in human cells, under at least some stress
conditions. The full extent of human conservation of our newly identified catalogue
of p53-regulated lncRNAs remains to be explored in future studies.
Our work also considerably increases our understanding of the broader p53
transcriptional response to oncogenic stress. It is clear that transcriptional
regulation is a key aspect of p53-mediated tumor suppression (Brady et al. 2011;
Jiang et al. 2011), but the full set of specific p53 targets that underlie said tumor
suppression are elusive. Moreover, p53 suppresses tumorigenesis through a
variety of cellular processes, two important examples being apoptosis and cellular
senescence, though by what mechanisms these different cellular processes are
initiated in different tumor types is less clear. By characterizing the p53 response
across multiple tumor types facing the same oncogenic stressor, we shed new light
onto these fundamental questions of p53 regulation in several ways. First, we
identified a set of target genes activated by p53 in LA, SA, and LY KPR cells,
suggesting that this small but robustly-activated group of genes may be critical for
p53 sensing and/or responding to oncogenic signaling. These Core genes included
important mediators of central p53 processes, such as cell cycle regulation and
apoptosis, as well as genes involved in autophagy, metabolism, and tumor
microenvironment signaling, which are more recently appreciated p53-regulated
processes that have been associated with tumor suppression (Kaiser and Attardi
2018). As expected, many of these genes represented known p53 targets that are
activated by p53 in other stress conditions as well. This was in contrast to the panel
of lncRNAs we uniquely identified as p53 targets for the first time in this work.
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Thus, it may be the case that p53-activated lncRNAs are more stressor-specific
than protein coding p53 target genes.
Additionally, our data strongly suggest that tumor type-specific differences
in the cellular consequences of p53 stabilization do not stem from significant
differences in p53 transcriptional activation. This is in contrast to some postulated
models of p53 decision-making, in which the expression of clearly delineated
outcome-specific gene networks is proposed to underlie outcome-specificity
(Weinberg et al. 2005; Schlereth et al. 2010). Instead, our data is in line with more
recent reports where genomic p53 binding patterns (Nikulenkov et al. 2012;
Botcheva and McCorkle 2014) and p53 network activation correlated more with
cell identity than stress stimuli or ultimate cellular outcome enacted in a number
of human and mouse cell lines (Tonelli et al. 2017; Catizone et al. 2019; Zhang et
al. 2013b). These cell identity-specific factors may be related to p53-dependent
functions but have fate-determining patterns of regulation that are either partially
p53-independent or pre-exist p53 pathway activation. “Mitochondrial priming” is
one example of this, in which a given cell type’s characteristic ratio of
mitochondrially-localized pro-apoptotic versus anti-apoptotic BCL-2 family
member proteins can determine whether said cell type is inherently apoptosisresistant or apoptosis-prone (Chonghaile et al. 2011; Liu et al. 2013a). However, it
is indisputable that the p53 network is regulated at multiple, intricately-woven
levels. We acknowledge that stimuli-specific inputs such as the nature of the stress
encountered can also influence p53 pathway activation in some settings, for
example by dictating where in the genome p53 binds (Menendez et al. 2013) or by
altering the dynamics of p53 protein stabilization (Purvis et al. 2012). Our work
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joins this dialogue to provide additional, novel perspective on this fundamental
question regarding how inputs into the p53 network modulate network activation.
Interestingly, we uncovered an unexpected association between p53mediated gene repression and senescence. In contrast, gene repression
downstream of p53 was not a feature of the core transcriptional response to
oncogenic stress, nor apoptosis. How p53 represses this senescence-specific gene
network remains to be determined, as experimental evidence for direct gene
repression by p53 is very limited (Vousden and Prives 2009). P53’s role in indirect
repression is clearer, as p21 activation downstream of p53 is important for gene
repression by the E2F/DREAM complex (Engeland 2018). Intriguingly, a recent
cross-species metanalysis of orthologous human and mouse genes regulated by
p53 found that p53-repressed genes were more likely to be similarly regulated
across the two species than p53-activated genes (Fischer 2019), raising the
fascinating question of whether a link between p53-dependent gene repression and
senescence is also conserved. The functional importance of this p53 gene
repression in senescence is largely unknown, though our work does provide one
specific example by demonstrating that Pvt1b/Myc negative co-regulation is
necessary for the maintenance of growth arrest in LA KPR cells. However, our
lncRNA data suggest that most p53-dependent gene repression is not
accomplished through lncRNA cis-regulation. Further exploring the mechanisms
by which p53 gene repression is established and the biological importance of
repressive p53 regulation are important avenues of inquiry for future work.
Similar to other genome-wide profiles of the p53 network, we found that key
protein coding p53 targets involved in cell cycle arrest and apoptosis were activated
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by oncogenic stress in an outcome-agnostic manner. This in part led us to explore
whether lncRNAs, which did exhibit outcome-specific activation in our data, could
underlie outcome-specificity. LncRNAs have previously been hypothesized to be
drivers of cell fate due to their cell identity- or state-specific expression patterns
(Cabili et al. 2011; Derrien et al. 2012). However, our lncRNA GOF and LOF studies
did not yield any evidence for any individual lncRNA contributing to the
establishment of cellular senescence in LA and SA KPR cells, even when lncRNA
expression patterns were highly correlated with senescence and anticorrelated
with apoptosis in our KPR model. Thus, while examples of lncRNAs demonstrably
regulating cell fate decisions do exist (Kretz et al. 2013; Grote et al. 2013;
Lewandowski et al. 2019), our research joins an growing body of literature
(Goudarzi et al. 2019) encouraging caution when interpreting correlative lncRNA
associations as functional in the absence of experimental validation. It is possible
that our panel of senescence-associated lncRNAs are not drivers of senescence but
are rather transcriptional read-outs of specific cellular characteristics that are
unique to cells primed to undergo senescence in response to p53 activation.
Alternatively, it is also possible that these lncRNAs function at a longer time-scale
than investigated in this work and contribute to the long-term maintenance of
senescence, which is a uniquely stable biological state.
However, our single lncRNA LOF data are also consistent with the
functional redundancy of the p53 network hinted at in our KPR transcriptome
profiling data and other studies. In this paradigm of p53 network function, the loss
of expression of one or even several p53 target genes can be compensated for by
others to maintain a robust p53 response. For example, in one recent shRNA
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screen for p53 targets important for mediating growth arrest in human
osteosarcoma cells, the only significant hit identified was p53 itself (Andrysik et al.
2017), suggesting that even the loss of key protein coding mediators of growth
arrest can be insufficient to bypass p53-directed growth arrest. Importantly, there
has not been a single p53 target gene to date in which genetic knockout in vivo is
able to recapitulate the dramatic spontaneous tumorigenesis observed in p53
knockout mice, including mice lacking key drivers of p53-dependent cell cycle
arrest [p21 (Brugarolas et al. 1995); Gadd45α (Hollander et al. 1999); PML (Gang
Wang 1998)], apoptosis [Puma; Noxa (Villunger 2003); Perp (Ihrie et al. 2006);
Bax (Knudson et al. 2001)], or combinations of target genes important for these
processes (Michalak et al. 2008; Valente et al. 2013). Nevertheless, these protein
coding genes demonstrably contribute to p53-dependent anti-growth responses in
various in vitro settings (perhaps reflecting tissue- or cell type-specific functions)
and/or in the context of specific in vivo cancer models. Thus, many of the lncRNAs
we have found to be activated by p53 in response to oncogenic stress may also play
subtle, redundant, or context-specific roles in the p53 pathway that collectively
support the overall robustness of this tumor suppressive stress response. This
functional subtlety and/or redundancy seems to be likely true for many lncRNAs
in other tightly regulated biological processes as well, such as development
(Goudarzi et al. 2019).
Our research strongly suggests that cis-regulatory lncRNAs predominate
within the p53 network. While we cannot formally exclude trans activities for all
identified lncRNAs, the vast majority of lncRNAs found in this study were enriched
at the chromatin, relatively low in abundance, and transcriptionally linked to the
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expression of their neighboring genes, all of which are features associated with cisregulation. Moreover, our thorough locus investigation of one of the more
abundant, partially cytoplasmically-localized lncRNAs, 2310008N11Rik (lncRNA
7), did not reveal a trans phenotype. Thus, our research adds to a growing body of
work suggesting that most p53-activated lncRNAs function in the nucleus to
regulate the transcriptional output of the p53 network (reviewed in Chapter 1).
We demonstrate that lncRNA locus-mediated cis-regulation is a much more
common mechanism by which lncRNAs achieve this than previously appreciated.
As our characterization of the lincRNA-Gadd45γ locus demonstrates, this cisregulation can tie-in protein coding genes not directly regulated by p53 into the
broader p53 transcriptional network. Our LOF characterization of several other
lncRNA loci suggests that this positive cis-regulation is not unique to this locus.
Conversely, our work also demonstrates that Pvt1b’s regulation of Myc represents
an exceptional example of cis-repression within the p53 network, suggesting that
lncRNAs do not significantly contribute to p53-mediated gene repression. Thus,
we show that lncRNAs can fine-tune p53’s transcriptional response on a locus-bylocus basis, with likely locus-specific RNA-dependent and RNA-independent
mechanisms.
Furthermore, our discovery of Pvt1b’s importance in mediating growth
arrest in LA KPR cells demonstrates that lncRNA-mediated cis-regulation can be
important for p53 pathway function downstream of oncogenic stress. Our data
suggest that this phenotype is not driven through changing the cell fate of LA cells,
which remained resistant to apoptosis, but rather through Pvt1b’s effect on Myc
levels. Indeed, other work from our lab further supports the conclusion that the
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cellular consequences of Pvt1b loss are solely mediated through Myc derepression
(Olivero et al. 2020). Myc is a universal regulator of cellular growth, thus it is not
surprising that dysregulating Myc levels would have profound effects on cellular
proliferation. The functional consequences of disrupted cis-regulation at other
p53-activated lncRNA loci may be more context-specific in a manner related to the
normal functions of the protein coding genes under regulation.
The senescence-associated Ltc4s-as locus and its positive reinforcement of
Ltc4s expression may represent an example of this scenario. Ltc4s is an enzyme
involved

in

the

catalysis

of

leukotrienes,

which

are

important

lipid

proinflammatory molecules (Funk 2001). One hallmark of senescence is the
secretion of a variable suite of proinflammatory and ECM remodeling molecules
that drive senescence-associated autocrine and paracrine signaling (i.e.
senescence-associated secretory phenotype; SASP), which can be oncogenic or
tumor suppressive (Campisi 2013; Collado and Serrano 2010). Leukotriene
signaling has recently been shown to be a part of the SASP of several senescent
human cell lines and linked to senescence-associated lung fibrosis (Wiley et al.
2019). Thus, we imagine that Ltc4s-as-dependent cis-regulation of Ltc4s could be
important for phenotypes associated with cellular senescence or inflammation
more broadly in contexts beyond the in vitro stress models we assessed in this
work.
Lastly, we do not claim that all lncRNA-mRNA co-regulatory relationships
are indicative of direct cis regulation. Rather, they are demonstrative of linked gene
regulation within the p53 network and provide a conceptual platform for potential
secondary, fine-tuning transcriptional inputs from lncRNA loci downstream of the
131

primary input from p53 at these lncRNA-mRNA transcriptional units. Prior to our
work, direct lncRNA-mediated cis-activation within the p53 network had only been
demonstrated for lincRNA-p21; we expand this to two novel lncRNAs chosen from
our identified catalogue of co-regulated loci. Support for Ltc4s-as and lincRNAGadd45γ being representative examples of a wider cis-activating cohort of p53induced lncRNAs includes the fact that co-regulation in addition to chromatin
enrichment has been shown to be predictive of cis-regulation in other cellular
systems (Werner et al. 2017). Whether true, lncRNA locus-driven cis-activation
contributes to the positive co-regulation observed at the other loci we uncovered
will be work for future investigation.
As for cis-repression, we speculate that the presence of a negative coregulatory relationship is likely to be predictive of true lncRNA mediated cisregulation, especially when negative co-regulation involving intergenic (i.e. nonoverlapping) lncRNA loci is observed. This is based on the rationalization that
lncRNA cis-activation may more readily evolve through either the simple act of a
lncRNA locus being transcribed or through the modulation of pre-existing
transcription-activating signals at a given locus. For example, the transcription of
a lncRNA locus may be sufficient to promote the recruitment of positive
transcriptional regulators or RNA pol II itself to another genomic region as well, if
said region is in close proximity to the lncRNA locus in either linear or three
dimensional genomic space, in much the same way enhancers are thought to
function. In contrast, cis-repression is likely to necessitate additional molecular
inputs that are able to overcome and reverse these activating inputs (e.g. the
recruitment of repressive epigenetic machinery by XIST). Furthermore, the rarity
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of such negative co-regulatory relationships compared to positive ones in our data
and in other genome-wide surveys of lncRNA regulatory patterns (Basu and
Larsson 2018) further suggests that sites of negative lncRNA-mRNA co-regulation
arise from an evolutionary trajectory distinct from those of positive co-regulation.
Pvt1b’s activation by p53 and cis-repression of Myc (a transcription factor in its
own right) suggest that such negative cis-regulatory relationships may be most
likely to emerge at key nodes in transcriptional networks, functioning to adjust
critical biological outputs.
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Final remarks

Mammalian genomes are complex, both in organization and in regulation.
It’s long been appreciated that lncRNAs can significantly contribute to both of
these features, but our understanding of the importance of lncRNAs in complex
regulatory networks remains incomplete. One emerging regulatory theme our
work expands upon is that of lncRNA-mediated cis-regulation [e.g. (Dimitrova et
al. 2014; Olivero et al. 2020; Joung et al. 2017; Werner et al. 2017; Engreitz et al.
2016)], namely its previously underappreciated prevalence in the centrally
important tumor suppressive p53 pathway. Unlike transcription factors or other
nuclear-acting proteins, which are invariably translated distally from their sites of
action, lncRNA loci are uniquely positioned to rapidly respond to stimuli by
engaging with and modulating the expression of other nearby genes. Within the
p53 transcriptional network, we find at least one example of lncRNA-mediated cisregulation being important for tumor suppression in the context of oncogenic
stress and speculate that lncRNA local regulation may contribute to the highly
tissue- and stimuli-specific nature of the p53 stress response in other settings as
well. The ability of cis-acting lncRNA loci to dynamically and flexibly fine-tune
transcriptional outputs may be especially important in stress responses in general,
warranting closer examination of this mode of lncRNA-mediated gene regulation
in other tumor suppressive or oncogenic transcriptional networks.
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Chapter 7: Materials and Methods
Cell lines and treatments: KPR cell lines were previously established from
spontaneously arising primary lung adenocarcinoma (LA1, LA2), sarcoma (SA1,
SA2), or lymphoma (LY1, LY2) tumors isolated from KrasLA2-G12D/+ ; p53LSL/LSL;
Rosa-CreERT2 mice (Feldser et al. 2010). Puromycin-sensitive LA1 cells (LA1.1)
were previously described (Olivero et al. 2020). In brief, LA1 cells were transiently
transfected with a guide RNA targeting the ORF of puromycin to inactivate the
puromycin-resistance gene expressed from the Rosa-CreERT2 allele, followed by
clonal expansion. gRNAs were introduced cloned downstream of a U6 promoter in
a lentiviral vector co-expressing SpCas9 and GFP (BRD004; gift from the Broad
Institute, MIT). Puromycin-sensitive LA2 cells (LA2.5) were similarly generated.
Primary WT mouse embryonic fibroblasts (MEFs) were isolated from embryos at
E13.5 from timed matings of WT C57BL/6J mice. LincRNA-RAPT1fl/fl; Rosa26CreERT2 MEFs were isolated at E13.5 from timed homozygote matings, while
littermate lincRNA-RAPT1+/+ and lincRNA-RAPT1-/- MEFs were isolated from
lincRNA-RAPT1+/- (heterozygote) matings. All primary MEF experiments were
performed at passages 2-10. p53LSL/LSL; Rosa-CreERT2 (p53-restorable) MEFs
were previously described (Ventura et al. 2007).
LA and SA cells were maintained in DMEM (GIBCO) supplemented with
10% FBS, 50 U/mL pen/strep, 2 mM L-glutamine, 0.1 mM non-essential amino
acids, and 0.055 mM β-mercapatoethanol. LY cells were cultured in IMDM
(GIBCO) supplemented with 10% FBS, 50 U/mL pen/strep, and 0.055 mM βmercapatoethanol. MEFs were cultured in DMEM supplemented with 15% FBS,
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50 U/mL pen/strep, 2 mM L-glutamine, 0.1 mM non-essential amino acids, and
0.055 mM β-mercapatoethanol. All cells were grown at 37°C in a humidified
incubator with 5% CO2.
To excise the LSL cassette and restore p53 expression, KPR cells and p53restorable MEFs were treated with 0.5 µM 4-hydroxytamoxifen (Tam, Cayman
Chemical Company) at time points indicated in text and figure legends. To ablate
lincRNA-RAPT1 expression in the conditional knockout system, lincRNARAPT1fl/fl; Rosa26-CreERT2 MEFs were treated with 0.5 µM Tam for 72-96h. To
induce DNA damage, cells were treated with Doxorubicin (Doxo, Sigma-Aldrich),
at dosage concentrations and lengths indicated in text and figure legends. To
activate Tetracycline-dependent gene expression in LA1-TRE-dCas9-KRAB and
SA1-TRE-dCas9-KRAB cell lines, cells were treated with 2 µg/mL Doxycycline
(Doxy, Sigma-Aldrich) for lengths of time indicated in text and figure legends.

Viral transductions: Lentivirus was produced in 293 cells by co-transfecting
lentiviral constructs with pCMV-Δ8.2 (Addgene plasmid #8455) and pCMV-VSVG (Addgene plasmid #8454) viral packaging constructs. Fresh virus-containing
supernatants supplemented with 4 µg/mL polybrene (Millipore Sigma) were used
to infect cells in 2-3 consecutive lentiviral infections, collected and delivered at 24h
intervals. For retroviral transduction experiments, virus was produced in Phoenix
cells transfected with retroviral constructs. Viral supernatant was collected at four
consecutive 12h intervals, supplemented with 4 µg/mL polybrene, and
immediately used to infect cells. Following infections, cells were selected with
Puromycin (2 µg/mL for MEFs, 5 µg/mL for KPR cell lines), hygromycin (400
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µg/mL for MEFs, 800 µg/mL for KPR cell lines), neomycin (400-600 µg/mL), or
blasticidin (5-10 µg/mL), as appropriate. All viral constructs and gRNA/dRNA
sequences used in this work can be found in Supplementary Tables 1 and 2.
LncRNA p53RE mutagenesis: CRISPR-Cas9 mutagenesis was performed by
infecting LA1.1 or LA2.5 cells with site-specific gRNAs cloned downstream of an
hU6 promoter in BRD001, a lentiviral vector co-expressing SpCas9 and an IRESdriven puromycin-resistance gene (gift from the Broad Institute, MIT). dTomatotargeting gRNA served as a negative control. Mutagenesis efficiency was assessed
by Sanger sequencing using PCR and sequencing primers in Supplementary Table
2 and quantified using the TIDE (Tracking of Indels by Decomposition) webtool
(Brinkman et al. 2014). For sequencing of individual mutated alleles, PCR products
were subsequently cloned into the pCR-Blunt II-TOPO vector (Invitrogen) and
individual clones submitted for Sanger sequencing.
LincRNA-Gadd45γ CRISPRi and CRISPRa: CRISPRi was performed by
expressing 15-mer ‘dead RNAs’ (dRNAs) (Dahlman et al. 2015) from BRD001,
targeting a region downstream of the transcription start site of lincRNA-Gadd45γ
or a non-targeting control region (Con). For CRISPRa experiments, an SpCas9IRES-GFP-expressing stable cell line was first generated by introducing lentiviral
vector BRD004 (gift from the Broad Institute, MIT) into LA1 cells and selecting for
GFP expression by FACS. CRISPRa of lincRNA-Gadd45γ was subsequently
achieved by the CRISPR-SAM system employed in (Olivero et al. 2020). In brief,
MS2-tagged gRNAs and HSF-p64-MBP (SAM module) were stably introduced into
LA1-SpCas9-GFP cells via a single vector co-expressing both, lenti SAM Hygro
(generated by E. Martínez-Terroba), followed by hygromycin selection.
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LncRNA 7 exogenous overexpression and E1A MEF sensitization: Fulllength lncRNA 7 cDNA was synthesized as a gene block (IDT) and cloned into
MSCVpuro and pWZL Hygro (Addgene# #18750) retroviral vectors. Empty
vectors (EV) served as controls. MSCVpuro was used to deliver lncRNA 7 into
primary MEFs, while pWZL Hygro was used for LA and SA KPR cells, followed by
puromycin or hygromycin selection, respectively. For E1A sensitization
experiments, pLPC 12S E1A puro (Addgene plasmid #18740) or EV control
retroviral constructs were introduced into control or lncRNA 7-overexpressing
p53-restorable MEFs and puromycin selection applied.
LncRNA 7 and senescence-associated lncRNAs CRISPRi and CRISPRa: For
lncRNA 7 CRISPRi experiments in p53-restorable MEFs and LA1.1 cells, stable
dCas9-KRAB cell lines were first generated by introducing pHR-SFFV-dCas9-BFPKRAB (Addgene plasmid #46911) into cells via lentiviral transduction and
selecting for BFP expression by FACS. gRNAs targeting lncRNA 7’s TSS were
subsequently delivered to cells by BRD003, a lentiviral vector for expressing hU6driven SpCas9 gRNAs (gift from the Broad Institute, MIT), and cells selected for
puromycin resistance. CRISPRi efficacy was assessed in comparison to dTomatotargeting Con gRNA. For lncRNA 7 CRISPRa experiments performed in Chapter
4, dCas9-VP64-expressing cell lines were generated by introducing Lenti dCasVP64_Blast (Addgene plasmid #61425) into LA1.1 and LA1 cells and selecting for
blasticidin resistance. gRNAs were lentivirally delivered by either BRD003 for
LA1.1 cells or pLenti BsmBI sgRNA hygro (Addgene plasmid #62205) for LA1 cells,
due to the latter’s puromycin resistance. After the appropriate selection regimes,

138

lncRNA 7 CRISPRa was assessed compared to the same dTomato-targeting Con
gRNA.
For CRISPRi experiments performed in Chapter 5, Doxy-inducible dCas9KRAB cell lines were generated by introducing Phage TRE-dCas9-KRAB (Addgene
plasmid #50917) into LA1 and SA1 cells and selecting for neomycin/G418
resistance. gRNAs were introduced into cells by lentiviral delivery in pLenti BsmBI
sgRNA hygro, followed by hygromycin selection. For CRISPRa experiments
performed in Chapter 5 (VP64-SAM), dCas9-VP64 cell lines were generated by
introducing Lenti dCas-VP64_Blast into LA1 and SA1 cell lines. MS2-tagged
gRNAs and HSF-p64-MBP were subsequently introduced into cells by lenti SAM
Hygro, followed by hygromycin selection. For calculations of CRISPRi and
CRISPRa efficiencies, RNA values relative to an endogenous control gene (Gapdh)
were individually calculated for two independent non-targeting control gRNAs and
averaged, yielding a control average relative expression value. LncRNA TSStargeting gRNA relative expression values were then normalized to this control
average relative expression value.

RNA isolation and qRT-PCR: For RNA analysis of MEF samples, RNA was
isolated with the RNeasy Mini Kit (Qiagen). For RNA analysis of KPR samples,
RNA was isolated using TRIzol reagent (Invitrogen). 1.0 µg total RNA was reverse
transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). SYBR Green PCR master mix (Kapa Biosystems) was used for
quantitative PCR in triplicate reactions. Primers sequences are listed in
Supplementary Table 3. RNA expression levels relative to the housekeeping gene
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Gapdh were calculated using the ddCt method and normalized to control samples
when noted.

Genotyping: KPR cells were lysed in 1 M Tris-HCl pH 8.0, 0.5 M EDTA pH 8.0,
20% SDS, 5 M NaCl supplemented with 1 mg/mL Proteinase K at 55 °C. Total
genomic DNA was extracted by isopropanol precipitation, and genotyping was
performed by PCR with primers listed in Supplementary Table 3.

Immunoblotting: Cells were lysed in 2x Laemmli buffer (100 mM Tris-HCl
pH6.8, 200 mM DTT, 3% SDS, 20% glycerol) at 1x104 cells/µL. Samples were
heated at 95°C for 7 minutes and passed through an insulin syringe. Protein from
1x105 cells was separated on 12% SDS-polyacrylamide gels and transferred to
nitrocellulose membranes (Bio-Rad). After blocking (5% milk-PBST), membranes
were incubated overnight at 4°C in primary antibody, then 1hr at RT in secondary
antibody. The following antibodies were used: anti-p53 (1C12) (1:1,000, 2524S,
Cell

Signaling

Technology),

anti-p21(F-5)

(1:250,

sc-6246,

Santa

Cruz

Biotechnology), anti-cleaved caspase 3(Asp175) (1:250, 9661, Cell Signaling
Technology), anti-cleaved PARP (Asp214)(7C9) (1:500, 9548S, Cell Signaling
Technology), anti-α tubulin (DM1A) (1:1000, 3873S, Cell Signaling Technology),
anti-β tubulin (9F3) (1:1000, 2128S, Cell Signaling Technology), anti-Hsp90
(C45G5) (1:1,000, 4877S, Cell Signaling Technology), goat anti-mouse secondary
antibody (1:50000,1706516, Bio-Rad), and donkey anti-rabbit secondary antibody
(1:50000, 711-035-152, Jackson ImmunoResearch). Protein bands were visualized
using Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare).
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Quantitative densitometry analysis was performed using background adjusted
volume intensities normalized to loading control on Image Lab software (BioRad).

Gene set enrichment analysis (GSEA): GSEA was performed on p53-induced
and p53-repressed gene sets identified by RNA-seq analysis using the Molecular
Signature Database (MSigDB) (Subramanian et al. 2005).

Antisense oligonucleotide (ASO) knockdown: For lincRNA-Gadd45γ
knockdown, 1 µM lncRNA-targeting (ASO1, ASO2) or control (CON) antisense
LNA Gapmers (Exiqon, QIAGEN) were transfected into 1x106 LA1.1 cells treated
with Tam for 48h using the Amaxa Primary Mammalian Epithelial Cells
Nucleofector Kit (Lonza, VPI-1005) and the Nucleofector 2b Device (Lonza).
Knockdown of lincRNA-Gadd45γ and subsequent effects on Gadd45 γ expression
were assayed by qRT-PCR at 24h post-transfection (72h Tam treatment). For
Ltc4s-as knockdown, 1 µM lncRNA-targeting (ASO) or control (Con) antisense
LNA Gapmers were transfected into 3x105 LA1.1 cells using Attractene transfection
reagent (Qiagen). Ltc4s-as, Ltc4s, and Maml1 expression was assessed by qRTPCR at 24h post-transfection, in mock- or Tam-treated cells. ASO sequences are
listed in Supplementary Table 2.

Subcellular fractionation: Subcellular fractionation was performed as
previously described (Conrad and Ørom 2017) with some modifications. Briefly,
cells were harvested by trypsinization, rinsed once in PBS, and re-suspended in
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PBS-1 mM EDTA. Half of this cell suspension was set aside for whole cell (WC)
RNA isolation using TRIzol reagent. The remaining cells were lysed in 0.4 mL cell
lysis buffer for 5 min on ice. Lysis buffer composition for primary MEFs= 10 mM
TrisHCl pH 7.5, 0.15% NP-40, 150 mM NaCl, 100 U/mL RNase-IN (Promega); for
LA1.1 cells= 10 mM TrisHCl pH 7.5, 0.20% NP-40, 150 mM NaCl, 100 U/mL
RNase-IN. Lysate was layered on a sucrose cushion (24% w/v sucrose, 150 mM
NaCl, 10 mM TrisHCl pH 7.5,100 U/mL RNase-IN) and centrifuged for 10 min at
3500g for primary MEFs and at 3000g for LA1.1 cells, yielding the cleared
cytoplasmic fraction (supernatant) and pelleted nuclei. Nuclear pellets were
washed once in PBS-1 mM EDTA, re-suspended in 0.25 mL glycerol buffer (50%
glycerol, 20 mM Tris-HCl pH 7.5, 75 mM NaCl, 0.5 mM EDTA, 0.85 mM DTT, 100
U/mL RNase-IN), and lysed by the immediate addition of an equal volume nuclear
lysis buffer (10 mM HEPES pH 7.6, 7.5 mM MgCl2, 0.2 mM EDTA, 300 mM NaCl,
1% NP-40, 1 mM DTT, 1M Urea, 100 U/mL RNase-IN) with 2 min incubation on
ice. Centrifugation for 2 min at 18800g yielded the nucleoplasmic and chromatinassociated fractions in the supernatant and pellet, respectively. Chromatin pellets
were washed once in PBS-1 mM EDTA and solubilized in 1 mL TRIzol reagent by
syringing. RNA was extracted from the cytoplasmic and nucleoplasmic fractions
using TRIzol-LS (Invitrogen) and from the chromatin-associated fraction using
TRIzol, following the manufacturer’s protocols. Subcellular RNA enrichment was
determined by qRT-PCR, normalizing fraction Ct values to WC Ct values.
Cytoplasmically-enriched RNA Rn7s1 and chromatin-enriched RNA Kcnq1ot1
served as fractionation quality controls. Primers sequences can be found in
Supplementary Table 3.
142

Single-molecule RNA FISH (smRNA-FISH): smRNA-FISH was performed
as previously described (Olivero et al. 2020). In brief, cells were grown on
coverslips and fixed for 10 min at RT in 4% methanol-free formaldehyde (Thermo
Scientific). Cells were permeabilized overnight at 4°C in 70% EtOH-DEPC H2O.
Coverslips were then transferred to a hybridization chamber, equilibrated in Wash
Buffer A (Stellaris, LGC Biosciences) supplemented with formamide (Millipore
Sigma), and incubated overnight at 30°C with probes diluted 1:50 in Hybridization
Buffer (Stellaris, LGC Biosciences) with formamide. The following day, cells were
washed twice for 30 min at 30°C in Wash Buffer A, incubated for 5 min at RT in
Wash Buffer B (Stellaris, LGC Biosciences), and mounted in Vectashield Mounting
medium with DAPI (Vector Laboratories). LincRNA-RAPT1 spanning probes were
labeled with Quasar® 570 (LGC Biosearch Technologies). Images were captured
using an Axio Imager 2 microscope with a PlanApo 63x 1.4 oil DIC objective lens
(Zeiss) and edited using Adobe Photoshop.

Senescence-associated β-gal assay: Primary MEFs were cultured in 0.1 µM
Doxo for 168 hours to induce senescence. LA and SA KPR cells were grown in
normal media or media supplemented with Tam for 168 hours. Cells were fixed for
15 min at RT in 0.5% glutaraldehyde diluted in PBS, washed 3 times in 1 mM MgCl2
in PBS (not pH adjusted) and once in 1 mM MgCl2 in PBS (pH 5.5 for MEFs and
LA cells; pH 5.0 for SA cells). Cells were then stained in β-gal staining solution (5
mM potassium ferrocyanide, 5 mM potassium ferricyanide, 1 mg/mL X-gal, 1 mM
MgCl2 in PBS, pH 5.0 or 5.5) for 8-12h at 37°C. Cells were rinsed once in PBS before
imaging.
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Proliferation and colony formation assays: Growth curves were generated
for various transgenic and genetically engineered primary MEF lines, p53restorable MEFs, and mock-treated (no Tam) KPR cell lines by passaging cells,
counting cumulative cell numbers, and calculating population doublings over time.
p53-proficient growth or growth arrest bypass was assessed by plating cells
in Tam-supplemented media and counting cells at intervals of indicated lengths,
changing media every three days. Cumulative cell numbers over time were plotted
as the average of three independent experiments, when appropriate. For p53proficient colony formation assays, 4x105 cells/6 cm dish were grown in Tamsupplemented media and monitored for colony growth. For p53-deficient (-Tam)
colony formation assays, 1x105 cells/6 cm dish were plated and grown in normal
media. After 7-10 days, dishes were washed with PBS, fixed in 0.5% Crystal Violet;
25% methanol for 10 minutes, and thoroughly washed in ddH2O prior to colony
counting. Whenever shown, averages represent three independent experiments.

BrdU incorporation: Cells were grown on coverslips to roughly 50% confluency
in Tam-supplemented media. At 22h post-Tam treatment, cells were labeled with
10 µM 5-bromo-2-deoxyuridine (BrdU; Sigma-Aldrich) for 2h for KPR cells or 4h
for p53-restorable MEFs, washed once in PBS, and fixed overnight at -20 °C in
Fixation Buffer (75% ethanol, 25% 0.05 M glycine pH 2.2). Fixed cells were then
washed in PBS and incubated for 10 min at RT in 4N HCL, followed by three PBS
washes. In a covered humidified chamber, coverslips were blocked in PBG (0.5%
w/v BSA [Sigma A-2153], 0.2% w/v cold water fish gelatin [Sigma G-7765] in PBS)
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and stained with FITC-conjugated anti-BrdU antibody diluted 1:100 in PBG for 45
min at RT. Coverslips were washed three times in PBG and mounted in Vectashield
Mounting medium with DAPI before imaging. Nuclei were scored for BrdU
positivity and data presented as fraction BrdU positive over negative.

Apoptosis assays: Cleaved caspase 3 (CC3) levels, as assessed by
immunoblotting, were used as a read out for apoptosis induced by oncogenic and
genotoxic stressors, with the appropriate Tam and/or Doxo treatments indicated
in text and figure legends. Pro-apoptotic genotoxicity was induced in MEFs and
KPR cells by treating cells with 1 µM Doxo for 24h. Apoptosis was also monitored
in LA1 and LA2 cells using the Alexa Fluro 488® Annexin V/Dead Cell Apoptosis
kit (Invitrogen), following the manufacturer’s protocol, and analyzed on a FACS
Aria III sorter equipped with FACS DIVA software (BD Biosciences).

Statistical Analysis: Statistical tests and sample sizes used for each analysis are
indicated in figure legends. Analyses were performed using GraphPad Prism 8.
p<0.05 was considered statistically significant, with the following significance
thresholds used: * p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001.
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Supplementary Tables
Supplementary Table 1: Key plasmids used in this work
Name

Details

pCMV-VSV-G

lentiviral packaging

BRD001

lentiviral; SpCas9; hU6-gRNA; Puro

BRD003

lentiviral; hU6-gRNA; Puro

BRD004

lentiviral; SpCas9; hU6-gRNA; GFP

lenti SAM Hygro
MSCV Puro

lentiviral; p65-HSF1-MBP; hU6-gRNA-MS2;
Hygro
retroviral mammalian expression; Puro

pWZL Hygro

retroviral mammalian expression; Hygro

pLPC 12S E1A
puro
pHR-SFFV-dCas9BFP-KRAB
Lenti dCasVP64_Blast
Phage TRE-dCas9KRAB
pLenti BsmBI
sgRNA hygro
pCR-Blunt IITOPO vector

retroviral; E1A; Puro

pCMV-dR8.2

Source

lentiviral packaging

Addgene plasmid #8455

lentiviral; constitutive dCas9-BFP-KRAB; BFP
lentiviral; constitutive dCas9-VP64; Blast
lentiviral; Doxy-inducible dCas9-KRAB; Neo/G418
lentiviral; hU6-gRNA; Hygro
Blunt DNA cloning vector
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Addgene plasmid #8454
Broad Institute gift
Broad Institute gift
Broad Institute gift
Generated by
E. Martínez-Terroba
Addgene plasmid
#18750
Addgene plasmid
#18740
Addgene plasmid #46911
Addgene plasmid
#61425
Addgene plasmid
#50917
Addgene plasmid
#62205
Invitrogen (K280002)

Supplementary Table 2: gRNA, dRNA, and ASO information
Name
gRNA-Control 1 (Con)
gRNA-Control 2

Target
dTomato
mCherry

ΔRE-Zmat3-as
ΔRE-lincRNA-Spag9
ΔRE-lincRNA-Gadd45γ
ΔRE-Ltc4s-as
ΔRE-2310008N11Rik
ΔRE-Pvt1b
ΔRE-lincRNA-p21
ΔRE-Rhod-as

SpCas9 gRNAs

Sequence
GGCCACGAGTTCGAGATCGA
GTATTACTGATATTGGTGGG

*Score
---

lncRNA p53RE
lncRNA p53RE
lncRNA p53RE
lncRNA p53RE
lncRNA p53RE
lncRNA p53RE
lncRNA p53RE
lncRNA p53RE

CATGCTCCCAAGACATGCCT
CTGCTGTGCTTGGACTTGTT
GTGACATGCCTGTCCCCGAC
TCTGAGGCCTGGGACTTGCC
GGTCCACATTGCAGTTCTTC
ATATGGGCAGTGACAAGTTT
GATGCAACCGAAGGCAAGCC
TCAGAGCTAGCTCTGGCACA

88
84
91
70
90
87
90
81

gRNA #7
gRNA #8
gRNA #9;
lncRNA 7 gRNA 1
gRNA #10;
lncRNA 7 gRNA 2
gRNA #12
gRNA #13
gRNA #14

lncRNA 7 TSS (+43)
lncRNA 7 TSS (+68)
lncRNA 7 TSS (-10)

TGCTCAGACATGTCTAAGCC
GGTCCACATTGCAGTTCTTC
AAACACAGTGCCTTCGCTCT

91
90
94

lncRNA 7 TSS (-123)

AGCTATAGATCTGTCAGTAC

91

lncRNA 7 TSS (-340)
lncRNA 7 TSS (-180)
lncRNA 7 TSS (-120)

AGTCACCAGCTTTGGCGCCC
TACATGGTACTCATGACCCT
GCTTTCTGGCTTAACATGTA

92
90
90

Ltc4s-as gRNA 1
Ltc4s-as gRNA 2
Bfsp2-as gRNA 1
Bfsp2-as gRNA 2
Neat1 gRNA 3
Neat1 gRNA 4

TSS (-134)
TSS (-46)
TSS (-65)
TSS (-19)
TSS (-78)
TSS (-130)

CGGGCTACACCGGCTCGCTA
CCCACCCTTTGAGCGGCGTT
AGCTATAGATCTGTCAGTAC
TGCAGCTGTCTCAGCGACAT
TCCTGATGGCTTTTGCACCC
GGCCATGACCCGCCCCTCGT

99
98
90
78
92
86

Name
dRNA-Control (dCon)
dRNA-A1
dRNA-I1

SpCas9 dRNAs
Target
dTomato
lincRNA-Gadd45γ TSS (-10)
lincRNA-Gadd45γ TSS (+3)

Sequence
gCGAGTTCGAGATCGA
GACCTACCGCGGCTC
CTCAGAAGAGTGACT

-----

Name
Con
ASO 1
ASO 2
ASO (Ltc4s-as)

Target
N/A
lincRNA-Gadd45γ
lincRNA-Gadd45γ
Ltc4s-as

Sequence
GCTCCCTTCAATCCAA
GGTCAAATCGGTGCAG
ACCATTACTCCTCAAT
TGTCGGTTAGTAGATG

-----

ASOs

*CFD specificity score determined by CRISPOR (Haeussler et al. 2016); scores range from 0-100.
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Supplementary Table 3: qRT-PCR, PCR, and sequencing primer information
Gene
Gapdh
p53
p21
p16
Rn7s1
Kcnq1ot1
Zmat3-as
Bahcc1-as
lincRNA-Spag9
lincRNA-Gadd45γ
lincRNA-Gadd45γ (2)
lincRNA-Gadd45γ (3)
Ltc4s-as
2310008N11Rik (lncRNA 7)
Neat1
Malat1
Pvt1a
Pvt1b
Rhod-as
Sesn2-as
Bfsp2-as
lincRNA-p21
Zmat3
Bahcc1
Spag9
Gadd45γ
Ltc4s
Maml1
Myc
Sytl12
Rhod
Sestrin2
Bfsp2
Thap1
Zfp703
Erlin2
Rnf170
LincRNA-RAPT1 [aka (2)]

qRT-PCR primers (mouse); 5’ 3’
Forward sequence
Reverse sequence
AGCTTGTCATCAACGGGAAG
TTTGATGTTAGTGGGGTCTCG
ACGCTTCTCCGAAGACTGG
AGGGAGCTCGAGGCTGATA
TCCACAGCGATATCCAGACA
GGACATCACCAGGATTGGAC
CATCTGGAGCAGCATGGAGTC
TACGACCGAAAGAGTTCGGGG
CTGTAGTGCGCTATGCCGA
GTTCACCCCTCCTTAGGCAA
GGCCAGAAGCAGAGGTGATT
CCGAGCCGTAACTGCAAAAC
AGCCTACCCTGAAAGCGATG
TTCCAATGTCTTTGGGCGGA
AAGGCCGCTTGATGAAAGGA
TGGCCTGATTCAATCGCGTA
GCCTCATGAGACCTGCTGAA
GCCCCTGTGTAGCAATCACT
GCTCCGTTCCACGAAGTTTT
TGGGCTAGGCAGGTTAGGTA
CTCAGAAGAGTGACTCGGCG
AGGCAATAACTCCAGCTCTTTGA
ACTCTTATCAGCACACTCCAGC
CAGGCATGAGGGTCTGTGTC
CCTTGGCTGACACCCGAACC
CCGAGTTCGAGCGCGTCTTC
AGGAAAGAAGCGACTGAACACT
GATGACGAAGGTGAGGCACA
GGTTGACGCCTACACAGTGA
CTGCTGCCATTCATGCATCC
AACCAGTTTCCCCAGCTTTT
CTACATTCCCACCCAGCACT
ACTTAGCATTCCCAGAGCCC
TGGAGGGCATCTTCTTACCG
CCATGACTGGGAAAAACCTCG
TGGAGGGCATCTTCTTACCG
GGCAAGTTCTGAAGCCCACA
CCTGGGGGATTTCTCATCAGC
GGTCCGAGTGCTTTATGGGT
TTGCTCTGTTCCCACACCAC
TTGGCTATGGGTGCTTCGGC
AGCCGGGACTCTATCCATCC
CCTGTCCCACTCGCTTTC
GGAACTGGAGACGGAATGTCTC
TGTCACCTTGAACTCCGCTC
GCACAGCTTACAGTAGTCATTCT
GGGATTCATGGGATTGCCCT
GGCCAGCACATCCTCATCTT
GAATGGGTCGTGAGGTGGAG
TCTGCACGAGCTTTCCTGAG
GTGGCCAGGATACAGTTCCG
CAGGGTCCACATTCAGGACTT
CCCTCGTGGGAGTTCTGTTG
GCGTATAGGGGAGTCAGCCT
ACACAAAGCACCTTCCCACA
GAGGACAGCTGGAGTTGGAC
TTCATCTGCGATCCTGACGAC
CACTGAGGGGTCAATGCACTC
ACAGCAATGAGGGCAAAGGA
GCTGGATCCACCAAACTGGA
GCTCCTCTGCTTCGATGTGAC
TGAGAGCCACTTCTGCTGCTT
CACTGCGTCTTTGGCATCAG
GGTCGTCTTCTCAGGGTAGC
GGAAAACAGCTTGCACGACG
TGAGGTTCTTCAGACGTCACC
CCAGAAGGATGGTGCAGTCC
GGGCGAGTAAGAGGAAACTTGT
CCAATTGAGCTGGACGCCAA
CGGAGTTGAGCTTGGATGAG
CTGGAGGGACAGCCTGGATA
ACAGCTGAGAAGAGAGATGCA
AGCTAGGTAGTCCCCGGAAA
CTTAGACGCCCTAAGCTCG
ACAGCTGGCAAGTGGCAAAGCA
CCACCCACCTGCTTCTGTGTCC

Dhx15

CAGCCCAGGAGAGTGGCTGC

ACGCTCCAGAAGGGGATCGTTCA

LincRNA-RAPT1 (1)

GCCGCCTGGAGTTCGTTGGG

CCTGCTTTGCCACTTGCCAGC

LincRNA-RAPT1 (6)

GCCTCTCGTCCATCTCTGGGGA

LincRNA-RAPT1 (8)

TGTTAGCACGTGGTTTGTCTAAG
GTG
AGCTTCTCAGGACCTCTCTGCA

LincRNA-RAPT1 (2kb)

GCCTGATAGACTGAGAGGCAC

AGCTATACTTTCCTGAACCCAGAC
GA
CTAGGCAAGTGTGAGTGGTGAA

LincRNA-RAPT1 (4kb)

TGACCCCATCCACATCAGTC

GTATGGAGCCCCGATTGAGA

LincRNA-RAPT1 (6kb)

TACCAAAACTCAGGGTAAGGGAA

AAGGCATCCGTGAGGTTGATGG

LincRNA-RAPT1 (8kb)

TATGGCTGAATAGTGTCTCTGCT

CCCTTCTCACTCTACGCTCGTG

qRT-PCR primers (human); 5’ 3’
Gene

Forward sequence

Reverse sequence

LINC01605

AGGCTGGAGAGAGGGAACATG

CCAAGTTCGATGGAGAGCCTT
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Genotyping PCR primers; 5’ 3’
Name

Sequence

p53 LSL-1

CTT GGA GAC ATA GCC ACA CTG

p53 LSL-2

CAA CTG TTC TAC CTC AAG AGC C

SD5

AGC TAG CCA CCA TGG CTT GAG TAA GTC TGC A
Mutagenesis efficiency PCR primers; 5’ 3’

Name

Forward sequence

Reverse sequence

Zmat3-as PCR

GAGCTTCCCTGTCTGTGATGA

ATCCTTCGTGTCTGCCATCG

lincRNA-Gadd45γ PCR

CTTGCAGACCCGTCTTGAGT

CAGGCATGAGGGTCTGTGTC

lincRNA-p21 PCR

ATTGGCTAACCCCATGAGCAC

CTCTTCTTGCAGAAAGCCGCA

Pvt1b PCR

ATTGCGTTCCTGTGTTCGTG

AGGCAAAACAACAAGGCAGTC

Ltc4s-as PCR

GCAGCTGGACAGATAGATACC

GCTAACAACCACAGTGCAGG

Name

TIDE sequencing primers; 5’ 3’
Sequence

Zmat3-as seq

CAACTACCCGTATCTCTGGAAAC

lincRNA-Gadd45γ seq

CTGACTCCAGTTCTACCACAAG

lincRNA-p21 seq

GCCCTCTCTCCATCCTCAATG

Pvt1b seq

CTGCTCTTGTGTTTTTAAGGGG

Ltc4s-as seq

GGACCCTTAGAGTGTTGTTGTTG
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